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Medicinal plants still hold their strong position in the therapy of 
various human diseases, even in the modern era. Seven medicinal plants long 
known for their use in the treatment of cardiovascular disorders were chosen 
for this thesis, namely Allium sativum L. (garlic), Crataegus spp. (hawthorn), 
Digitalis spp. (foxglove), Leonurus cardiaca L. (motherwort), Olea europaea L.  
(olive), Nigella sativa L. (black cumin), and Viscum album L. (European 
mistletoe). Their beneficial effects on the cardiovascular system (antioxidant, 
cardioprotective, vasorelaxant, antiatherosclerotic, antihypertensive, and 
lipid-lowering actions) were reviewed with an emphasis on information 
concerning humans. When possible, the mechanism explanation, results of 
clinical trials, and established dosage range for the respective fields of action 
are presented. 
The consumption analysis of the preparations containing the 
abovementioned medicinal plants was conducted with a total number of 
33 over the counter herbal preparations and 2 prescription-restricted 
medicinal products. The products contain either the medicinal plant itself, its 
extract or active compound(s), and only those available on the Czech Republic 
pharmaceutical market were chosen for the consumption analysis. The years 
2015 - 2019 were established as the reporting time period.  
Data collected from participating pharmacies was categorized as big 
city (included pharmacies in cities with more than 50 thousand of 
inhabitants), small town (included pharmacies in towns under 50 thousand of 
inhabitants), and e-shop (pharmacies with home delivery regardless of the 
population size).  
The majority of herbal preparations were represented by garlic herbal 
preparations, both in the number of the evaluated products and the 
consumption rate. High consumption rates were also observed for hawthorn 
and mistletoe preparations. The consumption of other medicinal plants 
preparations (motherwort, olive leaf, and black cumin) were remarkably 
lower than that of the aforementioned medicinal plants. The consumption of 
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garlic and hawthorn preparations showed a more or less stable trend with no 
significant fluctuations during the evaluated time period. Mistletoe and 
motherwort preparations exerted an increasing consumption trend, while 
olive leaf and black cumin preparations exhibited a decreasing consumption 
trend during the reporting time period. 
The main issue with the OTCs is the lack of medicinal productss 
among them. Only two herbal teas are registered with SUKL, the remaining 
31 preparations are categorized as food supplements. On the other hand, 
several of the food supplements were standardized for a certain amount of 
the active compounds and according to the available literature, some of these 
supplements may have a positive influence on human cardiovascular health. 
The prescription-restricted medicinal preparations were represented 
by different-strenght digoxin tablets. While digoxin consumption during the 
reporting time period exerted a remarkable decreasing trend with the 
exception of 2018 in big city pharmacies, small town pharmacies exhibited a 
slower onset of the reduction in digoxin consumption and an increase in 
digoxin consumption in 2018. These differences were likely the consequence 
of two different impacts: the decrease in digoxin use in the heart failure 
treatment according to the newest guidelines that are applied more rapidly in 
big cities, and the outage of digoxin supplementation in 2018 due to the 















Léčivé rostliny jsou i v současné době nedílnou součástí terapie nejen 
lidských nemocí. Pro tuto práci bylo vybráno sedm léčivých rostlin s dlouhou 
tradicí léčby různých kardiovaskulárních onemocnění. Jedná se konkrétně o 
tyto rostliny: Allium sativum L. (česnek kuchyňský), Crataegus spp. (hloh), 
Digitalis spp. (náprstník), Leonurus cardiaca L. (srdečník obecný), Olea 
europaea L. (olivovník evropský), Nigella sativa L. (černucha setá) a Viscum 
album L. (jmelí bílé). Jejich příznivý účinek na kardiovaskulární systém 
(antioxidační, kardioprotektivní, vasorelaxační, antiaterosklerotické, 
antihypertenzivní, hypolipidemické) byl podrobně popsán s důrazem 
především na informace týkající se lidí. Pro jednotlivé oblasti byl popsán i 
mechanizmus účinku, výsledky klinických testů a doporučené dávkování, 
pokud byly tyto informace k dispozici. 
Pro přípravky z vyjmenovaných léčivých rostlin byla provedena 
analýza spotřeby. Celkem bylo zahrnuto 33 volně prodejných přípravků a 2 
přípravky vázané na recept. Tyto přípravky obsahují buď přímo rostlinnou 
drogu, nebo jednotlivé účinné látky nebo jejich kombinace. Pro tuto analýzu 
byly vybrány výhradně přípravky dostupné na farmaceutickém trhu v České 
republice. Rozhodné období pro pro hodnocení byly roky 2015 – 2019. 
Data získaná ze zapojených lékáren byla rozdělena do třech kategorií: 
velká města (více než 50 tisíc obyvatel), malá města (méně než 50 tisíc 
obyvatel) a e-shop (lékárny doručující na domácí adresu bez ohledu na počet 
obyvtel daného města). 
Přípravky s obsahem česneku představují největší objem v počtu 
prodaných balení. Současně mají největší spotřebu během celého 
hodnoceného období. Poměrně vysoká spotřeba byla zjištěna i u přípravků 
obsahujících hloh a jmelí. Spotřeba přípravků s obsahem ostatních 
hodnocených léčivých rostlin (srdečník, olivovník a černucha) byla výrazně 
nižší. Křivka spotřeby česneku a hlohu byla více-méně stabilní a nevykazovala 
žádné výrazné výkyvy. Spotřeba přípravků s obsahem srdečníku a jmelí 




Největším problémem volně prodejných přípravků je nedostatek 
léčivých přípravků v této skupině. Pouze dva z nich mají registrační číslo 
SÚKLu a spadají do kategorie léčivý přípravek, zbylých 31 je v kategorii 
doplněk stravy. I přesto je význámné procento přípravků standardizováno na 
určitý obsah účinných látek a podle dostupné literatury některé z nich by 
mohly vykazovat pozitivní vliv na lidský kardiovaskulární systém. 
Léčivé přípravky vázané na recept, které byly zahrnuty do analýzy, 
představují tablety s digoxinem v různých sílách. Zatímco spotřeba digoxinu 
ve velkých městech během sledovaného období plynule klesala s výjimkou 
roku 2018, malá města vykazovala pomalejší nástup poklesu ve spotřebě a 
zvýšení této spotřeby v roce 2018. Příčina rozdílu je pravděpodobně dána 
poklesem v preskripci dle nejnovějších doporučení pro léčbu srdečního 
selhání a rychlejším uváděním nových postupů do praxe ve větších městech. 





















Since the rise of the first human civilization, medicinal plants have 
been widely used for the treatment of all the known diseases. For thousands 
of years people exploited a large variety of herbal species occurring around 
the world. From Eber's papyrus, through Dioscorides De materia medica, up 
to modern pharmacopoeias, herbal drugs and preparations have 
accompanied people on their journey to regain and keep their health.  
Even now, in the age of advanced technologies, specialized medical 
care and an immense amount of various chemical drugs, medicinal plants 
firmly hold their significant position in human therapy. Current investigations 
in the field of phytochemistry and the therapeutic potential of medicinal 
plants are very intensive and numerous scientific papers dealing with these 
topics have been submitted in the last years. Recent requirements of an 
evidence-based approach in human medicine are also reflected in the 
research, and many clinical trials evaluating the efficacy and safety profiles of 
several medicinal plants have been successfully conducted, offering valuable 
knowledge. 
It is well known that for people in developing countries medicinal 
plants sometimes still represent the only accessible treatment for the 
majority of their ailments. However, people of the Western civilizations also 
often choose herbal preparations as their first therapeutic option due to 
various reasons, be it the availability of the product or their inner belief in the 
efficacy of traditional systems of medicine. 
And finally, regardless of the extraordinary headway in chemical 
sciences and biotechnologies, not all chemicals can be synthetized de novo in a 
laboratory because of their structural complexity. A brilliant representative of 
such compounds is digoxin, a cardenolide naturally occurring in foxglove, that 
has for more than 200 years been used in cardiology and that will be focused 
on in following chapters. 
In the presented thesis I focused on the medicinal plants used in the 
treatment of various cardiovascular diseases with the emphasis on 
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cardioprotection, heart failure, and hypertension. Hypertension is a global 
health issue, some 600 million people worldwide have high blood pressure 
and nearly 3 million die every year as a direct result. And yet, according to the 
World Health Organization, seven out of ten people are not receiving 
adequate treatment.  
Furthermore, hypertension is a component of the metabolic syndrome, 
a multifactorial metabolic disbalance with a high prevalence among the adult 
population. Although the definition of the metabolic syndrome has changed 
several times during the past two decades, the conditions of this syndrome 
represent a useful tool for identifying subjects at high risk of cardiovascular 
diseases. As dyslipidemia is another important component of the metabolic 
syndrome, I also focused on the action of selected medicinal plants on the 
lipid profile.  
The medicinal plants mentioned in this thesis were chosen according 
to the availability of the herbal preparations on the Czech pharmaceutical 
market, and the consumption analysis of these products in the years 2015 – 

















AIMS OF THE PRESENT RESEARCH 
 
1. To present a comprehensive overview of medicinal plants 
contemporary used in the Czech Republic in the treatment of various 
conditions of the human cardiovascular system, with the emphasis on 
cardioprotection, heart failure, and hypertension. 
 
2. To evaluate the consumption of over the counter herbal preparations 
(both food supplements and medicinal products) in the Czech 
Republic in the years 2015 – 2019. 
 
Solved questions: 
• Are there enough OTC medicinal products containing selected 
medicinal plants on the pharmaceutical market of the Czech 
Republic? 
• Are there any preferences in the consumption of herbal 
preparations regarding the plant species and/or pharmacy 
category? 
• Are the recommended dosages in accordance with the information 
in scientific papers? 
 
3. To evaluate the consumption of the foxglove cardenolide digoxin in 
the Czech Republic in the years 2015 – 2019. 
 
Solved questions: 
• Does the consumption of digoxin change in the reporting time 
period? 
• Are the any differences in digoxin consumption between big 








2.1. GARLIC – ALLIUM SATIVUM L. – FAM. AMARYLLIDACEAE 
 
2.1.1. CHARACTERIZATION OF ALLIUM SATIVUM L. – A PHARMACOGNOSTIC CONTEXT 
 
 The genus Allium comprises more than 900 species, making it one of 
the largest monocotyledonous genera. Most likely the genus Allium originated 
during the late Eocene (approximately 40 millions of years ago) from central 
Asia and underwent different geographical pathways. It was firstly placed in 
the family Lilliaceae, then Alliaceae and after the revision of the classification 
system it now belongs to the family Amaryllidaceae. Many economically 
important species are included such as onion, leek, and garlic (Li et al., 2016; 
Huo et al., 2019; Xie et al., 2020 and references therein). 
Garlic, Allium sativum L. (Fig. 2.1.), is a perennial plant although often 
grown as annual. It is grown asexually from cloves. The cloves in a bulb are 
covered by a whitish or pinkish tunic named papery coat. Leaves (four to 
twelve) are long, sword-shaped, and attached to an underground stem. 
Flowers are greenish-white or pinkish, borne in a dense, spherical cluster on 
a spike up to 25 cm long. Seeds are not usually produced in the wild but have 
been produced under laboratory conditions. They have a black coat and are 
half the size of onion seeds (Wichtl, 2004; Alam, Hoq and Uddin, 2016). 
 For medicinal use (Allii sativi bulbi pulvis) the bulbs or separated 
cloves of the species Allium sativum L. are usually cut into 5 mm thick flakes 
and immediately either dried at a temperature not exceeding 65 °C or freeze-
dried and then powdered in order to preserve the alliinase-allicin complex 
and to prevent, through dehydration, any further reaction of the already 
present allicin (see Ch. 2.1.2.). According to the European Pharmacopoeia, 
garlic powder must not contain less than 0.45% of allicin calculated with the 
reference to the dried drug. The European Pharmacopoeia also inlcudes a 
monograph on garlic for use in homeopathic medicinal products (Allium 
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sativum ad praeparationes homeopathicas; ESCOP, 2003; Wichtl, 2004; 





2.1.2. PHYTOCHEMISTRY OF GARLIC 
 
 The genus Allium is rich in both non-volatile and volatile compounds. 
Non-volatile compounds are represented by sapogenins, steroidal saponins, 
and flavonoids. The first furostanol saponin isolated from garlic bulbs was 
proto-eruboside B, its spirostanol analogue, eruboside B, was obtained by its 
enzymatic hydrolysis. Several other furostanol and spirostanol saponins have 
since been identified in garlic bulbs. Garlic flavonoids include apigenin, 
quercetin, nobiletin, rutin, allixin, tangeretin, and myricetin (Matsuura et al., 
1988; Lanzotti, 2006; EMA/HPMC/7686/2013). 
The volatile compounds are probably the most important active 
constituents of garlic. They are represented by organosulfur compounds, 
mainly thiosulfinates. Thiosulfinates are very unstable compounds and give 
rise to further rearrangements leading to a wide variety of derived sulfur 
compounds such as thiosulfonates, di- and tri-sulfur compounds, and ajoenes. 
At temperatures about 100 °C poly-sulfur compounds are formed (Lanzotti, 




2006; Jangan and Badole, 2014). Some of the important garlic organosulfur 
compounds are depicted in Fig. 2.2. 
 
The volatile compounds are responsible for both the pharmacological 
as well as the organoleptic properties of garlic. Their content is variable and it 
is strongly influenced by both pre- and post-harvest factors, such as genotype, 
irrigation, fertilization, and processing. Intact garlic has four major 
organosulfur compounds: S-allyl cysteine, alliin, S-methyl cysteine, and S-ethyl 
cysteine, although a total number of 85 sulfur containing compounds have 
been reported in garlic so far (Lanzotti, 2006; Martins, Petropoulous and 
Ferreira, 2016; Zeng et al., 2017 and references therein; Abe, Hori and Myoda, 
2020). 
 S-allyl cysteine is a water soluble compound, which has been 
identified as the major active compound in aged garlic. It has good 
bioavailability (more than 90%) and it is principally metabolized into the 
metabolite N-acetyl-S-allyl cysteine. S-methyl cysteine can also be found in 
aged garlic. Both S-methyl cysteine and S-ethyl cysteine are hydrophilic 
compounds (Amano et al., 2015; Amano, Kazamori and Itoh, 2016; Kanamori 
et al., 2020). 
Alliin (S-allyl cysteine sulfoxide) is a hydrophilic and odorless non-
proteinogenic amino acid and it represents the major odor precursor in garlic. 
Fig. 2.2. Some of the Allium sativum L. active compounds. Upper left – ajoenes (E and Z isomeres), 
upper right – allicin, down left – S-allyl cysteine, down right – alliin. Courtesy of doc. Macáková. 
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The biosynthesis of alliin takes place in the leaves, where alliin is accumulated 
at the earlier growth stages. Several biosynthetic pathways of alliin were 
proposed (involving two organosulfur compounds – either S-2-carboxypropyl 
glutathione or S-2-carboxypropyl cysteine) but the whole process still 
remains unclear. It is especially problematic determinig the origin of the allyl 
group and the double bond in alliin. Enzymes required for alliin biosynthesis 
are located partially in cytoplasm and partially in chloroplasts, it is therefore 
also unclear where the biosynthesis of alliin is located. After bulb formation is 
initiated, alliin is then translocated and stored in the bulbs (in cytoplasm or 
cytoplasmic vesicles), which represents approximately 85% of total alliin 
content. In the leaves remain about 12% of total alliin content. Application of 
sulfur during the growing season significantly increased the alliin content in 
bulbs (from 5.1 to 11.2 mg/g of dry weight), whereas high nitrogen rates had 
no significant effect (Bloem, Haneklaus and Schnug, 2010; Yamaguchi and 
Kumagai, 2019). 
Allicin (diallyl thiosulfinate or S-(2-propenyl)-2-propene-1-
sulfinothioate) is a bright yellow lipid-soluble sulfur-containing volatile 
compound. It is responsible for the pungent odor of fresh garlic and is 
considered to be the most biologically active organosulfur compound present 
in garlic. Allicin is formed when garlic cells are mechanically disrupted – by 
crushing or chopping of garlic cloves – from its precursor alliin and the 
enzyme alliinase (EC 4.4.1.4), which has optimum pH for activity 6.5. Alliin 
and alliinase are stored in different compartments (in cytoplasm and in 
vacuole, respectively) and if the cell is damaged they come into contact. Alliin 
is hydrolyzed by alliinase to allyl sulfenic acid, pyruvic acid, and ammonium. 
Two molecules of allyl sulfenic acid (a highly reactive intermediate) then 
condense spontaneously to form one molecule of allicin. Allicin represents 
about 70% of total thiosulfinates existing in the crushed garlic cloves. Allicin 
is not a very stable compound; it is further metabolized to form other 
compounds with the typically strong garlic odor, such as diallyl disulfide and 
diallyl trisulfide. It can be easily damaged by cooking and it is unstable even at 
room temperature. Its degradation products include ajoenes and 
vinyldithiins, which are more stable than allicin. Ajoenes are present as (E) 
and (Z) isomers, where (E)-ajoene is usually found in double amounts (Mazelis 
21 
 
and Crews, 1968; Borlinghaus et al., 2014; Yamaguchi and Kumagai, 2019; El-
Saber et al., 2020 and references therein). 
 
2.1.3. MEDICINAL USE OF GARLIC 
 
 Garlic is among the oldest of all cultivated plants. It has been used as a 
spice, food, and folklore medicine for over 4000 years, and is the most widely 
researched medicinal plant. As early as 3000 B.C., in ancient civilizations, 
including Egyptian, Phoenicians, Greek, Indian, Roman, Babylonian, Viking, 
and Chinese, garlic was used for the treatment of headache, heart conditions, 
arthritis, pulmonary complaints, respiratory infections, skin disease, wounds, 
symptoms of aging, diarrhea, bites, worms, abdominal growths (particularly 
uterine), ulcers, and tumors. Codex Ebers, an Egyptian medical papyrus 
dating to about 1550 B.C., includes 22 therapeutic formulations that mention 
garlic as an effective remedy for a variety of ailments (Block, 1985; Milner, 
1996; Rahman, 2006). 
According to EMA, garlic bulb as single herbal substance is authorized 
in Denmark, France, Germany, Hungary, Latvia, Poland, Spain, Sweden, and 
the United Kingdom. Several garlic preparations are present on the market: 
powder, liquid extraction preparation (extraction solvent refined rapeseed 
oil), and dry extract (extraction solvent ethanol 34%). Most of these 
preparations are marketed in Germany (EMA/HPMC/7686/2013). EMA lists 
two therapeutic indications of garlic – as an adjuvant for the prevention of 
atherosclerosis and the use for the relief of the symptoms of a cold 
(EMA/HPMC/7685/2013). 
Lately, aged (or black) garlic preparations have become popular. Aged 
garlic is produced from fresh garlic bulbs under controlled high temperature 
and humidity. Changes in 38 compounds during the thermal processing of 
raw garlic were reported by Liang et al. (2015). Kodera et al. (2020) also 
focused on the changes in the chemistry of aged garlic and noted that the 
production mechanisms of several compounds identified in aged garlic have 
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yet to be elucidated. It is therefore to be expected that aged garlic can exert 
different biological properties from those of raw garlic. 
Great attention is paid to the often problematic standardization of 
the active compounds content in garlic preparations, although the 
requirement for allicin content in garlic powder is clearly defined by the 
respective authorities.  For example, Ghani (2010) determined the content of 
alliin and allicin in 7 garlic extracts (standard, Iraqi, Iranian, Lebanese, 
French, and Chinese), and the content varied significantly for both 
constituents. For alliin, the lowest content was in standard garlic (0.00025%), 
while Iraqi and Iranian garlic was alliin-rich (0.900% and 0.660%, 
respectively). The allicin content was again low in the standard garlic 
(0.00025%), while its highest values were detected in Iraqi and Lebanese 
garlic (1.290% and 0.330%, respectively). This particular problem was also 
noted by EMA in the assessment report on garlic: As very various extracts, 
quite often not standardized, are used in the experimental literature, it 
appears quasi impossible to generalize many of the results to a given herbal 
preparation (EMA/HPMC/7686/2013).  
  
2.1.4. EFFECTS OF GARLIC ON SELECTED CARDIOVASCULAR CONDITIONS 
 
2.1.4.1. ANTIOXIDANT EFFECT OF GARLIC 
 
 Phelps and Harris (1993) reported a significant decrease (by 34%) in 
the ex vivo susceptibility of apolipoprotein B-containing lipoproteins to 
oxidation in healthy volunteers treated with garlic powder (600 mg) for 
2 weeks. A similar trend of decreased susceptibility of lipoproteins to 
oxidation was also noted by Steiner and Lin (1998) who used aged garlic 
extract in moderately hypercholesterolemic men. Ahmadi et al. (2010) also 
reported a decrease in oxidized phospholipids in volunteers taking aged 
garlic extract for 12 months. Munday et al. (1999) found that in vitro, aged 
garlic extract has a stronger beneficial effect on the susceptibility of 
LDL particles to copper ions-mediated oxidation than raw garlic. 
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Dhawan and Jain (2004) investigated the effect of short-term garlic 
supplementation on the indices of oxidative stress in essential hypertensive 
patients. Twenty volunteers were administered with garlic pearls at a dose of 
250 mg for 8 weeks. Garlic treatment led to a moderated increase of total 
antioxidant status and to a significant reduction in both urinary concentration 
of 8-iso-prostaglandin F2α (a biomarker of oxidative stress in vivo) and 
oxidized LDL cholesterol. In their subsequent study Dhawan and Jain (2005) 
further explored the antioxidant properties of garlic in hypertensive 
volunteers. Again, the dose of 250 mg of garlic pearls was used for 8 weeks. A 
significant reduction in lipid peroxidation and 8-hydroxy-2'-deoxyguanosine 
(a marker of oxidative stress-induced DNA damage) and a significant increase 
in total antioxidant status were observed at the end of the trial. 
A remarkable decrease of lipid peroxidation products in volunteers 
with primary arterial hypertension taking 6 capsules of garlic preparations 
daily for 4 weeks was also reported by Duda, Suliburska and Pupek-Musialik 
(2008). The authors furthermore observed that treatment with garlic 
markedly increased vitamin E concentration in serum and led to a positive, 
although non-significant trend in increases in the levels of other antioxidant 
vitamins and glutathione peroxidase activity (Duda, Suliburska and Pupek-
Musialik, 2008). 
Aged garlic extract also exhibits a favorable antioxidant activity, 
partially due to S-allyl cysteine, the most abundant organosulfur compound 
present in the extract. The DPPH radical scavenging activity of S-allyl cysteine 
was higher than that of vitamin C and it furthermore showed good hydroxyl 
radical-scavenging properties. The antioxidant activity of S-allyl cysteine was 
concentration-dependent in both cases (Sun and Wang, 2016). S-allyl cysteine 
as well as other organosulfur compounds isolated from aged garlic were 
proven efficient in the inhibition of advanced glycation end-products (Wang, 
Sun and Chen, 2018). Intraperitoneal administration of either pure S-allyl 
cysteine (200 mg/kg) or aged garlic extract (1.2 mL/kg) every other day for 
4 weeks in 5/6 nephrectomized rats resulted in an increase of superoxide 
dismutase activity (Cruz et al., 2007). 
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Similarly, the positive effect of garlic on the activity of superoxide 
dismutase was observed after oral treatment of rats with either fresh garlic 
homogenate (125 or 250 mg/kg) or pure S-allyl cysteine sulfoxide (0.111 or 
0.222 mg/kg) for 3 weeks. Both superoxide dismutase and catalase activities 
in the heart tissue were significantly increased (Asdaq and Inamdar, 2010).  
The antioxidant activity of garlic is most likely dose-dependent. Pure 
allicin neutralized DPPH radical to a higher degree in higher concentrations, 
with the maximal inhibition being 90%. The transformation products of 
allicin (transformation was performed in methanol by using microwaves) had 
a lower antioxidant activity than the original compound (Ilić et al., 2015). Li 
et al. (2017) also observed a concentration-dependent scavenging capacity of 
pure allicin, the maximal inhibition again being around 90%. And similarly, 
Oboh et al. (2019) stated that the aqueous garlic extract was able to scavenge 
the DPPH free radical and to reduce ferric ions in a dose-dependent manner. 
The hydroxyl radical-scavenging properties of heated and unheated garlic 
were evaluated by Prasad et al. (1996). Although heating of garlic to 100 °C 
decreased the ability to scavenge hydroxyl radicals generated by photolysis of 
hydrogen peroxide, approximately by 10%, the radical scavenging activity of 
garlic remained concentration-dependent in both cases. The unheated garlic 
was able to scavenge 30 – 100% of the exogenously produced radicals. 
Aside from the organosulfur compounds, garlic protein and its 
hydrolysate obtained by the enzymatic activity of pepsin and trypsin also 
possess appreciable antioxidant activities and offered significant protective 
effects against hydrogen peroxide-induced oxidative damage in rats 
(Gao et al., 2020). 
 
2.1.4.2. DIRECT EFFECT OF GARLIC ON MYOCARDIUM 
 
 The influence of garlic's active compounds on cardiomyocytes is 
mostly mediated via their antioxidant activity (see Ch. 2.1.4.1.). However, 
several reports of other direct effects of garlic on myocardium can be found in 
the available literature. For example, Martín et al. (1994) investigated the 
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anti-arrhythmic effect of garlic dialysate on dogs and isolated rat atria. 
Garlic suppressed premature ventricular contractions and ventricular 
tachycardia in dogs intoxicated with ouabain. Furthermore, garlic dialysate 
also subdued the ectopic rhythms induced by isoprenaline and aconitine on 
electrically driven left rat atria.  
 Pretreatment of rats with garlic powder added to standard chow (1%) 
for 10 weeks resulted in a significantly reduced incidence of ventricular 
tachycardia and ventricular fibrillation. Further, the time until occurrence in 
extrasystoles and ventricular tachycardia or fibrillation was prolonged in 
most cases, and the duration of arrhythmias was abbreviated, as observed on 
isolated rat hearts by Isensee, Rietz and Jacob (1993). 
Sungnoon et al. (2008) tested on pigs if garlic could decrease the 
inducibility of ventricular arrhythmia. Although the intravenously 
administered garlic (standardized to contain 1.3% of allicin, used at doses of 
20 or 40 mg/kg) did not alter the ventricular fibrillation threshold, it 
significantly decreased the upper limit of vulnerability (it is the stimulus 
strength above which electrical stimulation cannot induce ventricular 
fibrillation even when the stimulus occurs during the vulnerable period of 
the cardiac cycle). 
The anti-arrhythmic effect of garlic is, however, limited to a certain 
concentration range. Higher doses of garlic aqueous extract were reported to 
cause arrhythmias in isolated rat hearts (Sharma et al., 2012), or even bizarre 
EKG pattern in frog hearts treated with fresh garlic juice (Yadav and Verma, 
2004). 
A dose-dependent depressant effect of garlic dialysate on heart was 
observed by Martín et al. (1992) who reported a decrease in heart rate of 
anesthetized dogs. Preincubation of isolated rat left atria with garlic dialysate 
moreover partially antagonized the positive inotropic and chronotropic 
effects of isoproterenol. A decrease of positive inotropic and chronotropic 
effects of isoprenaline on isolated rat hearts was also influenced by garlic 
dialysate in a dose-dependent manner (Martín et al., 1994).  
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Negative chronotropic and negative inotropic effects of fresh garlic 
juice applied direct on frog hearts were observed by Yadav and Verma 
(2004). Similarly, Radenković et al. (2010) reported negative inotropic and 
chronotropic effects of aqueous and ethanolic garlic extract on isolated rat 
atria. The ethanolic extract exhibited stronger negative inotropic properties 
(58.33%) than aqueous extract (43.66%). The difference in chronotropism 
between the two tested garlic extracts was very prominent – while the 
aqueous extract reduced the heart rate only slightly, the ethanolic extract 
reduced it by more than 40%. Intravenous administration of garlic ethanolic 
extract to normotensive rats also led to a significant decrease in heart rate 
(Branković et al., 2011). 
The administration of garlic dialysate with verapamil, diltiazem, or 
nifedipine (Ca2+ channel blockers) induced a concentration-dependent 
synergism on rat left atria. Based on their experiments with the garlic 
dialysate on isolated rat left atria, Martín et al. (1997) suggested that the 
negative inotropic effect of garlic is related to calcium availability.  
 In the ischemia/reperfusion myocardial injury, the cardioprotective 
effect of garlic was reported by several authors. Asdaq, Inamdar and Asad 
(2010) pretreated rats with an orally administered garlic homogenate (at 
doses of 125, 250, or 500 mg/kg) for 4 weeks and then induced  
ischemia/reperfusion injury on the isolated hearts. Garlic pretreatment at 
doses of 125 and 250 mg/kg provided significant protection to myocardium 
and offered a remarkable increase in levels of several antioxidant enzymes, 
such as superoxide dismutase and catalase. However, the highest dose of 
garlic failed to show any cardioprotection.  
Similar results were obtained by Sharma et al. (2012) who evaluated 
different concentrations of garlic aqueous extract (ranging from 0.01% to 
0.50%) on isolated rat hearts exposed to 20 minutes of ischemia followed by 
40 minutes of reperfusion. Treatment with garlic significantly reduced the 
size of infarct area and lactate dehydrogenase release. The effective 
cardioprotective concentration of garlic aqueous extract was 0.05%. Lower 
garlic concentrations offered no protective effect, while higher concentrations 
were toxic, caused cardiodepression or even arrhythmias.  
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 Administration of pure diallyl trisulfide (20 mg/kg), one of the major 
active garlic compounds, to rats undergoing myocardial ischemia/reperfusion 
surgery also resulted in a significantly improved heart function and a 
decrease in apoptosis of cardiomyocytes. Diallyl trisulfide (10 µmol/L) also 
attenuated the in vitro simulated ischemia/reperfusion injury in H9c2 cell 
culture. The molecular mechanism of diallyl trisulfide's cardioprotective 
effect included an increased phosphorylation of AMPK (Yu et al., 2017).  
A synthetic structural analog of S-allyl cysteine, known under the name 
ZYZ-802 (S-propargyl cysteine), reduced the infarct size area and partially 
recovered cardiac function in heart failure rat model, especially when linked 
with leonurine (see Ch. 2.4.4.2). This analog showed a more extensive 
cardioprotection in the ischemic rat heart model than S-allyl cysteine (Wen 
and Zhu, 2015). 
Comparisons of the cardioprotective effects of raw garlic and aged 
garlic extract were performed by Czompa et al. (2018). Rats were treated 
with either raw garlic or aged garlic extract at a dose of 300 mg/kg for 
4 weeks and then their isolated hearts were exposed to ischemia/reperfusion 
injury (30/120 minutes). While both garlic preparations had a significant 
protective effect on the cardiac functions, such as increased cardiac output, 
aortic flow, and stroke volume, no significant differences were observed 
between the effects of raw and aged garlic. 
 
2.1.4.3. EFFECT OF GARLIC ON BLOOD, BLOOD CELLS, AND BLOOD VESSELS 
 
Garlic was shown to be effective against platelet aggregation several 
decades ago. Bordia (1978) studied the effect of garlic essential oil on platelet 
aggregation in vitro and in healthy volunteers after 5 days of oral treatment 
with garlic essential oil at a daily dose of 0.5 mg. Garlic inhibited ADP-, 
epinephrine-, and collagen-induced platelet aggregation in a dose-dependent 
manner in both cases. Garlic aqueous extract in a dose-dependent manner 
also inhibited ADP-, epinephrine-, collagen, and arachidonate-induced platelet 
aggregation in vitro (Srivastava, 1984b). 
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Dried garlic powder at a daily dose of 900 mg in healthy volunteers 
significantly decreased platelet aggregation after one week and two weeks of 
administration. The ADP- and collagen-induced platelet aggregation was 
remarkably inhibited mere two hours after garlic ingestion (Lagnani et al., 
1993).  
Kiesewetter et al. (1993) explored the effect of garlic in 60 volunteers 
with cerebrovascular risk factors and constantly increased platelet 
aggregation. Powdered garlic at a dose of 800 mg administered for 4 weeks 
significantly decreased both the pathologically increased value of circulating 
platelets and the spontaneous platelet aggregation. Similarly, Karagodin, 
Sobenin and Orekhov (2016) investigated the cardioprotective effects of time-
released garlic pills. When administered to patients with cerebral 
atherosclerosis for 14 days, a decrease in ADP-induced platelet aggregation 
by 24% was observed. In their preliminary in vitro study, incubation of garlic 
with human plasma resulted in an even more pronounced decrease of ADP-
induced platelet aggregation (by 36%; Karagodin, Sobenin and Orekhov, 
2016). 
The efficacy of garlic antiplatelet properties was also evaluated by 
some authors in the context of antiplatelet agents contemporarily used as a 
standard blood-thinning therapy in human patients. For example, the 
comparison of antiplatelet activity of garlic and acetylsalicylic acid in vivo was 
performed by El-Sabban and Radwan (1997). Mice were administered with 
different doses of garlic (12.2, 25, 50, and 100 mg/kg) and acetylsalicylic acid 
(25, 50, and 100 mg/kg) and then the time of appearance of the first platelet 
aggregate in pial arterioles was measured. A significant delay in platelet 
aggregation was observed at the dose of 100 mg/kg in the garlic group, while 
all doses of acetylsalicylic acid were able to postpone the platelet aggregation. 
Fakhar and Hashemi (2012) conducted another comparative study 
with 36 healthy volunteers focused on the platelets anti-aggregatory effect of 
garlic and one of the standardly used blood thinners, Plavix (clopidogrel). 
After 3 weeks of treatment, ADP- and collagen-induced platelet aggregation 
was significantly decreased in volunteers taking 1200 mg or 2400 mg garlic 
and 75 mg Plavix. A low dose of garlic (600 mg) had no effect on platelet 
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aggregation except for the ristocetin-induced aggregation, which in turn was 
not affected by Plavix.  
The mechanism of garlic's inhibitory effect on platelet aggregation 
was suggested by Vanderhoek, Makhej and Bailey (1980) who observed a 
pronounced decrease in the formation of both the thromboxane B2 and the 
12-hydroxyheptadecatrienoic acid from arachidonic acid. Garlic essential oil 
at intermediate concentrations (10 – 30 µg/mL) induced a redistribution of 
the lipooxygenase pathway products in platelets and at higher concentrations 
(30 – 60 µg/mL) the formation of all oxygenase products was completely 
suppressed. The alteration of the arachidonic acid metabolism (namely 
inhibition of biosynthesis of 6-keto prostaglandin F1⍺) by garlic aqueous 
extract was also reported by Srivastava (1984a). 
Later, Mohammad and Woodwart (1986), in a series of experiments 
with aqueous garlic extract, identified the potent inhibitor of platelet 
aggregation as allicin. Lawson, Ransom and Hughes (1992) found that in 
platelet-rich plasma most of the anti-aggregatory activity of garlic clove 
homogenates was due to adenosine. However, in full blood all of the anti-
aggregatory activity was due to allicin and other thiosulfinates. The authors 
also tested several commercially available garlic preparations and concluded 
that the best garlic powder tablets were equally active as clove homogenates, 
while steam-distilled oil and oil-macerates possessed a significantly lower 
activity against platelet aggregation (by 35% and 12%, respectively). A 
reduced inhibitory effect of boiled garlic extract on platelet aggregation was 
also reported by Ali, Bordia and Mustafa (1999). 
Another garlic organosulfur compound derived from garlic through 
the conversion of alliin into allicin is ajoene (4,5,9-trithiadodeca-1,6,11-
triene-9-oxide), which was also shown to possess antiplatelet activity. Ajoene 
strongly inhibited the fibrinogen-induced platelet aggregation in a dose-
dependent manner, it had however no effect on ADP or epinephrine 
membrane receptors, even though it also inhibited ADP-, epinephrine-, and 
collagen-induced platelet aggregation (Apitz-Castro et al., 1986a; Srivastava 
and Tyagi, 1993). Ajoene most likely interacted directly with the fibrinogen 
receptor (Apitz-Castro et al., 1986b). Furthermore, ajoene inhibited the 
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formation of thromboxane A2 and in higher concentrations it also inhibited 
the incorporation of arachidonic acid into platelet phospholipids (Srivastava 
and Tyagi, 1993). High concentrations of ajoene (50 µmol/L) or long periods 
of incubation of ajoene with platelets (10 minutes) led to a non-selective 
hyperphosphorylation of numerous proteins. Ajoene inhibited protein 
tyrosine phosphatase activity in platelets (Villar, Alvariño and Flores, 1997). 
The antiplatelet action of ajoene was synergistically increased with the 
presence of other physiologically and pharmacologically active antiplatelet 
agents, such as prostacyclin, indomethacine, and dipyridamol (Apitz-Castro 
et al., 1986a). 
The anti-aggregatory effect of aged garlic extract is probably mediated 
either by the suppression of the calcium ions influx by chelating calcium with 
platelet cytosol or by altering other intracellular second messengers within 
the platelets (Allison, Lowe and Rahman, 2006). In their latter study, Allison, 
Lowe and Rahman (2012) suggested that aged garlic extract inhibits platelet 
aggregation via inhibition of the GPIIb/IIIa receptor and an increase in cAMP 
and confirmed these findings four years later (Rahman, Lowe and Smith, 
2016) with a new observation of a platelet shape change influenced by the 
aged garlic extract. Morihara and Hino (2017) observed a changed functional 
property of platelets exposed to aged garlic extract (namely a significantly 
increased amount of both the extracellular ATP, and the extra- and 
intracellular thromboxane B2).  
The effect of garlic on erythrocytes has been explored to a lesser 
extent. Harauma and Moriguchi (2006) noted that aged garlic extract 
treatment in spontaneously hypertensive rats for 10 weeks led to a decrease 
in the count of erythrocytes. Budoff (2006) also reported a lowered value of 
hematocrit in volunteers treated with aged garlic extract for one year. On the 
other hand, Moriguchi, Takasugi and Itakura (2001) added various 
concentrations of aged garlic extract to a rat erythrocyte suspension 
pretreated with tert-butyl hydroperoxide in order to induce lipid 
peroxidation. Aged garlic extract significantly lowered the increase in 
hemolysis caused by lipid peroxidation. Further, the oxidized erythrocytes 
became more rigid and lost their flexibility and deformability when exposed 
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to lipid peroxidation. The addition of aged garlic extract exhibited a dose-
dependent significant prevention of the erythrocyte deformability loss. 
Moreover, aged garlic extract led to membrane stabilization of erythrocytes 
(Moriguchi, Takasugi and Itakura, 2001). 
Kempaiah and Srinivasan (2002) also noted the positive effect of the 
addition of garlic powder (2.0%) to the cholesterol-enriched chow in rats. The 
erythrocytes of rats fed a high-cholesterol diet were markedly more 
osmotically fragile when compared to the control, while garlic appeared to 
correct this increased fragility of the erythrocytes. The structural changes in 
the membrane of erythrocytes in garlic powder-treated elderly volunteers 
(aged 70 years and over) included significantly increased mean membrane 
concentrations of phospholipids and cholesterol (an increase by 5.7% and 
6.1%, respectively; Brosche, Platt and Dorner, 1990). 
There are numerous investigations focused on the beneficial effect of 
garlic on endothelial dysfunction. For example, the effect of garlic extract on 
isolated rat pulmonary arteries was explored by Kim-Park and Ku (2000). 
Garlic extract at a concentration range 3 – 5 µg/mL produced a dose-
dependent and nitric oxide-dependent vasorelaxation. In a hypoxic 
environment, the maximum garlic vasorelaxation was reduced but recovered 
after reoxygenation. Garlic further significantly inhibited endothelin-1-
induced contractions of pulmonary artery in a dose-dependent manner (Kim-
Park and Ku, 2000). Sun and Ku (2006) observed that only raw garlic with the 
active metabolite allicin elicited a potent, dose-dependent vasodilatation of 
rat isolated coronary arteries. Boiled garlic or aged garlic did not exhibit 
vasodilatatory activity, indicating that allicin is responsible for the 
vasodilatatory effect of raw garlic. 
Baluchnejadmojarad et al. (2003) investigated the effect of 
intraperitoneally administered garlic aqueous extract in streptozocin-induced 
diabetic rats for 8 weeks. Streptozocin markedly increased contractile 
responses to phenylephrine and impaired endothelium-dependent 
relaxations to acetylcholine in aortic rings. Garlic treatment led to a 
remarkable improvement of the impaired endothelium-dependent 
relaxations and decreased the enhanced contractile response to 
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phenylephrine in the isolated rat aortic rings. The development of abnormal 
contractility was prevented with garlic treatment most likely through both 
endothelium-dependent and endothelium-independent mechanisms 
(Baluchnejadmorad and Roghani, 2003). A significant protection against high 
cholesterol diet-induced deterioration of aortic endothelium-dependent 
vasorelaxation to acetylcholine and an elevation in the intima/media ratio 
was also provided by the administration of pure allicin (10 mg/kg) for 
4 weeks to rabbits (El-Sheakh et al., 2016). 
Contrary to the findings of Sun and Ku (2006), the beneficial effect of 
aged garlic extract on endothelium function was reported by Williams et al. 
(2005). They treated 15 volunteers with coronary artery disease with aged 
garlic extract for 2 weeks. Even this short-term garlic treatment led to a 
significantly increased flow-mediated endothelium-dependent dilatation of 
brachial artery (by 44%). Weiss et al. (2006) treated healthy volunteers with 
aged garlic extract during acute hyperhomocysteinemia induced with oral 
administration of methionine. The pretreatment with aged garlic extract for 
6 weeks significantly diminished the adverse effects of an acute 
hyperhomocysteinemia (microvascular endothelial dysfunction indicated 
namely by a significant decrease in flow-mediated vasodilation of the brachial 
artery and a decrease in acetylcholine-stimulated skin perfusion). 
Furthermore, aged garlic extract was reported to restore nitric oxide 
bioavailability in human endothelial cells, as observed by Weiss et al. (2013) 
in their in vitro study with human endothelial EA.hy 926 cells incubated with 
several different agents (hypoxanthine, aminopterin, thymidine, and 
methionine) in order to induce hyperhomocysteinemia leading to endothelial 
dysfunction. Aged garlic extract prevented the decline of nitric oxide output, 
increased cellular thiol antioxidant (cysteine and glutathione), and averted 
the oxidation of tetrahydrobiopterin. 
Endothelial dysfunction is a risk factor for the development of 
atherosclerosis. Treatment with garlic may alleviate some of the negative 
changes leading to atherosclerosis. For example, Brändle et al. (1997) carried 
out an interesting investigation on the long-term effects of a dietary 
application of garlic (dried powder, 0.5% in weight of standard laboratory 
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chow) on the lifespan of spontaneously hypertensive rats. The dietary 
intervention started at the age of three weeks. Garlic treatment prolonged the 
life span significantly (453 days in garlic group vs. 434 days in control group). 
Moreover, neither signs of stroke nor arteriosclerotic plaques were detected 
in the rats treated with garlic.  
The reduction in the progression of plaque formation was also 
reported by Budoff (2006) who treated volunteers on a standard statin and 
aspirin therapy with aged garlic extract for one year. In patients with the 
placebo (and aspirin and statin therapy), the arterial calcification progressed 
by 22.2% per year, while the addition of aged garlic extract reduced this 
progression to 7.5% per year. Szulińska et al. (2018) observed a reduced 
arterial stiffness index and improvement in endothelial function markers in 
obese patients treated with 400 mg of garlic extract for 12 weeks. 
 
2.1.4.4. ANTIHYPERTENSIVE EFFECT OF GARLIC 
 
 The antihypertensive effect of garlic has been studied by scientists for 
several decades and plentiful works focused on this topic were published. 
Among these studies on both animal models and human volunteers were 
submitted works with strong evidence for the beneficial action of garlic on 
blood pressure, as well as works where garlic offered no significant 
antihypertensive effect. Taking into account the quantity of the available 
works dealing with the blood pressure-lowering properties of garlic, it was 
impossible to mention all the meta-analyses or even primary trials conducted 
in this field of research, therefore only a selection of these studies will be 
presented in the following text. 
The question of the duration of the onset of garlic hypotensive action 
was solved by several authors. In an animal model (spontaneously 
hypertensive rats), Foushee, Ruffin and Banerjee (1982) evaluated three 
different doses of garlic extract (0.1, 0.25, and 0.5 mL/kg) administered 
orally. A marked decrease in the systolic blood pressure occurred in each case 
within 30 minutes after the garlic ingestion. The lower doses of garlic extract 
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were able to sustain blood pressure within normal range for a very short time 
period (under two hours) but the dose of 0.5 mL/kg was efficient enough for 
24 hours. Similar results were obtained in the rat two-kidney-one-clip 
Goldblatt model where rats were administered with 0.5 mL of garlic aqueous 
extract. A single dose exerted the maximum hypotensive effect 2 – 6 hours 
after administration and its residual effect continued for up to 24 hours (Al-
Qattan, Alnaqeeb and Ali, 1999).  
McMahon and Vargas (1993) administered a garlic preparation, 
standardized to contain 1.3% allicin, at a large dose of 2400 mg to human 
patients with rather severe hypertension (diastolic blood pressure ≥115 mm 
Hg). The peak effect of garlic was about 5 hours after the administration of 
the preparation with a significant decrease in blood pressure persisting for 
5 – 14 hours. 
Oral administration of a pure aged garlic extract constituent,  
S-1-propenyl cysteine, to spontaneously hypertensive rats resulted in a 
significantly decreased systolic blood pressure (by 10%), exerting the 
maximal effect 3 hours after administration. The values of blood pressure 
returned to the original levels within 24 hours after administration. The 
hypotensive effect of S-1-propenyl cysteine was dose-dependent, and the dose 
of 6.5 mg/kg was evaluated as the most effective (Ushijima et al., 2018). 
Several works focused on the comparison of efficacy of garlic 
treatment with the standardly used antihypertensive drugs, especially the 
blockers of the angiotensin converting enzyme (ACE inhibitors). When 
compared to cilazapril, the hypotensive effect of garlic in both unilaterally 
clipped and unclipped rats was significant (decrease from 196 mm Hg to 
169 mm Hg) but lower than that of cilazapril (decrease to 137 mm Hg;  
Al-Qattan et al., 2001). A similar trend of blood pressure reduction in 
fructose-induced hypertensive rats administered with either allicin or 
enalapril was also observed by Elkayam et al. (2001). In both cases the 
hypotensive effect was statistically significant but treatment with allicin 
(reduction by 11 mm Hg) resulted in a smaller decrease in blood pressure 
than treatment with enalapril (reduction by 30 mm Hg).  
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However, when allylmercaptocaptopril (a conjugate of allicin and 
captopril (53.5 mg/kg) and pure captopril at equimolar dose (40 mg/kg) 
were administered to spontaneously hypertensive, obese rats, the 
hypotensive effect of the conjugate was significantly pronounced when 
compared to pure captopril (reduction by 55 mm Hg and 37 mm Hg, 
respectively; Ernsberger et al., 2007). The co-administration of pure allicin 
and captopril (4:1 ratio) for 3 weeks was also more effective in reducing 
systolic blood pressure in rats than treatment with allicin or captopril only 
(Asdaq and Inamar, 2010). 
As to antihypertensive drugs other than ACE inhibitors, the diuretic 
agent hydrochlorothiazide (10 mg/kg) added with garlic homogenate at a 
dose of 250 mg/kg administered to hypertensive rats for 3 weeks exhibited 
synergistic hypotensive properties against fructose-induced hypertension 
(Asdaq and Inamar, 2011). 
When compared to atenolol (a beta-blocker), garlic tablets at doses 
900, 1200, and 1500 mg were more effective in both systolic and diastolic 
blood pressure reduction than atenolol at doses 50 or 100 mg in patients with 
essential hypertension during a treatment for 24 weeks (Ashraf et al., 2013). 
Silagy and Neil (1994) submitted a meta-analysis of the effect of 
garlic on blood pressure. They included only randomized controlled trials of 
garlic preparations with at least 4 weeks-duration on volunteers with mild 
hypertension. Out of the seven trials meeting the requirements, three showed 
a significant reduction in systolic blood pressure and four in diastolic blood 
pressure. A more comprehensive meta-analysis on the hypotensive effect of 
garlic was performed by Ried et al. (2008) who included 11 randomized 
controlled trials using various garlic preparations. The results (for systolic 
blood pressure a general mean decrease of 4.6 mm Hg, in the hypertensive 
subgroup the mean decrease was 8.4 mm Hg) suggest that garlic preparations 
are superior to placebo in reducing blood pressure in individuals with 
hypertension.  
A similar conclusion of another meta-analysis of 10 trials was offered 
by Reinhart et al. (2008) who also included German language-written studies. 
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In patients with elevated blood pressure, the reduction of systolic and 
diastolic blood pressure was significant (reduction by 16.3 mm Hg and 
9.3 mm Hg, respectively), however, garlic failed to exert any hypotensive 
action in patients without elevated blood pressure.  
A deeply critical review regarding the quality of the existing trials 
focusing on the hypotensive effect of garlic was presented by Simons, 
Wollersheim and Thien (2009), who stated that previous meta-analyses have 
been based on trials with inadequate study designs, methodological 
deficiencies, and with too little information about the blood pressure 
measurements. 
Stabler et al. (2012) provided another analysis of randomized, 
placebo-controlled trials of garlic preparations. The mean reduction of 
systolic and diastolic blood pressure was 10 – 12 mm Hg and 6 – 9 mm Hg, 
respectively. And similarly, another meta-analysis on the hypotensive effect 
of garlic that included nine trials with 482 individuals reported a mean 
decrease of systolic blood pressure by 9.1 mm Hg and of diastolic blood 
pressure by 3.8 mm Hg with high heterogenity (Rohner et al., 2015).  
Xiong et al. (2015a) in their meta-analysis offered even smaller 
changes in the mean values of systolic blood pressure (reduction by 
6.7 mm Hg), although the mean decrease of diastolic blood pressure was 
higher (by 4.8 mm Hg). Ried (2016) in his updated meta-analysis on the garlic 
hypotensive effect included 20 trials with 970 participants and concluded a 
more significant blood pressure reduction in the hypertensive subgroup (a 
reduction of systolic blood pressure by 8.7 mm Hg and of diastolic blood 
pressure by 6.1 mm Hg). 
However, all of the abovementioned works provided mean values of 
blood pressure reduction that fall within the known variability in blood 
pressure measurements, and thus this makes it difficult to determine the true 
impact of garlic on blood pressure lowering. 
The antihypertensive mechanism of garlic has yet to be elucidated to 
a full extent. Several actions of garlic or its individual active compounds were 
proposed. Pedraza-Chaverrí et al. (1998) tested the effect of L-NAME (a 
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blocker of the nitric oxide synthase) on garlic-fed rats. While in control rats 
the administration of L-NAME induced hypertension, the garlic-fed rats had 
approximately the baseline values of nitric oxide stable end products (nitrite 
and nitrate, measured in urinary excretion) indicating that garlic activated 
nitric oxide synthase (Pedrraza-Chaverrí et al., 1998). It was later shown that 
garlic-derived polysulfides stimulate the production of the vascular 
gasotransmitter hydrogen sulfide (H2S) and enhance the regulation of 
endothelial nitric oxide, which subsequently induces smooth muscle 
relaxation, vasodilatation, and reduction of blood pressure (Ried and Falker, 
2014). 
Mohamadi et al. (2000) also suggested the involvement of the nitric 
oxide system in the hypotensive effect of garlic, although based on their 
experiment with losartan, the renin-angiotensin system (RAS) is also 
involved. This hypothesis was further supported by several observations. 
Garlic has been shown to significantly down-regulate angiotensin II 
AT1 receptors to levels comparable with those of control animals in 
streptozocin-induced diabetic rats (Mansour et al., 2013). The involvement of 
RAS in the hypotensive effect of garlic was also suggested by Oboh et al. 
(2019) who reported the inhibition of angiotensin-converting enzyme by 
garlic aqueous extract (IC50 = 0.59 mg/mL, the effect was significantly higher 
than that of purple or white onion). Similarly, appreciable angiotensin 
converting enzyme-inhibitory activity of garlic protein and its pepsin and 
trypsin hydrolysates were observed by Gao et al. (2020). 
Furthermore, fresh garlic extract (final concentration 1%) and pure 
allicin decreased transmembrane currents of human epithelial sodium 
channels expressed in Xenopus oocytes in a dose-dependent manner within 
10 minutes. These sodium channels represent a key factor in the 
transepithelial movement of sodium and consequently salt and water 
homeostasis in various organs. Dysregulated activity of these channels is 
associated with several diseases including hypertension. Contrary to allicin, 
the thiol non-reactive compounds alliin and diallyl sulfides had no effect on 
the epithelial sodium channels (Krumm et al., 2012). 
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A metabolomic insight on the hypotensive mechanism of garlic was 
presented by Matsutomo et al. (2017). Treatment of spontaneously 
hypertensive rats with aged garlic extract led to changes in 30 endogenous 
metabolites and 7 of these metabolites were changed by S-1-propenyl 
cysteine, one of the major aged garlic extract constituents. The authors 
suggested that S-1-propenyl cysteine could exert its antihypertensive effect by 
affecting the metabolism of glycerophospholipids, threonine, tryptophan, 
glycine, and/or serine (Matsutomo et al., 2017). 
 
2.1.4.5. EFFECT OF GARLIC ON PLASMATIC LIPID PROFILE 
 
The beneficial influence of garlic on the lipid profile is still the focus of 
detailed investigations because the existing evidence is a little controversial. 
However, without any doubts the antioxidant properties of garlic offer a 
strong protection of LDL cholesterol against oxidation (see Ch. 2.1.4.1.). 
The lipid-lowering effect of garlic has been reported by many 
authors in both animal models as well as human volunteers treated with 
different garlic preparations. In animal models, for example, Ali et al. (2000) 
administered garlic powder containing 1.3% alliin (equivalent to 0.6% allicin) 
for 6 weeks to high cholesterol diet-fed rats. Significant reductions of serum 
cholesterol and triglyceride levels were observed at the end of the trial. A 
significant decrease in serum triglyceride level was also reported in high-
fructose diet-fed rats obtaining synthetic allicin for 2 weeks (Elkayam et al., 
2001). And similar results were reported by Elkayam et al. (2013) in their 
study with purified natural allicin administered at a dose of 80 mg/kg to rats 
for 6 weeks – the triglyceride levels were significantly decreased, while allicin 
had no effect on cholesterol. 
Ernsberger et al. (2007) investigated if the conjugation of allicin to 
captopril (an angiotensin-converting enzyme inhibitor) may offer additional 
therapeutic actions in metabolic disease. Both captopril (40 mg/kg) and the 
conjugate allylmercaptocaptopril (53.5 mg/kg) administered to 
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spontaneously hypertensive, obese rats for 8 weeks were able to decrease the 
triglyceride values. 
One of the first published investigations on the effect of garlic on blood 
lipids in humans was by Bordia et al. (1975) who treated healthy subjects 
with freshly extracted garlic juice of 50 g of garlic or ether-extracted essential 
oils after feeding them with 100 g of butter. Both garlic and its essential oil 
(mainly containing allylpropyl disulfide and diallyl disulfide) had a significant 
protective action against the fat-induced increases in serum cholesterol.  
Auer et al. (1990) used garlic powder administered to volunteers for 
12 weeks. The serum cholesterol and triglyceride levels were significantly 
lowered more rapid – only after 8 weeks of treatment. The reduction of 
triglycerides (by 15.9%) was also observed by Brosche, Platt and Dorner 
(1990) who treated 40 volunteers aged 70 years and over with 600 mg of 
garlic powder for 12 weeks. On the other hand, primigravidas with high risk 
of preeclampsia administered with 800 mg garlic tablets during the third 
trimester of pregnancy showed a significantly decreased total cholesterol, 
while garlic had no effect on the triglyceride level (Ziaei et al., 2001). 
Similarly, Karagodin, Sobenin and Orekhov (2013) observed a decrease in 
LDL cholesterol (by 11.8%) and an increase in HDL cholesterol (by 11.5%) in 
mildly hypertensive men treated with garlic for 12 weeks. 
Raw crushed garlic at daily dose of 100 mg/kg administered to 
40 metabolic syndrome patients for 4 weeks was effective enough to 
significantly decrease the triglyceride levels and to significantly increase 
serum HDL cholesterol (Choudhary, Jani and Sharma, 2018). 
Aged garlic extract also seems to have a positive influence on blood 
lipids, although higher doses are probably required to achieve a sufficient 
lipid-lowering performance. Steiner et al. (1996) administered aged garlic 
extract at a daily dose of 7.2 g to moderately hypercholesterolemic men for 
24 weeks. At the end of the trial, total serum cholesterol was reduced by 7% 
and LDL cholesterol was reduced by 4%. A significant increase in 
HDL cholesterol after 12 weeks of treatment with a daily dose of 6 g of aged 
garlic extract with healthy volunteers was reported by Jung et al. (2014). A 
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markedly lower dose of aged garlic extract (only 1.2 g containing 1.2 mg of  
S-allyl cysteine) was used by Ried, Travica and Sali (2016) in volunteers for 
12 weeks. Although the end-trial values were not statistically significant, 
trends in beneficial effects of aged garlic on the total cholesterol, 
LDL cholesterol, and apolipoproteins were still observed. 
 Contrary to the abovementioned works, several authors observed a 
lack of efficacy of garlic on the blood lipid parameters. Luley et al. (1986) 
tested two different doses of dried garlic (198 mg and 450 mg, three times 
daily) in hyperlipoproteinemic patients for 6 weeks. Neither dosage 
influenced total cholesterol, HDL cholesterol, LDL cholesterol, or triglyceride 
levels.  
McCrindle, Helden and Conner (1998) evaluated the effect of 900 mg 
garlic extract in pediatric hypercholesterolemic patients (aged 8 to 18 years) 
for 8 weeks. No significant relative attributable effect on total cholesterol or 
LDL cholesterol was observed at the end of the trial. Superko and Krauss 
(2000) used the same dose of garlic extract (900 mg) in moderately 
hypercholesterolemic patients for 12 weeks with again no significant change 
in total, LDL, or HDL cholesterol. Overweight and smoking (more than 
10 cigarettes/day) subjects treated with 2.1 g garlic powder for 12 weeks did 
not also exhibit any significant changes in the evaluated blood lipid 
parameters (total cholesterol, LDL cholesterol, and triglyceride levels; van 
Doorn et al., 2006).  
Even standardized garlic extract (1.12% allicin or 5.6 mg/tablet) 
administered to hypercholesterolemic volunteers for 12 weeks exhibited no 
significant changes in total, HDL or LDL cholesterol, or triglyceride levels 
(Satitvipawee et al., 2003).  
This discrepancy in results of various works may be the consequence 
of a different study design. A comprehensive meta-analysis on the effect of 
garlic on cholesterol was presented by Ried (2016) who included randomized 
controlled trials published between the years 1955 and 2013. The resulting 
total amount of 39 primary trials that involved 2300 adults treated for a 
minimum of 2 weeks was then analyzed. Garlic was suggested to be effective 
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in reducing total and LDL cholesterol by 10% if taken for more than 8 weeks 
by volunteers with slightly elevated concentrations. Thus, garlic may not offer 
any benefit regarding the blood lipid spectrum in volunteers with more 
pronounced hypercholesterolemia and/or treated for a too short time period.  
Interestingly, Zhang et al. (2001) observed a remarkable difference in 
the effect of garlic oil between men and women for HDL cholesterol and total 
cholesterol values. The treatment with cyclodextrin-bound garlic oil for 
11 weeks was more favorable for women than for men. It is therefore 
possible that the effect of garlic may also be dependent on gender.  
The mechanism of the lipid-lowering effect of garlic is multifactorial. 
S-allyl cysteine, S-ethyl cysteine and S-propyl cysteine, which are abundantly 
present in aged garlic extract, were reported to decrease the incorporation of 
acetate into triglycerides in cultured rat hepatocytes. The inhibition was 
concentration-dependent, with S-allyl cysteine being the most effective 
compound (inhibition by 81%). Both S-allyl cysteine and S-propyl cysteine 
were also effective in decreasing the activity of fatty acid synthase in the rat 
hepatocytes culture (the activity was lowered by 32% and 27%, respectively; 
Liu and Yeh, 2001).  
Nam et al. (2017) also tried to elucidate the mechanism of aged garlic 
extract on lipid metabolism. Treatment of mature 3T3-L1 adipocytes with 
aged garlic extract suppressed lipogenesis and induced lipolysis in a dose-
dependent manner. At concentrations 2.5 and 5 mg/mL aged garlic extract 
significantly reduced protein expression of PPARγ. Similarly, Baek et al. 
(2019) reported a reduced expression of adipogenic genes (including PPARγ, 
Adipsin, and Adipoq) and inhibition of adipogenesis of 3T3-L1 preadipocyte 
cell culture treated with a β-carboline alkaloid isolated from garlic methanolic 
extract (namely (1R,3S)-1-methyl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic 
acid).  
As to inhibition of cholesterol synthesis, Yeh and Liu (2001) 
characterized the inhibitory potency of individual water-soluble and lipid-
soluble compounds in garlic. While the lipid-soluble compounds exhibited at 
acceptable concentrations only a slight inhibitory effect on cholesterol 
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synthesis (by 10 – 15%), among the water-soluble organosulfur compounds 
especially S-propyl cysteine and γ-glutamyl-S-allyl cysteine offered a 
satisfactory inhibition activity of the cholesterol synthesis (by 40 – 60% and 
20 – 35%, respectively). This inhibition was due to deactivation of 3-hydroxy-
3-methylglutaryl coenzyme A reductase via enhanced phosphorylation but 
not via changing the levels of mRNA or the quantity of the enzyme (Liu and 
Yeh, 2002). 
 
2.1.5. SAFETY PROFILE OF GARLIC PREPARATIONS 
 
 Garlic has been used as a spice and in traditional medicine for 
thousands of years and is therefore considered safe. The medicinal use of 
garlic has, however, its limitations. For example, EMA in the herbal 
monograph on Allium sativum L., bulbus stated that use of garlic in the 
treatment of a cold in children under 12 years of age has not been established 
due to the lack of adequate data. For the treatment of atherosclerosis, the age 
limit was set even higher; garlic is not to be used in children and adolescents 
under 18 years of age (EMA/HPMC/7685/2013). 
 A comprehensive review on garlic's adverse effects and drug 
interactions in humans was presented by Borrelli, Capasso and Izzo (2007). 
The well-documented adverse effects of garlic treatment were garlic odor, 
allergic reactions, photoallergy, cutaneous manifestations, coagulation 
alterations, and gastrointestinal adverse effects.  
The allergenic potential of garlic is well recognized and the allergens 
have been identified as diallyl disulfide (which is considered to be the 
primary allergen), allylpropyl sulfide, and allicin (the latter may be an 
irritant). Contact dermatitis is the most common allergic reaction associated 
with garlic use. On the other hand, photoallergy occurs rarely, again 
originating from the organosulfur compound diallyl disulfide (Borreli, 
Capasso and Izzo, 2007 and references therein). 
 Studies on the possible impact of garlic on cytochrome P450 metabolic 
enzymes, and thus the potential of pharmacokinetic interactions indicate 
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consistently that neither single nor repeated administration of various garlic 
formulations up to 4 weeks may have the potential to exert notable 
alterations (inhibition or induction) of CYP1A2, CYP2D6, or CYP3A4 activities 
in humans, which are important metabolic pathways for many drugs likely to 
be coadministered with garlic supplements (Hermann and von Richter, 2012). 
On the other hand, garlic extract has been shown in human studies to 
decrease concentrations of drugs that are transported by the P-glycoprotein. 
These drugs (e.g. digoxin, quinidine, rosuvastatin, and verapamil) should 
therefore not be combined with garlic supplements (Asher et al., 2017). 
 Due to the possible clinically significant pharmacokinetic interaction 
of garlic with some HIV protease inhibitors, EMA listed saquinavir/ritonavir 
therapy under the contraindications section for garlic use. The study on 
which this statement was based on was, however, criticized for its design and 
that it could be most conceivable that the study results merely mirrored 
saquinavir-mediated induction processes of its own metabolism and 
disposition rather than indicating a relevant garlic-mediated drug interaction 
(Herrman and von Richter, 2012; EMA/HPMC/7685/2013). 
 As to pharmacodynamic interactions of garlic, synergistic effect of 
garlic concomitantly administered with hydrochlorothiazide, diltiazem, and 
nifedipin was reported (Martín et al., 1997; Asdaq and Inamar, 2011).  
The greatest safety concern is about the influence of garlic on blood 
coagulation, especially the possible pronounced effect of garlic administered 
concomitantly with other blood thinning drugs because they may increase 
bleeding times. Seeing as the consequences could be severe, EMA 
recommends that garlic preparations should be used with caution in patients 
taking oral anticoagulation therapy and/or anti-platelet therapy. Garlic 
consumption should be avoided 7 days before surgery because of the post-
operative bleeding risk (EMA/HPMC/7685/2013). However, Ge, Zhang and 
Zuo (2014) in their review, focused on updates on the clinically evidenced 
herb-warfarin interactions, concluded that although the interaction between 
warfarin and garlic is possible, serious interactions seem unlikely to happen. 
Aged garlic extract also seems to be safe for patients on warfarin therapy 
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(Macan et al., 2006). In general, higher precaution in garlic use is 
recommended for older adults on warfarin therapy (Agbabiaka et al., 2017). 
 
2.2. HAWTHORN – CRATAEGUS SPP. FAM. ROSACEAE 
 
2.2.1. CHARACTERIZATION OF THE CRATAEGUS GENUS – A PHARMACOGNOSTIC CONTEXT 
 
Crataegus comprises a complex group of trees and shrubs. Shrubby 
hawthorn genera are mainly up to 3 m of height, while hawhorn tree species 
can grow up to 12 m. There are approximately 280 species in the genus 
around the world. Hawthorn is native to the Northern temperate zones, 
mostly between the latitudes of 30° and 50° N (North America, Europe, Asia) 
and various introducted hawthorn species can be found in temperate South 
America (including equatorial Andes), south Africa, New Zealand, and 
Australia. The plants are heliotropes varying sometimes to mesophylls. For 
hawthorns, the soil water regime is more important then the soil type. 
Hawthorns are generally considered as aggressive settlers, especially in their 
non-native environment (Kumar et al., 2012; Phipps, 2020). 
Short twigs and branches up to 2.5 mm in diameter in the beginning of 
flowering or leaves in full bloom are collected for medicinal use (Crataegi 
folii cum flore). The European Pharmacopoeia requires a minimum content 
of 1.5% of total flavonoids expressed as hyperoside, calculated with the 
reference to the dried drug. Chinese and European Pharmacopoeias both also 
recognize hawthorn fruits – Crataegi fructus. In Europe, plant material is 
collected from the hawthorn species Crataegus monogyna Jacq. (common 
hawthorn; Fig. 2.3.) and C. laevigata Poir. in Lam. (midland hawthorn) or their 
hybrids, less often from other Crataegus species. However, all the white-
flowering hawthorn species are authorized for plant material collecting. In 
China, the species C. pinnatifida Bunge (Chinese hawthorn; Fig 2.3.) is 
prevalently used as a source of hawthorn plant material (Tomko et al., 1989; 




The European Pharmacopoeia further includes two monographs on 
hawthorn extracts (Crataegi folii cum flore extractum fluidum 
quantificatum and Crataegi folii cum flore extractum siccum). Extraction 
solvents permitted in hawthorn plant material processing are methanol, 
ethanol (both in various w/w ratio), water, or even sweet wine 
(EMA/HMPC/159075/2014; EMA/HPMC/159076/2014; European 
Pharmacopoeia 10.0). 
Fig. 2.3. Crataegus monogyna Jacq. Upper left – flowers, upper right – fruits. Crataegus 
pinnatifida Bunge. Down left – flowers, down right – fruits. From mailordertrees.co.uk, etsy.com,  
greenleafnurseries.co.nz, and pinterest.co.uk. 
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Lately, alternative methods for obtaining biologically active 
compounds from hawthorn plant material have also been suggested. For 
example, Hu et al. (2019) established a simple, rapid, and sensitive method 
for extraction of phenolic compounds from hawthorn leaves using a 
microwave-assisted extraction. In order to avoid the use of organic solvents, 
aqueous solutions of solid reagents (sodium carbonate and sodium borate) 
were used. The optimal extraction procedure conditions included an 
extraction time of 10 minutes, a temperature set to 50 °C, and the pH adjusted 
to a value of 7. 
 
2.2.2. PHYTOCHEMISTRY OF HAWTHORN 
 
Nabavi et al. (2015) in their review on phytochemistry of 
C. monogyna Jacq. noted that the most common polyphenolic compounds 
present in this species are flavonoids, chlorogenic acids, and triterpenes. 
Among them, the monomeric flavan-3-ol compound (-)-epicatechin is 
abundantly present in the plant. The most important hawthorn flavonoids 
are represented by quercetin and apigenin glycosides: hyperoside (quercetin-
3-O-glucoside), rutin (quercetin-3-O-rutinoside) and vitexin (apigenin-8-C-
glucoside). These three flavonoids are depicted in Fig. 2.4. Vitexin was found 
to be the dominant compound in C. monogyna Jacq. leaves, while hyperoside 
was reported as one of the major components in the flowers, although other 
glycosides, such as rutin and spiraeoside, were also present. Cyanidin- 
3-O-galactoside (anthocyanin) was identified as the flower pigment in 
C. monogyna Jacq. (Raudonis et al., 2009; Nabavi et al., 2015 and references 
therein). 
The triterpenic fraction isolated from aerial parts of hawthorn plants 
(including twigs, stems, and leaves) is represented by tetracyclic triterpenic 
alcohols butyrospermol and cycloartenol as well as by pentacyclic triterpenic 
acids arising from triterpenic alcohols by oxidation reactions. The most 
common hawthorn triterpenic acids are crataegolic (also known as maslinic), 
oleanic, and ursolic acid (Tomko et al., 1989; García et al., 1997; Froehlicher 




The content and composition of phenolic compounds in hawthorn is 
influenced by a number of factors, such as genotype, plant organ, seasonal 
and geographical variation. Crataegus species, subspecies, and even varieties 
differ in their content of phenolic compounds, as observed by several authors. 
For example, Bahri-Sahloul et al. (2009) compared the total phenols content 
Fig. 2.4. Some of the Crataegus spp. active compounds. Upper left – hyperoside, upper right – 
vitexin, middle – rutin, down  – crategolic acid. Courtesy of doc. Macáková. 
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of two C. azarolus L. varietes. The variety producing yellow fruits (C. azarolus 
var. aronia (Willd.) Batt.) was richer in phenolic compounds than the variety 
with red fruits (C. azarolus var. eu-azarolus Maire), with the contents being 
16.4 mg of gallic acid/g of dry weight and 14.2 mg of gallic acid/g of dry 
weight, respectively. Belkhir et al. (2013) also noted that the yellow-fruited 
hawthorn species C. azarolus L. had significantly higher polyphenol content 
than the red-fruited species C. monogyna Jacq. Furthermore, while hyperoside 
was the main phenolic in yellow fruits, procyanidin B2 represented the major 
phenolic compound in red fruits.  
Calişkan et al. (2012) analyzed the total phenolic content of five 
European hawthorn species and reported the highest phenolic content in 
C. monogyna subsp. azarella (Griseb.) Franco (55.2 mg of gallic acid 
equivalent/g of dry weight) and the lowest phenolic content in C. aronia 
subsp. aronia (L.) Rouy & E. G. Camus (35.7 mg of gallic acid equivalent/g of 
dry weight). Varieties of Chinese hawthorn species C. pinnatifida Bunge also 
differed in the phenolic content. Out of the three evaluated varieties, the 
shanlihong variety exhibited elevated levels of total phenolic and flavonoids 
content, including free and bond phenolics (Wen et al., 2015). 
The impact of the plant organ on the hawthorn phenolic content was 
also noted in some papers. For example, floral buds had higher total phenol, 
proanthocyanidin, and flavonoid content than opened flowers (Bahri-Sahloul 
et al., 2009). Hawthorn flowers contained higher levels of hydroxycinnamic 
acids, vitexin derivates, and flavonols compared to fruits, while anthocyanins 
were present only in fruits (Issaadi et al., 2020). Unripe hawthorn fruits were 
richer in phenolic compounds than ripened or over-ripened fruits, which in 
turn contained more sugars and saturated fatty acids (Barros, Carvalho and 
Ferreira, 2011). Hawthorn leaves contained more phenolic compounds than 
fruits (Šavikin et al., 2017).  
Seasonal variation of phenolic compounds in hawthorn C. pinnatifida 
Bunge was investigated by Luo et al. (2016) who found a positive correlation 
of the phenolic content with daytime light and temperature. While leaves, 
roots, and twigs underwent more or less significant fluctuations in phenolic 
content during the year (May – October), the phenolic content in the fruits 
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seemed to be quite consistent during the growth season. Seasonal changes are 
probably not affecting all types of phenolic compounds, as noted by 
Hellenbrandt et al. (2015) for procyanidins in C. monogyna Jacq. Their 
distribution during seasonal growth showed more or less constant contents 
with strong accumulation in the flowers and fruits. 
Geographical variation of phenolics in the hawthorn species 
C. monogyna Jacq was also noted by Abuashwashi, Palomino and Gómez-
Serranillos (2016). Aerial parts of hawthorn were collected from different 
locations in central Spain. The total polyphenol content in these samples 
ranged between 117.7 and 204.3 mg of gallic acid equivalent/g of extract with 
predominant content of kaempferol (flavonoid) and ursolic acid (phenolic 
acid). Similarly, Alirezalu et al. (2020) noted a difference in the phenolic 
content in hawthorn samples collected from different locations in Iran. The 
variations in values of phenolic compounds content could be, however, 
caused due to sampling of various hawthorn species. 
 
2.2.3. MEDICINAL USE OF HAWTHORN 
 
Hawthorn is commonly used in traditional medicine, it was mentioned 
in Dioscorides De Materia Medica and the traditional Chinese medicine uses 
the fruit of the hawthorn species C. pinnatifida Bunge under the name Shan-
Zha. Hawthorn is considered to be a cardiotonic plant, it can also be used 
against sleep and stomach problems (Rigelski and Sweet, 2002; Nabavi et al., 
2015). According to EMA, hawthorn preparations are intended for use in two 
indications: (1) to relieve symptoms of temporary nervous cardiac complaints 
such as palpitations or perceived extra beat due to mild anxiety, or (2) for 
relief of mild symptoms of mental stress and aid to sleep. Hawthorn can be 
used in various preparation forms: comminuted or powdered herbal 
substance, dry extract, liquid extract, expressed juice from the fresh leaves 
and flowers, and tinctures (EMA/HMPC/159075/2014). 
Two commercially available hawthorn preparations are the most often 
mentioned in the reviewed literature: WS 1442 and LI 132.  
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WS 1442 is a Crataegus special extract. It is a dry extract from 
hawthorn leaves with flowers (4 – 6.6:1) extracted with 45% ethanol (w/w) 
and then adjusted for certain oligomeric procyanidins (OPC) content. The 
extract usually contains 18.75% of OPCs, the range of OPCs can, however, 
vary between 17.3 and 20.1%. This extract also contains other active 
compounds, e.g. several flavonoids (including hyperoside, vitexin-
rhamnoside, rutin, and vitexin), triterpenoids, and phenol carboxylic acids.  
LI 132 is a hawthorn extract prepared from the leaves and flowers 
(extraction solvent 70% methanol), and standardized to contain 2.2% of 
flavonoids. 
 
2.2.4. EFFECTS OF HAWTHORN ON SELECTED CARDIOVASCULAR CONDITIONS 
 
2.2.4.1. ANTIOXIDANT EFFECT OF HAWTHORN 
 
 The significant antioxidant activity of hawthorn has been known for a 
long time. Hawthorn is considered a plant with strong antioxidant properties. 
For example, Kiselova et al. (2006) compared the antioxidant activity of 
23 Bulgarian herbs with that of mate; hawthorn and some other species 
exhibited higher antioxidant activity. Similarly, Hela et al. (2013) evaluated 
the antioxidant potential of 110 selected Egyptian plants. Out of them, the 
hawthorn species C. sinaica Boiss. exerted the third highest antioxidant 
activity. Furthermore, Jeong, Tulasi and Koyyalamudi (2016) investigated the 
antioxidant properties of 11 Chinese fruits, with hawthorn C. pinnatifida 
Bunge exerting the highest antioxidant activity. Hendrich et al. (2020) also 
reported excellent antioxidant properties of hawthorn in comparison with 
three other plant species known for their high phenolic content. 
Several authors proposed that the antioxidant properties of hawthorn 
are mainly thanks to the content of phenolic compounds, especially the 
flavonoids. A strong positive correlation between the antioxidant capacity 
and hawthorn polyphenol, flavonoid, and/or phenolic content was reported, 
for example, by Kiselova et al. (2006), Luís, Domingues and Duarte (2011), 
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Abuashwashi, Palomino and Gómez-Serranillo (2016), and Issaadi et al. 
(2020). On the other hand, Masteiková et al. (2008) found no correlation 
between phenolics and antioxidant activity in hawthorn and motherwort 
tinctures, while Egea et al. (2010) and Aslam et al. (2017) reported only a 
weak correlation between antioxidant activity and the total phenolic and 
flavonoid contents. 
Various compounds contribute to the antioxidant activity of 
hawthorn, mostly of the phenolic type. Masteiková et al. (2008) reported that 
epicatechin and hyperoside were present in great amounts in hawthorn 
tincure and also significantly contributed to the antioxidant properties. On 
the other hand, procyanidine B2, which was present in lower amount than 
rutin and quercetin, exerted higher antiperoxynitrite activity than the two 
aforementioned compounds. Bernatoniene et al. (2008) also noticed that in 
hawthorn aqueous and ethanolic extracts, epicatechin and catechin 
contribute to radical-scavenging properties more than the other compounds. 
Raudonis et al. (2009) observed that vitexin rhamnoside, the dominant 
compound of C. monogyna Jacq. leaves, was not a significant radical 
scavenger. In both hawthorn leaves and flowers, chlorogenic acid seemed to 
be the most active antioxidant compound.  
In an ethyl acetate extract of another hawthorn species (C. azarolus L.), 
eight significant phenolic antioxidants were determined: chlorogenic acid, 
hyperoside, rutin, isoquercitrin, quercetin, procyanidin B2, (-)-epicatechin, 
and spiraeoside (Bahri-Sahloul et al., 2009). Most of the newly isolated 
pinnatifidins C (dihydrobenzofuran neolignans) and pinnatifidaninside A – D 
(neolignan glycosides) from hawthorn seeds as well as proanthocyanidins 
from the hawthorn fruit stone also exerted potent antioxidant activity (Huang 
et al., 2013; Huang et al., 2014; Chai et al., 2014). Benmalek et al. (2013) 
further noted that hawthorn flavonols presented high antioxidant activity 
when compared with anthocyanidins and standard antioxidants (ascorbic 
acid and quercetin). 
The antioxidant activity of hawthorn is influenced by a variety of 
factors that have impact on the content of antioxidant compounds and the 
resulting antioxidant activity. Two of these factors are of great importance: 
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the extraction solvent and plant material used for the preparation of the 
extract. Bernatoniene et al. (2008) reported that ethanolic hawthorn fruit 
extract contained threefold more phenolic compounds than aqueous extract, 
with the antioxidant activity being 2.3 times higher. Similar results were 
obtained by Shao et al. (2016) who reported that the total phenols content in 
ethanolic hawthorn fruit extract was 3.9 times higher than that in aqueous 
extract and the ethanolic extract exerted stronger antioxidant activity.  
The antioxidant activity of two hawthorn fruit extracts was also 
evaluated by Ebrahimzadeh and Bahramian (2009) who observed a higher 
antioxidant activity in aqueous rather than methanol extract. The 
determination of antioxidant activity of aqueous, methanolic, and ethyl 
acetate extracts from hawthorn leaves with flowers, fruit peel, and seeds 
revealed that the strongest antioxidant properties were exhibited by the ethyl 
acetate extract (approximately threefold higher than that of aqueous extract; 
Öztürk and Tunçel, 2011). Similarly, the ethyl acetate hawthorn extract was 
evaluated as being the most antioxidant active form by Wang et al. (2018). 
Plant material is another crucial factor influencing the antioxidant 
properties of hawthorn extracts although the studies are not completely 
consistent in their findings. Barros, Carvalho and Ferreira (2011) performed a 
complete chemical and bioactive characterization of flower buds, flowers, 
unripe, ripened, and over-ripened hawthorn fruits. Their results suggested 
that unripe fruits have the highest phenolic levels and the most promising 
antioxidant properties (better than Trolox). Similarly, Keser et al. (2014) 
found the highest antioxidant activity in hawthorn fruits as compared to 
leaves and flowers. 
On the other hand, Öztürk and Tunçel (2011) evaluated the 
antioxidant activity of hawthorn fruit peel, seed, and leaves with flowers and 
found the highest DPPH radical-scavenging activity in leaves with flowers. 
High antioxidant activity of hawthorn leaves was also confirmed by Belkhir 
et al. (2013) who furthermore observed that C. azarolus L. had higher 
antioxidant activity than C. monogyna Jacq. And similarly, Šavikin et al. (2017) 
reported that the leaf extract of the hawthorn species C. orientalis Pall. ex M. 
Bieb. was more effective as a DPPH radical scavenger than the fruit extract. 
53 
 
The beneficial antioxidant properties of hawthorn were also shown on 
cellular and whole organism levels. On the cellular level, a significant 
reduction of oxidative stress after incubation with hawthorn extract was 
observed, for example, in human blood lymphocytes (Hosseinimehr et al., 
2011), mouse lymphocytes (Cheng et al., 2013), mouse lymphocytes and 
macrophages (Mustapha et al., 2016b), PC12 cells (derived from 
pheochromocytoma of rat adrenal medulla; Chang, Lin and Lai, 2012), human 
myelogenous cells K562 (Mustapha et al., 2014), HepG2 cells (human liver 
carcinoma cells; Krajka-Kuźniak et al., 2014), or primary human keratocyte 
cells (Mustapha et al., 2016a). 
In various animal models, hawthorn extracts exerted hepatoprotective 
effects against both non-alcoholic (Al Humayed, 2017; Saeedi et al., 2018) and 
alcoholic (Martínez-Rodríguez et al., 2019) fatty liver disease, doxorubicin-
induced (Mecheri et al., 2019), carbon tetrachloride- or paracetamol-induced 
hepatotoxicity (Ganie et al., 2014), neuroprotective (Gazdik et al., 2008; 
Saoudi et al., 2019), or even an anticataract effect (Wang et al., 2011b). 
Furthermore, the protective effect of hawthorn against genotoxicity (Jalali, 
Hasanzadeh and Malekinejad, 2012; Shalizar Jalali and Hasanzadeh, 2013) 
and colitis (Malekinejad et al., 2013) has been reported. 
 
2.2.4.2. DIRECT EFFECT OF HAWTHORN ON THE MYOCARDIUM 
 
Hawthorn extract has been shown to exert various beneficial 
properties regarding the cardiovascular system. The positive inotropic 
effect of hawthorn preparations has been repeatedly reported through the 
last three decades (e.g. Leukel, Frick and Hölze, 1986; Pöpping et al., 1995; 
Schwinger et al., 2000; Rodriguez et al., 2008). 
 The cardioactive compounds responsible for the inotropic effect of 
hawthorn were identified by Leukel, Fricke and Hölze (1986) who 
fractionated a hawthorn aqueous extract into four fractions with two of them 
containing flavonoids and the other two proanthocyanidins. While all of the 
tested fractions exhibited a positive inotropic effect on isolated Guinea pig 
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hearts, fraction 4 (proanthocyanidins) was proven to be the most effective 
one followed by fraction 3 (proanthocyanidins). Both of the 
proanthocyanidins-containing fractions were effective in their inotropic 
actions at very low concentrations (0.5µg/mL and 50µg/mL, respectively). On 
the other hand, hawthorn flavonoids offered only slightly positive inotropic 
properties, mostly due to the presence of O-glycosides, such as luteolin-7-
glucoside, hyperoside, and rutin. The flavonoid C-glycosides vitexin and 
vitexin-rhamnoside were even less effective (Schüssler, Hölzl and Fricke, 
1995). 
One of the first investigations of the mechanism underlying hawthorn 
inotropic action was provided by Pöpping et al. (1995) who used the 
hawthorn extract LI 132 on isolated cardiomyocytes from adult rats. The 
positive inotropic effect was observed in a certain concentration range and 
was accompanied by a moderate elevation of energy turnover for both 
mechanical and ionic processes. This intervention was very economical to 
myocytes when compared to other performed inotropic interventions, such 
as the application of isoprenaline, ouabain, and elevation of extracellular Ca2+ 
concentration.  
Five years later Schwinger et al. (2000) in their study with another 
hawthorn extract (WS 1442) in the human myocardium from patients with 
congestive heart failure observed that both the force generation and the 
calcium transient were increased by WS 1442. However, while the extract in a 
concentration-dependent manner released the specifically bound 3H-ouabain 
from the Na+/K+ ATPase, the activity of adenylate cyclase was not affected and 
the authors proposed a cAMP-independent mechanism for the positive 
inotropic action of hawthorn glycosides.  
Rodriguez et al. (2008) compared the positive inotropic effect of two 
commercially available hawthorn ethanolic extracts on adult rat 
cardiomyocytes. One extract was obtained from mixed plant material – leaves, 
flowers and fruits, the other only from fruits. According to their findings, the 
fruit extract appeared to be more appropriate for therapeutic use, as it did not 
cause calcium overload in the cardiomyocytes. On the other hand, the 
administration of the mixed plant material extract to cardiomyocytes resulted 
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in robust calcium transients and an eventual calcium overload. Aside from the 
impact of hawthorn on intracellular calcium levels, the involvement of 
Na+/K+ ATPase in the mechanism of hawthorn cardiac activity was again also 
confirmed (Rodriguez et al., 2008). 
Similarly, Willer et al. (2012) observed the impact of WS 1442 on the 
Na+/K+ ATPase. The authors further explained the increase in the intracellular 
calcium concentration after hawthorn extract administration as a result of the 
sarcoplasmic/endoplasmic reticulum Ca2+ ATPase inhibition and the 
consequential activation of the inositol 1,4,5-trisphosphate pathway. The 
WS 1442 extract did not induce the store-operated calcium entry, thus 
preventing the deleterious rise of Ca2+. 
 Furthermore, anti-arrhythmic activity and negative chronotropic 
effect of hawthorn preparations have been reported. For example, Garjani 
et al. (2000) evaluated the effect of different C. meyeri A. Pojark extracts on 
arrhythmias induced by a period of myocardial ischemia in rats. Methanolic 
extract significantly reduced beats occurring as ventricular tachycardia, while 
chloroform extract reduced the occurrence of single extrasystoles. In both 
cases the effect led to a remarkable decrease in the total number of 
ventricular ectopic beats. Ethyl acetate and methanolic extracts further 
significantly reduced the time spent for ventricular fibrillation. 
Long et al. (2006) noted that several commercial hawthorn extracts 
were able to induce rhythmicity in quiescent cultured cardiomyocytes. 
Hawthorn, unlike other cardioactive drugs, did not cause β-adrenergic 
receptor blockade at concentrations which normally cause negative 
chronotropic activities. Alp et al. (2015) even reported that hawthorn offered 
a strong activity against digoxin-induced arrhythmias in rats. The 
administration of C. oxyacantha L. fruit extract shortened the duration of both 
atrial and ventricular arrhythmias, and also led to a significant bradycardia. 
A dose-dependent negative chronotropic effect of hawthorn leaf 
extract from C. pentagyna Waldst. & Kit ex Willd. was observed by Pahlavan 
et al. (2018) in their study with cardiomyocytes differentiated from healthy 
volunteers, long QT syndrome, and tachycardial patients-originating human 
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stem cells. This effect was further accompanied by a prolongation of the field 
potential durations in long QT syndrome patients-derived cardiomyocytes, 
and by a reduction of the beating frequencies and the occurrence of immature 
field potential, triggered by β-adrenergic stimulation in cardiomyocytes from 
tachycardial patients. The flavonoids isoquercetin and vitexin were especially 
efficient in the slowdown of isoproterenol-induced beating frequencies. 
Hawthorn furthermore exerts a strong cardioprotective effect. 
Jayalakshmi, Thiruparasundari and Devaraj (2006) investigated the effect of 
hawthorn on mitochondrial function during experimentally induced 
myocardial infarction (isoproterenol, 85 mg/kg) in rats. Pretreatment with 
hawthorn at a dose of 5 mL/kg for 30 days resulted in the preservation of the 
mitochondrial antioxidant status, and prevented both the mitochondrial lipid 
peroxidative damage and the decrease in Kreb's cycle enzymes. A longer 
pretreatment with hawthorn (8 weeks) before the induction of a myocardial 
infarction with isoproterenol in a rat model was conducted by Vijayan, 
Thiruchenduran and Devaraj (2012). Again, hawthorn administration had a 
significant effect on the reversing of deterioration of biochemical factors 
caused by isoproterenol (creatine kinase and lactate dehydrogenase levels in 
serum, and lipid peroxidation) to nearly normal levels. 
Swaminathan et al. (2010) also obsereved the beneficial effect of 
hawthorn on the myocardial ischemia/reperfusion injury (30 minutes/ 
45 minutes) in isolated rat hearts. Hawthorn extract administered for 
10 minutes during the reperfusion phase led to a significant recovery in 
cardiac contractile function, a reduction of infarct size, and a decrease in 
creatinine kinase and lactate dehydrogenase activities.  
Cuevas-Durán et al. (2017) induced myocardial infarction in rats 
surgically by ligating the left anterior descending coronary artery. In this case, 
the pretreatment with hawthorn extract administered intraperitoneally for 
one week at a dose of 100 mg/kg prior to the onset of myocardial infarction 
also resulted in a significantly increased total antioxidant capacity, expression 




Hawthorn also offers a significant protection against carbon 
tetrachloride-induced heart tissue damage. Rats pretreated with hawthorn 
extract at a dose of 300 mg/kg for 15 days had significantly decreased serum 
creatinine and malonyl dialdehyde levels. Furthermore, hawthorn restored 
the levels of glutathione and antioxidant enzymes glutathione reductase, 
glutathione peroxidase, and glutathione transferase in the heart tissue (Ganie 
et al., 2016). 
The mechanism of hawthorn cardioprotective effect includes the 
reduction of oxidative stress and consequent apoptosis of cardiomyocytes 
(Vijayan, Thiruchenduran and Devaraj, 2012). A significant upregulation of 
the anti-apoptotic proteins Bcl-2 and Hsp70 with a simultaneous 
downregulation of the pro-apoptotic proteins cytochrome c and cleaved 
caspase-3 was also reported by Swaminathan et al. (2010). 
Hawthorn exhibits several properties that may be highly beneficial in 
heart failure treatment, among them the anti-arrhythmic properties,  
anti-inflammatory, and antioxidant (see Ch. 2.2.4.1.) effects are of great 
interest. Schmidt et al. (1994) treated 78 chronic congestive heart failure 
patients (NYHA class II) with hawthorn extract LI 132 (600 mg per day) for 
8 weeks. The working capacity and clinical symptoms were significantly 
better in the hawthorn treated group than in the placebo group. 
The hawthorn extract LI 132 was also used in the study of Tauchert, 
Ploch and Hübner (1994). 132 stable heart failure patients (NYHA class II) 
were treated with either the hawthorn extract (900 mg per day) or the 
ACE inhibitor captopril (37.5 mg per day) for 8 weeks. In both groups the 
exercise tolerance increased significantly, and the incidence and severity of 
pursued typical symptoms were decreased by around 50%. 
Zapfe (2001) used another commercially available hawthorn extract in 
his smaller study with 40 congestive heart failure (NYHA class II) patients. 
Patients were treated for 12 weeks either with WS 1442 extract or placebo. 
The exercise tolerance was higher in the hawthorn group than in the placebo 
group at the end of the trial. 
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In 2000 Holubarsch et al. presented the design of a large study on 
congestive heart failure patients (NYHA class II and III) that was also partially 
conducted in the Czech Republic. The Survival and Prognosis: Investigation of 
Crataegus Extract WS 1442 in congestive heart failure (SPICE) study included 
around 2300 patients. Patients were treated either with WS 1442 (900 mg 
per day) or placebo for 24 months. The results of this study were presented 
by the authors several years later (Holubarsch et al., 2008). Among the final 
number of 2681 patients randomized to treatment, cardiac mortality in the 
hawthorn group as compared to placebo was reduced by 20%, with a 
significant reduction in sudden cardiac deaths by 39.7%. 
A distinctively critical voice on hawthorn's effect in heart failure 
patients is represented by Zick, Gillespie and Aaronson (2008) and Zick et al. 
(2009) in their HERB CHF (Hawthorn Extract Randomized Blinded Chronic 
Heart Failure) trial which included 120 patients with heart failure (NYHA 
classes II or III) and a decreased left ventricular fraction ejection (≤40%) on a 
standard medical therapy (an ACE inhibitor or angiotensin receptor 
antagonist, a beta-blocker, and a diuretic). Patients were treated for 6 months 
with either hawthorn extract WS 1442 (450 mg twice daily) or placebo. Zick, 
Gillespie and Aaronson (2008) focused on the inhibition of progression in 
heart failure patients treated with hawthorn extract and concluded it did not 
decrease the risk of clinical heart failure progression compared to placebo. 
The outcomes of Zick et al. (2009) showed no effect of hawthorn extract on 
blood pressure, heart rate, oxidative stress, inflammation, or studied quality 
of life parameters such as the six minute walk distance and patient or 
physician global assessment. More favorable results were obtained for the 
parameter of the left ventricular ejection fraction, where a mild improvement 
was observed in the hawthorn-treated group. 
However, the findings regarding hawthorn efficacy in chronic heart 
failure presented by the majority of investigators speak in favor of hawthorn 
use. Diehl (1998) found hawthorn extract to be useful in the management of 
symptoms of mild to moderate chronic heart failure. Rigelsky and Sweet 
(2002) in their clinical review on the therapeutic uses of hawthorn concluded 
that the limited data about hawthorn suggests it may be useful in the 
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treatment of chronic heart failure (NYHA class II) patients. Pittler, Guo and 
Ernst (2008) presented a comprehensive review on hawthorn extract for 
treating chronic heart failure. The results suggest that hawthorn extract 
(when compared with placebo) increases the maximal workload in patients 
with chronic heart failure. Koch and Malek (2011) also found hawthorn 
extract useful in chronic heart failure patients. 
 
2.2.4.3. EFFECT OF HAWTHORN ON BLOOD, BLOOD CELLS, AND BLOOD VESSELS 
 
The effect of hawthorn on platelet aggregation was investigated by 
several authors. Vibes et al. (1994) observed in vitro that C. oxyacantha L. 
flower extract caused inhibition of thromboxane A2 biosynthesis by reducing 
the arachidonic acid metabolism and inhibiting the cyclooxygenase pathway. 
Shatoor et al. (2012) also reported a significant dose-dependent inhibition of 
platelet function in rats treated with hawthorn C. aronia Bosc non Decne 
extract at a concentration range 100 – 500 mg/kg. Hawthorn significantly 
altered the bleeding time, the closure time, and the thromboxane B2 levels. 
Similarly, Li et al. (2015) observed significant in vitro platelet 
aggregation-inhibitory properties of Chinese hawthorn (C. pinnatifida Bunge) 
leaf extract. All of the 15 evaluated monoterpenes and flavones exerted 
appreciable antiplatelet activity, with the (6S,7Z,9R)-roseoside, eriodictyol, 
and 2˝-O-rhamnosyl vitexin being the most effective (inhibition of platelet 
aggregation in rat plasma by 87.18%, 72.92%, and 75.00%, respectively). 
Eriodictyol was further evaluated as the most active hawthorn extract 
compound exhibiting antithrombotic activity with significantly prolonged 
time to thrombus formation in zebrafish. 
Contrary to all of the abovementioned works, Dalli et al. (2011) found 
no effect of C. laevigata Poir. in Lam. extract on platelet aggregation, closure 
time or thromboxane B2 level after administration to healthy volunteers. 
The hawthorn vasodilatation effect was also observed in several 
studies. Kim et al. (2000) observed relaxation of vascular tone and increased 
production of cGMP in isolated rat aorta in response to an extract with 
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flavonoids and procyanidins isolated from hawthorn species C. oxyacantha L. 
and C. monogyna Jacq. While the flavonoid fraction containing rutin, 
hyperoside, and vitexin did not affect the vascular tone, the procyanidine 
fraction caused an endothelium-dependent relaxation associated with the 
production of cGMP. Based on their experiments with various inhibitors, the 
authors proposed the activation of tetraethylammonium-sensitive 
K+ channels as a possible mechanism of the endothelium-dependent NO-
mediated vasorelaxation (Kim et al., 2000).  
Similar results were obtained by Brixius et al. (2006) who evaluated 
the hawthorn extract WS 1442 or three of its fractions (described as A, B, and 
C) on phenylephrine-precontracted rat aorta and human mammarian artery. 
No vasodilatation was observed in vessel models with mechanically disrupted 
endothelium. On the contrary, the most effective was vasodilatation with 
intact endothelium when fraction C (meaning hydrophilic, essentially 
flavonoid-free and rich in high molecular weight oligomeric procyanidins) 
was used. The vasorelaxation was induced by NO liberation from the 
endothelial cells. Endothelial NO synthase (eNOS) was activated by 
phosphorylation at serine 1177 (Brixius et al., 2006). This eNOS 
phosphorylation-mechanism of vasorelaxation was further supported by 
Anselm et al. (2009) in their study on porcine coronary artery rings treated 
with hawthorn extract WS 1442. 
More recently, Topal et al. (2013) studied the effect of C. microphylla 
K. Koch leaf extract on endothelial dysfunction in aortic rings of diabetic 
rats. Endothelium-dependent relaxations were much weaker in diabetic rats 
compared with control, but chronic treatment with low doses of hawthorn 
extract or pretreatment with a higher dose of hawthorn extract remarkably 
attenuated the impaired relaxation. The authors suggested a reduction in the 
formation of pro-inflammatory cytokines, the expression of inducible 
NO synthase (iNOS), and the prevention of lipid peroxidation as the prevalent 
effect of hawthorn extract. 
Endothelial protection of hawthorn extract WS 1442 against 
endothelial barrier dysfunction was reported by Bubik et al. (2012). 
Hawthorn specifically interacted with endothelial permeability-regulating 
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systems by blocking or activating certain pathways (namely by blocking the 
Ca2+/PKC/RhoA pathway and by activating the cAMP/Epac1/Rap1 pathway) 
that subsequently led to strong cortical actin rearrangements, which in turn 
were able to prevent the vascular leakage. The influence of hawthorn extract 
WS 1442 on protection against vascular barrier dysfunction was also studied 
by Willer et al. (2012) who reported that endothelial calcium signaling 
seemed to play a great role in this process. 
Idris-Khodja et al. (2012) noted a beneficial effect of hawthorn extract 
WS 1442 on aging-related endothelial dysfunction in rats. Hawthorn 
treatment resulted in a remarkable improvement of both the aging-related 
endothelium-dependent relaxations and the induction of endothelium-
dependent contractile responses, most likely by attenuating the increased 
oxidative stress as well as the overexpression of the pro-inflammatory 
enzymes cyclooxygenase COX-1 and COX-2. 
An appreciable effect of hawthorn on the endothelial protection 
against atherosclerosis was also reported by Zhang et al. (2013) who found a 
reduced intima/media thickness ratio and a decrease in pathological changes 
in the arteries of rats administered with hawthorn for 12 weeks. And 
similarly, significantly decreased atherosclerotic lesions of aortic root in mice 
treated with hawthorn fruits were observed by Zhang et al. (2014b). 
 
2.2.4.4. ANTIHYPERTENSIVE EFFECT OF HAWTHORN 
 
Antihypertensive effect of hawthorn is well documented, several 
clicnical trials focusing on the effect of hawthorn on hypertension have been 
conducted in the last years.  
A significantly lower systolic blood pressure after 8 weeks of 
hawthorn extract LI 132 administration (600 mg/day) to patients with heart 
failure was reported by Schmidt et al. (1994). Walker et al. (2002) also found 
a very promising effect of hawthorn extract (500 mg/day) in patients with 
mild hypertension on diastolic blood pressure, even if it was not statistically 
significant. Four years later, in a randomized placebo-controlled trial, Walker 
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et al. (2006) treated the patients with higher doses of hawthorn extract 
(1200 mg/day) for 16 weeks. A significant mean diastolic blood pressure 
reduction in the hawthorn-treated group was observed at the end of the trial, 
indicating that the effect of hawthorn on blood pressure is both dose- and 
time-dependent. 
Asgary et al. (2004) used mixed leaf and flower extract of an Iranian 
Crataegus species, namely C. curvisepala Lind, in a placebo-controlled clinical 
trial with 92 mildly hypertensive patients with no medication. Treatment 
with hawthorn for 12 weeks resulted in a significant decrease in both systolic 
and diastolic blood pressure. 
 Similarly, Al-Gareeb (2012) conducted his clinical study on 60 newly 
diagnosed patients with stage 1 hypertension with no medication. After 
12 weeks of treatment either with WS 1442 extract (900 mg/day) or placebo, 
there were significant differences in blood pressure. Both the systolic and the 
diastolic blood pressure were significantly lower in patients treated with 
WS 1442 than in the placebo group after 4 weeks of treatment, and their 
systolic and diastolic blood pressure reached within the range of normal 
levels at the end of the trial. 
The mechanism of hawthorn's antihypertensive effect is very likely 
multifactorial, seeing that there are many active compounds. Beside the 
vasorelaxing properties of hawthorn (see Ch. 2.2.4.3.) contributing to its 
hypotensive effect, other mechanisms come into consideration. 
In 1987, Uchida et al. investigated the effect of condensed tannins from 
Rhei Rhizoma on angiotensin converting enzyme (ACE) and reported that 
procyanidins offered very good ACE-inhibitory activity. Lacaille-Dubois, 
Franck and Wagner (2001) later confirmed that flavonoids and 
proanthocyanidins from C. oxyacantha L. and C. monogyna Jacq. exhibit  
ACE-inhibitory activity, while phenolic acids offered no significant 
ACE inhibition. An ACE-inhibitory activity was also exerted by the extract 
from another hawthorn species, C. microphylla K. Koch (inhibition by ca 80%) 
as documented by Sharifi et al. (2013). Attard and Attard (2003) 
demonstrated the ACE-inhibitory activity of oleanolic acid in a hydroethanolic 
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C. monogyna Jacq. fruit extract, suggesting a minor role of triterpenic acids in 
the inhibition of ACE activity of hawthorn extract. 
Younis et al. (2020) also observed a significant ACE-inhibitory activity 
of hawthorn C. songarica K. Koch fruit extract. Normotensive rats were 
treated for one week with crude extract, aqueous soluble, and n-butanol 
soluble fractions. Remarkable diuretic and saluretic effects of hawthorn were 
observed especially in rats obtaining the aqueous soluble fraction. As the 
hypotensive and diuretic actions of this fraction were significantly reduced by 
atropine treatment, the involvement of the nitric oxide pathway activated by 
muscarinic receptors should also be taken into consideration (Younis et al., 
2020). 
Similar conclusions (i.e. the NO pathway activated by muscarine 
receptors) were earlier stated by Shatoor (2013) in his study of C. aronia Bosc 
non Decne whole plant extract (stems, leaves, and fruits) administered 
parenterally to normotensive rats. In rats pretreated with a ganglionic 
blocker (hexamethonium) and an inhibitor of NO synthase (L-NAME), 
complete elimination of the hawthorn-induced hypotension was observed. 
Haydari et al. (2017) studied the antihypertensive effect of C. aronia 
Bosc non Decne. fruit extract in rats. Treatment with hawthorn extract for 
4 weeks resulted in a significantly lower systolic blood pressure and 
phenylephrine maximal response as well as significantly higher serum 
superoxide dismutase and serum glutathione reductase, indicating that the 
antihypertensive properties of the hawthorn fruit extract may involve both 
the antioxidant and the NO-releasing effects. 
The nitric oxide-dependent hypotensive activity was further 
confirmed by Zheng et al. (2019) in their study on the effect of hawthorn fruit 
extract on high-salt hypertension. Hawthorn remarkably increased the 
NO concentration and decreased the concentration of hydrogen peroxide and 
malonyl aldehyde. This increase of NO synthase activity was especially 




On the other hand, some studies doubt the nitric oxide pathway as the 
hypotensive effect of hawthorn. For example, Asher et al. (2012) conducted a 
randomized, controlled trial in prehypertensive and mildly hypertensive 
patients. Standardized hawthorn extract at higher doses (1000 mg, 1500 mg, 
and 2500 mg twice daily) was administered for 3 ½ days followed by brachial 
artery flow mediated dilatation (FMD), an indirect measure of NO release. No 
evidence of dose-response effect of hawthorn extract on FMD was found, 
leading authors to suggest that blood pressure lowering effect of hawthorn 
extract is likely to be mediated via an NO-independent mechanism. 
 
2.2.4.5. EFFECT OF HAWTHORN ON PLASMATIC LIPID PROFILE 
 
Several studies focused on the impact of hawthorn on the plasmatic 
lipid spectrum and tried to illuminate the possible mechanism of action.  
A comparison of the effects of aqueous and ethanolic (extraction 
solvent 70% ethanol) extracts of C. pinnatifida Bunge fruits on lipid spectrum 
of high-fat diet fed rats was performed by Shao et al. (2016). After 4 weeks of 
treatment, both hawthorn extracts exhibited a dose-dependent manner in 
reducing triglycerides, total cholesterol, and LDL cholesterol but the efficacy 
of the extracts was different, with ethanolic extract decreasing the lipid levels 
at lower doses than the aqueous extract. The difference was likely due to the 
different phenolic compounds content of both extracts: ethanolic extract and 
aqueous extract exhibited total phenols content of 1.99% and 0.51% in the 
same quality of hawthorn fruit, respectively. 
The beneficial role of hawthorn triterpenic acids on lipid levels was 
demonstrated by Lin, Vermeer and Trautwein (2011) who treated hamsters 
either with hawthorn C. pinnatifida Bunge fruit extract, plant sterol esters 
(PSE), hawthorn plus PSE, oleanolic and ursolic acid combination, or control 
chow for 4 weeks. Non-HDL cholesterol (plasma VLDL and LDL fractions) was 
significantly lower in hamsters fed with hawthorn, hawthorn plus PSE, or PSE 
only than in the control group. The effect on triglycerides was similar, but it 
did not reach a statistically significant level. Moreover, only in the hawthorn 
65 
 
group a statistically non-significant trend of an increase of HDL cholesterol 
was observed. The most beneficial effect on cholesterol lowering was the 
combination of hawthorn extract and PSE. 
Al-Gareeb (2012) obtained similar results in his clinical trial with 
mildly hypertensive adults treated with hawthorn extract WS 1442 
(900 mg/day) for 12 weeks. In the hawthorn group, a significant reduction in 
mean total cholesterol and LDL cholesterol and a small non-significant 
decrease in serum triglyceride concentraction were observed. On the other 
hand, HDL cholesterol level was significantly higher in the hawthorn group. 
Xu, Xu and Ryan (2009) compared the effect of hawthorn fruit extract 
and simvastatin on mice fed with a high-cholesterol diet after 8 weeks of 
treatment. In both hawthorn and simvastatin-treated groups a significant 
reduction in triglycerides and in the LDL cholesterol/serum cholesterol ratio 
were observed. However, the reduction of LDL cholesterol was evident only 
in the hawthorn treated group. 
The hypolipidemic mechanism of hawthorn is multifactorial as both 
the cholesterol and triglycerides are influenced. Ye et al. (2010) isolated four 
compounds of ethanolic C. pinnatifida Bunge fruit extract with a high 
inhibitory activity against 3-hydroxy-3-methylglutaryl coenzyme A reductase 
(HMGR-CoA), namely quercetin, hyperoside, rutin, and chlorogenic acid. Rutin 
and chlorogenic acid were predominant in the mixture, representing 1.45% 
and 0.95%, respectively of the extract content. The in vivo results 
demonstrated a more pronounced lipid-lowering activity of the hawthorn 
fruit extract than that of pure compounds. This indicates synergistic effects on 
HMGR-CoA inhibition and lipid-lowering among the active compounds. 
Lin, Vermeer and Trautwein (2011) in their in vitro part of study 
incubated intestinal Caco-2 cell culture with increasing concentrations of 
C. pinnatifida Bunge fruit extracted with different solvents (dichloromethane, 
ethylacetate, acetone, ethanol, and heptane). The dichloromethane extract 
with the highest content of oleanolic and ursolic acid exerted the strongest 
inhibitory effects on acylCoA:cholesterol acyltransferase (ACAT) activity. 
When pure compounds were evaluated, ursolic acid had a slightly lower 
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ACAT-inhibitory effect than oleanolic acid. Both triterpenic acids had no effect 
on cell uptake on marked cholesterol or oleic acid from the medium, 
suggesting that the inhibitory effect is mediated via specific inhibition of the 
ACAT activity but not via inhibition of the transport of cholesterol esters 
precursors. 
Another hypolipidemic mechanism of hawthorn  was suggested by Niu 
et al. (2011) who analyzed the liver of high-fat diet-fed mice treated with 
hawthorn fruit extract (250 mg/kg) for one week. An increased expression of 
PPARα as well as of the PPARα-regulated β-oxidation-related enzymes in the 
liver were observed.  
 
2.2.5. SAFETY PROFILE OF THE HAWTHORN PREPARATIONS 
 
Seeing as hawthorn fruits are being used as food (e.g. jam, jellies, 
wine) in many countries, it is reasonable to expect a low risk of medicinally 
used hawthorn extracts to have adverse effects. According to EMA, hawthorn 
preparations have no contraindications (with the exception of 
hypersensitivity to the active substance), drug interactions, or adverse effects 
(EMA/HPMC/159075/2014; EMA/HPMC/159076/2014). 
A very comprehensive systematic review on the adverse effects of 
hawthorn human monopreparations (mainly the extracts WS 1442 and 
LI 132), which included data from 5577 patients, was presented by Daniele 
et al. (2006). Only 166 adverse events in total were reported, most of them 
being mild to moderate. The most frequently occurring adverse effects were 
dizziness, nausea, fall, erythematous rash, gastrointestinal hemorrhage, and 
circulation failure. 
Since then, the situation had not changed much. Wang, Xiong and Feng 
(2013) in their review of evidence-based approach on hawthorn usage in 
cardiovascular disease prevention did not mention any new observed adverse 
effects or drug interactions. Most lately Holubarsch, Colucci and Eha (2018) 
provided a new evidence-based review on hawthorn extract WS 1442 and 
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concluded that WS 1442 has a very favorable safety profile even when 
administered as a part of a polydrug regimen. 
As to pharmacodynamic interactions of hawthorn, some older 
studies mentioned in the Botanical Safety Handbook (Gardner and McGuffin, 
2013) indicated that hawthorn extracts could potentiate the effects of 
digitalis glycosides. However, Tankanow et al. (2003) performed an 
interaction study on the coadministration of hawthorn extract and digoxin. 
Healthy volunteers were treated with both WS 1442 (900 mg/day) and 
digoxin for 3 weeks. No significant differences were observed in digoxin 
pharmacokinetic and pharmacodynamic parameters when coadministered 
with hawthorn.  
Holubarsch, Colucci and Eha (2008) also found hawthorn safe for 
patients on digitalis therapy. Furthermore, no indications of possible drug 
interactions were observed in patients co-treated with hawthorn extract and 
ACE inhibitors, beta-blockers, spironolactone, and nitrates (Holubarsch, 
Colucci and Eha, 2008). 
 
2.3. FOXGLOVE – DIGITALIS SPP. – FAM. PLANTAGINACEAE 
 
2.3.1. CHARACTERIZATION OF THE GENUS DIGITALIS – A PHARMACOGNOSTIC CONTEXT 
 
 The genus Digitalis currently comprises 23 species including four 
species of the former genus Isoplexis, based on the molecular phylogeny of 
Bräuchler et al. (2004) and Herl et al. (2008). Formerly the genus Digitalis 
belonged into the family Scrophulariaceae, but since the family genera were 
regarded as a collection of unrelated lineages and the family was 
dismembered, Digitalis and some other genera of the former Scrophulariaceae 
family were integrated into the family Plantaginaceae (Kreis, 2017). 
 The genus Digitalis has two diversity centers, namely the Western 
species found on the Iberian Peninsula and in Northwestern Africa, and the 
Eastern species found on the Balkan Peninsula and in Asia Minor. However, 
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the species D. purpurea L. was introduced widely as an ornamental plant and 
it can readily be found along the West Coast of the USA and Canada as well as 
in New Zealand (Kreis, 2017). 
 The common foxglove, D. purpurea L. (Fig. 2.5., left), is an herbaceous 
biennial plant growing up to 150 cm of height. In the first year it forms a 
ground rosette of broad leaves and in the second year a simple leafy stem 
with terminal elongated inflorescence. The flowers are of outstanding purple-
red color (although also pink, rose, yellow, and white-flowering plants are 
grown), tubular-shaped and heavily dark speckled on the inside surface. It 
mostly grows on soils with a calcium content higher than 1% (Tomko et al., 
1989). 
 Woolly foxglove, D. lanata Ehrh. (Fig. 2.5., right), is cultivated on peaty, 
sandy and clay soils. The plant is biennial or perennial, usually 40 – 80 cm tall 
with oblong-lanceolate leaves. The stem is bare, while in the inflorescence 
noticeable woolly (hence the name woolly foxglove). The flowers are short-
stemmed, with crown of light yellow to whitish color with brown veins, 
arranged in a dense inflorescence (Mastenbroeck, 1985; Tomko et al., 1989). 
 
 
Foxgloves are commonly propagated by seeds, which are very small in 
size. The main sources for cardenolides used in therapy are D. lanata Ehrh. 
and D. purpurea L. Both species are cultivated for this purpose, however 
predominantly D. lanata Ehrh. is grown and used as the starting material for 




cardenolide isolation and production. In Europe (Netherlands), the crop is 
sown in mid-April and the leaves are harvested from September to late 
November and subsequently dried at 50 – 60 °C. Foxglove plants are 
cultivated to offer a high yield of digoxin, the variety currently cultivated has 
digoxin content of dried leaves around 2.5 – 3.0‰, which is about 50% 
higher than the digoxin content of the original accession (Mastenbroeck, 
1985; Kreis, 2017).  
The Czechoslovak Pharmacopoeia recognized two drugs originating in 
foxglove species D. purpurea L. and D. lanata Ehrh. However, Digitalis 
lanatae folium is not monographed in the actual edition of the Czech 
Pharmacopoeia anymore and therefore only the monograph on Digitalis 
purpureae folium is listed in the current edition of the European 
Pharmacopoeia. Digitalis leaf consists of the dried leaf of Digitalis purpurea L. 
It contains not less than 0.3% of cardenolic glycosides, expressed as digitoxin, 
calculated with the reference of the dried drug. The drug has a faint but 
characteristic odor. The whole leaf is about 10 cm to 40 cm long and 4 cm to 
15 cm wide, but being brittle, it often occurs broken. The upper surface is 
green and the lower surface is greyish-green. The leaf lamina is ovate 
lanceolate to broadly ovate. The winged petiole is from one quarter as long as 
to equal in length to the lamina (European Pharmacopoeia 10.0).  
The current edition of the European Pharmacopoeia further includes a 
monograph on common foxglove for the use in homeopathic medicinal 
products (Digitalis purpurea ad praeparationes homeopathicas) and two 
monographs on the individual foxglove cardiac glycosides (Digitoxinum and 
Digoxinum). 
 
2.3.2. PHYTOCHEMISTRY OF FOXGLOVE 
 
 Digitalis species offer a wide range of interesting phytochemicals. For 
example, digitanols, that are structurally resembling the cardioactive 
glycosides with their 14β-hydroxyl function and a sugar side chain, differ, 
however, significantly in their basic skeleton structure (Δ5-pregnene). 
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Foxglove furthermore contains rare phytosterols, anthraquinone derivates 
(digiferruginol), and more than 40 flavonoids (among them the highly 
oxidized digicitrin). However, no secoiridoid glycosides, otherwise commonly 
occurring in the Plantaginaceae family, have been identified in the genus 
Digitalis. This blockage of iridoid biosynthesis was likely replaced by the 
biosynthesis of cardenolides (Taskova, Godfredsen and Jensen, 2005; Kreis, 
2017). 
The most important foxglove compounds are cardioactive 
glycosides, more than 100 different cardenolides have been isolated from 
various foxglove species. Some of the foxglove cardenolides are shown in 
Fig. 2.6A – C. In D. lanata Ehrh, a total of 17 cardenolides have been detected 
with lanatoside A, C, and E as major compounds, while in D. purpurea L., seven 
cardenolides were identified, including purpurea glycoside A, B, and E. Plants 
of the genus Digitalis produce cardenolides of the 5β-type. Primary glycosides 
have a sugar component consisting of several sugar moieties. They are stored 
in the vacuoles and in the case of a vacuole disruption they come into contact 
with enzymes catalyzing their conversion into secondary glycosides. In the 
dried material, which can be stored over long periods of time, enzymes 
capable of hydrolyzing cardenolides are inactive, therefore  the conversion of 
primary to secondary glycosides is not yet completed at this stage (Kreis, 


























Fig. 2.6B. Some of the cardenolides occurring in the genus Digitalis. Up – digoxin, down – 






Among the cardenolides produced by various foxglove species, digoxin 
and digitoxin are of great economical and medical importance. However, 
digoxin is as a rule found in a mixture of glycosides with very similar chemical 
structure such as digitoxin and gitoxin, which makes it difficult to isolate the 
pure compounds (Novković et al., 2014).  
 Cardenolide biosynthesis is a complicated process of aglycone 
synthesis to which then sugar moietes are connected. The aglycone (genin) 




synthesis starts with precursors such as cholesterol, β-sitosterol, smilagenin, 
or sodium glycholate that are transformed to pregnenolone. This compound 
is converted into isoprogesterone that is subsequently isomerized to 
progesterone. Several specific enzymes catalyzing stereospecific reactions in 
order to determine that all foxglove cardenolides are β-configurated at 
carbon atoms C3, C5, C14, and C17 of the steroid skeleton are required during 
this process. An important enzyme (although not representing a major 
regulatory point of cardenolide biosynthesis) in the cardenolide biosynthetic 
pathway is the 3β-hydroxysteroid dehydrogenase (EC 1.1.1.145), responsible 
for the isoprogesterone synthesis. It was suggested that this enzyme may also 
possess the Δ5-Δ4-ketosteroid isomerase activity needed for the isomerization 
of isoprogesterone to progesterone. This activity was later confirmed. The 
first committed step in the branch pathway leading to cardenolides is, 
however, the subsequential 5β-reduction of progesterone to 5β-pregnan-
3,20-dione, a reaction catalyzed by the enzyme progesterone 5β-reductase 
(EC 1.3.1.3), which is considered to be a key enzyme in cardenolide 
biosynthesis. This enzyme is encoded by at least two genes (P5βR and P5βR2) 
in D. purpurea L., and while the expression of P5βR does not vary under stress 
conditions or chemical elicitors, the expression of P5βR2 is highly responsive 
to these factors. Both of these enzymes were detected not only in cardenolide-
accumulating foxglove leaves but also in cardenolide-free permanent cell 
suspension cultures initiated from foxglove leaf tissue (Seidel, Kreis and 
Reinhard, 1990; Finsterbusch et al., 1999; Ernst et al., 2010; Pérez-Bermúdez 
et al., 2010; van Wietmarschen et al., 2016 and references therein). 
Sugar moietes (up to 5 units in the sugar side chain per cardenolide 
molecule) are subsequently attached at the C3 carbon atom of the aglycone 
steroid skeleton to form primary glycosides such as the lanatosides. The 
sugar components may be represented by commonly occurring sugars, such 
as D-glucose or L-rhamnose, but also by those more unusual and generally 
confined to the various Digitalis species, such as D-digitalose, D-digitoxicose, 
or D-diginose. Usually a molecule of D-glucose is attached as the terminal 
sugar unit. Drying or mechanical disruption of the leaf material is 
accompanied by partial hydrolysis of these primary glycosides. Both the 
terminal glucose and the acetyl group will be released and the secondary 
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glycosides such as digoxin are formed. The hydrolysis of primary glycosides is 
catalyzed enzymatically by glucohydrolases with different substrate 
specificity and furthermore varying between different foxglove species (for 
example, glucohydrolase II exhibits high specificity towards cardenolide 
disaccharides, especially to those with a 1-4-β-linked glucose-digitoxose 
moiety). The importance of the sugar side chain lies in the modulation of the 
pharmacological effect of the cardioactive glycoside. Contrary to the 
remarkably more stereochemically complicated aglycones, the sugar moieties 
have been successfully surveyed in the stereochemical field and synthetized 
de novo. Changes in the sugar side chain are associated with a fundamental 
shift in their pharmacological effect from cardioactive to another such as 
anticancer (Tomko et al., 1989; Kreis and May, 1999; Hornberger et al., 2000; 
Ganapaty et al., 2009; Pérez-Bermúdez et al., 2010; Wang et al., 2011a; 
van Wietmarschen et al., 2016; Kreis, 2017). 
 As cardenolides primarily act as a plant defense against pathogens and 
herbivores, their synthesis has been shown to be influenced by various 
environmental factors. For example, Stuhlfauth, Klug and Fock (1987) 
reported an increase of cardenolides content by 160% in foxgloves grown at 
higher concentrations of carbon dioxide (CO2; 1000 ppm). CO2 enrichment 
increased mainly the yield of the pharmacologically relevant major compound 
digoxin, whereas contents of two other cardenolides were decreased. The 
addition of exogenous hydrogen peroxide (0.5 and 1 mmol/L) directly to the 
medium of undifferentiated foxglove cell cultures also resulted in a stimulated 
cardenolide production, whereas the addition of catalase markedly reduced it 
(Paranhos, Fernández-Tárrago and Corchete, 1999). Further, mechanical 
wounding of foxglove leaves was reported to lead to a significant increase in 
cardenolides content in the plants. The highest content of cardenolides in the 
leaves was observed approximately 4 hours after wounding of the plant 
(Pérez-Bermúdez et al., 2010). 
 The influence of naturally occurring phytohormones on cardenolide 
production in foxglove has also been investigated. Ethylene was shown to 
decrease the cardenolide synthesis (by 60%), whereas gibberelic acid had no 
significant effect on the accumulation of cardenolides in in vitro cultures of 
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different foxglove species (Berglund and Ohlsson, 1992; Gavidia, Segura and 
Pérez-Bermúdez, 1993). 
Seasonal variation in the content of cardenolides and the expression 
of the gene encoding the progesterone 5β-reductase in 10 natural populations 
of foxglove species D. obscura L. was investigated by Roca-Pérez et al. (2004). 
Cardenolide contents exhibited more or less stable values in terms of their 
chemical composition regardless of the population studied or the degree of 
leaf maturity. They did, however, change in quantity terms during the growth 
season: the lowest production was recorded in May, followed by a fast 
cardenolide accumulation in summer, a decreasing phase in autumn, and a 
stationary phase in winter. The gene encoding progesterone 5β-reductase 
showed increased expression from February to July, while a reduction in its 
expression was observed toward autumn.  
The importance of a sufficiently long light period for the cardenolide 
synthesis was also confirmed by Eisenbeiß, Kreis and Reinhard (1999) who 
reported a significant gradual decrease in cardenolide production in foxglove 
shoot cultures transferred to permanent darkness. After 12 weeks of this 
treatment, cardenolide content was non-detectable. 
Variation of foxglove cardenolides during the growth of plants was 
reported by Balbaa, Hilal and Haggag (1970). The maximum yield of 
cardenolides was obtained from leaves collected from woolly foxglove plants 
in the stage just before flowering. Braga et al. (1997) also investigated the 
change of cardenolides during plant growth. Younger plants (12 months old) 
were shown to have higher total amount of cardenolides than older plants 
(18 months old). Interestingly, foxglove plants treated with cold shock 
(windows opened at the coldest time of the night) during the growth season 
had significantly higher digoxin content, while the content of gitoxin was 
significantly decreased (van Wietmarschen et al., 2016). 
Significant variation of cardenolide content was also observed within 
and among natural foxglove populations. The amounts of digitoxigenin and 
gitoxigenin obtained from foxglove leaves sampled from six different 
Sardinian locations varied considerably (11 – 241 mg/kg of fresh weight and 
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4 – 178 mg/kg of fresh weight, respectively; Nebauer, Del Castillo-Agudo and 
Segura, 1999; Usai, Matzei and Marchetti, 2007). 
 
2.3.3. MEDICINAL USE OF FOXGLOVE 
 
Foxglove was introduced to modern medicine by the botanist and 
physician William Withering who used it for the treatment of patients 
suffering from "dropsy" (congestive heart failure) and in 1785 published the 
clinical importance of Digitalis. In the homeopathic system of medicine, 
Digitalis was introduced in 1803 by Samuel Hahnemann. In 1954, the 
American Food and Drug Agency granted permission for the use of Digitalis 
cardioactive glycosides (Ganapaty et al., 2009; Sharma and Purkait, 2012; 
Kreis, 2017). Contrary to all other medicinal plants reviewed in this work, no 
over the counter foxglove herbal preparations are on the market because of 
the nature of its active compounds. 
As of 2020, in the Czech Republic two cardiac glycoside-containing 
medicinal products Digoxin Léčiva 0.125 mg tablety and Digoxin Léčiva 
0.250 mg tablety are registered with SUKL for therapeutic use in adult 
patients and in children over 3 years of age with the following health 
conditions: (1) heart failure of hypertrophic and dilated heart with chronic 
pressure and volume overload, especially with a concomitant atrial 
fibrillation with rapid ventricular response, or (2) atrial fibrillation with rapid 
ventricular response, especially with a concomitant heart failure if 
cardioversion is not indicated (Digoxin Léčiva 0.250 mg SPC). 
 
2.3.4. EFFECTS OF FOXGLOVE ON SELECTED CARDIOVASCULAR CONDITIONS 
 
2.3.4.1. ANTIOXIDANT EFFECT OF FOXGLOVE 
 
 The in vitro antioxidant properties of digoxin were observed by 
Rogozhin and Verkhoturov (1998). Digoxin was found to bind with the 
enzyme-substrate complex of horseradish peroxidase and o-dianisidine, and 
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inhibited the oxidation of o-dianisidine in the intermediate form of a stable 
semioxidized product. Katanić et al. (2017) investigated the antioxidant effect 
of methanolic extracts of two foxglove species, namely D. ferruginea L. var. 
ferruginea and an endemic Turkish species D. lamarckii Ivan. Both of them 
exhibited good antioxidant properties in all tests performed (DPPH, ABTS 
radical scavenging, reducing power, and β-carotene bleaching test). 
D. lamarckii Ivan extract offered stronger antioxidant properties, probably 
due to a higher flavonoid content. 
Silva et al. (2017) investigated the differences of lipid membrane 
modulation and oxidative stress by digoxin and its semisynthetic derivate 
named BD-21 (21-benzylidene digoxin) and reported that lipid peroxidation 
and superoxide dismutase activity were decreased by digoxin and BD-21. 
Glutathione content and catalase activity were not affected by either of the 
tested cardiotonic steroids.  
Similarly, de Souza Gonçalves et al. (2019) used low concentrations of 
digoxin and three of its semisynthetic derivates (namely BD-14, BD-15 and 
BD-16) in murine neuroblastoma cells neuro-2a, which were exposed to 
partial chemical sodium azide-induced ischemia followed by reperfusion. 
Cells pretreated with the evaluated compounds at a concentration of 
150 nmol/L showed a decrease of the redox state, lipid peroxidation, 
hydrogen peroxide content, and glutathione peroxidase activity. The activity 
of superoxide dismutase remained higher than in control cells, and digoxin 
and its derivates did not have any influence on glutathione levels.  
On the other hand, Shahouzehi, Nasri and Masoumi-Ardakani (2018) 
observed a deterioration of antioxidative parameters of heart tissues in iron-
overloaded rats administered with digoxin at doses of 1 and 5 mg/kg for 
4 weeks. The level of malonyl dialdehyde (a lipid peroxidation marker) was 
significantly elevated in digoxin treated rats. The elevation of malonyl 
dialdehyde was much higher in animals administered with higher dose of 
digoxin (5 mg/kg) when compared to 1 mg/kg of digoxin. Furthermore, 
digoxin treatment resulted in an increased superoxide dismutase and 
glutathione peroxidase quantity in heart tissue. 
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2.3.4.2. DIRECT EFFECT OF FOXGLOVE ON MYOCARDIUM 
 
 Cardenolides possess positive inotropic and negative chronotropic 
properties, in other words, low concentrations of cardenolides are used to 
increase the contractile force of the heart and decrease its rate of contraction.  
The main mechanism of action of cardenolides is the inhibition of the 
cellular Na+/K+ ATPase. Cardiac glycosides bind to the subunit α of the 
enzyme. Inhibition of the ATPase leads to an increase of sodium and a 
decrease in potassium concentration in cardiomyocytes, thus the membrane 
potential is reduced, and the formation of spontaneous action potentials is 
enabled. The increase of intracellular sodium concentration is accompanied 
by an increase of calcium influx and an increase in contractility. This 
inhibition of Na+/K+ ATPase is highly specific, no other ATPase has been 
found to be altered by physiologically active concentrations of cardenolides. 
However, cardenolides (namely digitoxin, digoxin, and ouabain) have been 
shown to also bind to other proteins – transcriptional regulator steroid 
receptor coactivators 3 and 1, causing inhibition of cell proliferation 
(Godfraind, 1984; Lincová and Farghali, 2007; Wang et al., 2014; Askari, 
2019).  
The pharmacological activity of cardenolides is strongly dependent on 
their chemical structure. Choay, Corabeouf and Deroubaix (1978) suggested 
that the aglycone configuration in C5 and C17 positions is associated with 
different activity of two cardenolides, namely mitiphylline and holarosine B. 
In animal models (rat brain, cat left atrial strips) it was later shown that for 
the inotropic activity of foxglove cardenolides, the C17 side chain carbonyl 
oxygen distance of a given genin in relation to its position in the reference 
compound digitoxigenin was the primary determinant of its biological activity 
(Ahmed et al., 1983; From et al., 1984). 
Due to their inotropic properties, cardenolides are mainly used in 
heart failure treatment. The use of cardenolides in the treatment of 
arrhythmias is limited nowadays. For example, Sethi et al. (2018) performed 
a large meta-analysis of clinical trials focused on treatment of atrial 
fibrillation and atrial flutter with digoxin. 28 trials with 2223 participants 
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were included. Based on their findings, the clinical effect of digoxin on all-
cause mortality, quality of life, heart failure, and stroke remained unclear. The 
long-term effect of digoxin was also unclear, as all included trials offered only 
a short-term follow-up. In reducing of the heart rate, digoxin seemed to be 
superior to placebo but inferior to beta blockers. 
 Schupp et al. (2019) reported that in patients with an implantable 
cardioverter defibrillator suffering from atrial fibrillation and heart failure, 
digitalis treatment is associated with increased rates of recurrent ventricular 
tachyarrhythmias. 
 The efficacy of cardiac glycosides, regularly used in therapy of heart 
failure for their inotropic action for more than 200 years, still remains 
unclear. Aside from digitoxin and digoxin, the cardenolides digoxigenin, 
gitoxigenin, strophantidin, and ouabaigenin are also among the most 
prescribed commercial drugs for heart failure (El-Seedi et al., 2019).  
According to current guidelines for treatment of heart failure, cardiac 
glycosides (digoxin in case of the Czech Republic) are considered for 
treatment in patients with resistant symptoms even when on standard ACE 
and/or beta blockers therapy (Hradec, 2018). On an animal model (rats with 
heart failure and surgically induced myocardial infarction), dos Santos et al. 
(2013) showed that digitoxin treatment actually exerts more beneficial effects 
with the increasing severity of the disease. Digitoxin reduced mortality up 
to 43% in animals that showed parameters associated with a poor prognosis. 
On the other hand, in less severe cases, digitoxin led to an increased mortality 
of the animals (by approximately 20%). 
Digoxin was shown to be a useful agent in heart failure patients. The 
PROVED trial results showed that even mild to moderate heart failure 
patients remaining on digoxin therapy exerted better achievements in the 
exercise duration test and demonstrated a lower percentage of treatment 
failures when compared to patients without digoxin therapy (Uretski et al., 
1993). Worsening of health condition was also observed in chronic heart 
failure patients (NYHA functional class II and III) treated with ACE inhibitors 
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when digoxin was switched to placebo during the 12 weeks-lasting 
RADIANCE trial (Packer et al., 1993). 
Hood et al. (2004) in their meta-analysis that included 13 clinical trials 
with 7896 congestive heart failure patients reported a positive effect of 
digoxin on the clinical status of symptomatic patients and reduction of 
hospitalization incidence, although no effect of digoxin on the long-term 
mortality was observed. The effect of digitalis treatment in patients with 
heart failure does not depend on gender, and digoxin also exerts clinical 
benefits in elderly heart failure patients (older than 65 years of age) with 
sinus rhythm (Carosella et al., 1996; Domanski et al., 2005).  
Due to the lack of relevant data on the possible beneficial effect of 
digitoxin in heart failure treatment, Bavendiek et al. (2019) started a 
randomized, double-blind, placebo-controlled study, designed to demonstrate 
whether digitoxin on top of standard of care treatment improves mortality 
and morbidity in patients with heart failure and a reduced ejection fraction. 
This study was named DIGIT-HF (DIGitoxin to Improve ouTcomes in patients 
with advanced chronic Heart Failure). Only patients with chronic heart failure 
(NYHA functional class III-IV) and left ventricular ejection fraction ≤40% or 
patients in NYHA functional class II and left ventricular ejection fraction 
≤30% were enrolled. A total number of 2190 patients in approximately 
50 study centers in Germany and Austria were included. DIGIT-HF should 
provide important evidence, whether the cardiac glycoside digitoxin reduces 
the risk for all-cause mortality and/or hospital admission for worsening of 
heart failure in patients with advanced chronic heart failure with reduced 
ejection fraction, when concluded. 
 
2.3.4.3. EFFECT OF FOXGLOVE ON BLOOD, BLOOD CELLS, AND BLOOD VESSELS 
 
The influence of foxglove on platelet aggregation has yet to be fully 
understood and contradictory results regarding this topic have been reported 
throughout the time. For example, Ware et al. (1985) used blood samples 
obtained from healthy male volunteers before, and at 3, 5, and 7 weeks after 
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the beginning of digoxin therapy (0.375 mg/day). Digoxin treatment resulted 
in a significantly reduced total volume and mean size of platelet aggregates 
formed in response to ADP. The addition of nifedipine (a Ca2+ channel 
blocker), however, returned the parameters to baseline levels. 
On the other hand, Pettersen et al. (2002) evaluated the impact of 
digitoxin on platelet function in healthy volunteers administered with 
descending concentrations of digitoxin (starting with 0.6 mg and then 
reduced to 0.1 mg) for 10 days. No significant differences were observed 
between volunteers obtaining digitoxin and placebo in all parameters 
determined (expression of activated fibrinogen receptor, von Willebrand's 
factor receptor, P-selectin, formation of platelet-platelet and platelet-
leukocyte aggregates, and particle sizes). 
And finally, Chirinos et al. (2005) investigated the effect of digoxin on 
platelet aggregation in patients with nonvalvar atrial fibrillation. Patients on 
digoxin therapy exerted increased levels of P-selectin expression in platelets 
when compared to patients without digoxin. Further, an increased endothelial 
activation was also observed in patients with digoxin. These findings were 
also confirmed by the results of large cohort studies that reported an 
increased risk of ischemic stroke in patients with atrial fibrillation on digoxin 
therapy. Digoxin patients exhibited a 1.4-fold increase in the risk of ischemic 
stroke (Chang et al., 2013; Chao et al., 2014). Lai et al. (2018a) reported an 
increased risk of ischemic stroke in patients on digoxin therapy when 
compared to patients obtaining amiodarone. 
All of the abovementioned observations, with the exception of Ware 
et al. (1985), were surprisingly supported by Pastori et al. (2018), who 
performed the evaluation of digoxin's effect on platelet aggregation in healthy 
volunteers and in patients with atrial fibrillation both in vitro and in vivo. 
In vitro, platelets from healthy subjects and patients with atrial fibrillation 
were incubated with different digoxin concentrations in the range  
0.6 – 2.4 ng/mL, with or without the prestimulation with collagen. In patients 
with atrial fibrillation, an increased basal platelet activation was observed 
when compared to healthy subjects. Digoxin, at the highest concentration 
used, led to calcium mobilization and platelet aggregation in patients with 
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atrial fibrillation but not in healthy subjects. When compared in vivo, patients 
with atrial fibrillation on digoxin therapy were shown to have higher values 
of the 11-dehydrothromboxane B2, a marker of platelet activation, in urine 
than healthy volunteers (Pastori et al., 2018).  
As to the mechanism by which foxglove affects the platelet 
aggregation, the information is scarce. Le Quan-Sang et al. (1987) investigated 
the impact of digoxin on changes in cytosolic Ca2+ concentration in platelets 
and erythrocytes obtained from healthy volunteers before and during 
treatment with digoxin (0.250 mg) for six days. While digoxin had no effect on 
the calcium concentration in erythrocytes, the value of platelet cytosolic 
Ca2+ concentration was significantly increased. This change in calcium 
concentration was not a consequence of a reduced membrane sodium 
gradient but reflected either the overload of intracellular Ca2+ stores or 
enhanced in vivo stimulation by hormones or neurotransmitters. The 
involvement of calcium in platelet aggregation influenced by digoxin was also 
reported by Pastori et al. (2018) who observed increased platelet aggregation 
induced by a supratherapeutic dose of digoxin. This aggregation was 
mediated via calcium-related phospholipase A2 phosphorylation. 
 
2.3.4.4. ANTIHYPERTENSIVE EFFECT OF FOXGLOVE 
 
 Currently, the use of foxglove cardioactive glycosides (namely digoxin) 
in the Czech Republic is limited only to specific cases of heart failure or atrial 
fibrillation. However, several reports of the antihypertensive properties of 
foxglove can be found. For example, Ayachi and Hall (1976) used digitoxin 
(0.5 mg/day) in unilaterally nephrectomized rats with bilateral adrenal 
compression for 2 weeks, starting on day 8 postoperative. Rats were also 
administered with sodium chloride solution in order to induce hypertension. 
In the digitoxin treated group, 80% of rats were hypertensive at the end of 
the trial vs. 100% in the adrenal compression only group, and 30% in the 
control group. Furthermore, digitoxin treatment not only delayed the onset of 
hypertension, it also attenuated the hypertension parameters, such as systolic 
blood pressure, incidence and severity of renal lesions, and heart weight. 
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Neither adrenal enlargement nor thymic atrophy occurred in the rats treated 
with digitoxin.  
Digitoxin administered to rats at doses of 4-5 mg/kg for one week only 
also led to a decrease in systolic arterial pressure in spontaneously 
hypertensive rats, while this treatment had no effect of blood pressure of 
normotensive rats (Ayachi and Brown, 1980). 
Manunta et al. (2000) treated rats with ouabain, ouabagenin, digoxin, 
and digitoxin in infusions (30 µg/kg/day) for 5 weeks. While rats treated with 
ouabain and ouabagenin had significantly increased mean arterial blood 
pressure, rats obtaining digitoxin exhibited a significant decrease in mean 
arterial blood pressure. A decreasing tendency in mean arterial blood 
pressure was also observed in rats treated with digoxin, the result was, 
however, not statistically significant. Moreover, when rats with ouabain-
induced hypertension were administered digoxin, their values of mean 
arterial blood pressure decreased to control levels. 
Diuretic effect probably contributes to antihypertensive properties of 
foxglove cardenolides only to a small extent. Nearly 90 years ago Kellum 
(1932) reported that digitalis administered to healthy volunteers in 
therapeutic doses seemed to exert only a slight diuretic effect. Similarly, 
Navarro et al. (2000) observed a slight diuretic and natriuretic effect in 
rabbits treated with methanolic extract of D. purpurea L. spp. heywoodii, 
containing mostly gitoxin derivates,  at doses of 15 and 30 mg/kg. 
In 1991, a cardiotonic steroid structurally identical with the 
cardenolide ouabain was isolated from human plasma (Hamlyn et al., 1991). 
Since then, many works focusing on the structure and hormonal roles of these 
endogenous digitalis-like factors in hypertension were presented (e.g. 
Devynck et al., 1983 or reviews by Bagrov and Shapiro, 2008; Paczula, Więcek 
and Piecha, 2016). However, in 2019 Askari in his distinctly critical review 
regarding digitalis questioned both the role of such substances as well as their 




2.3.4.5. EFFECT OF FOXGLOVE ON LIPID PROFILE 
 
Foxglove is primarily not known for its beneficial effect on the serum 
lipid profile. When searching the literature on this topic, I found only one 
study dealing with foxglove. Ebaid et al. (2006) investigated the effect of 
digitonin on dyslipidemia induced by high sucrose intake in rats. After 
4 weeks of treatment with 30% sucrose, rats were administered with a single 
intra-gastric dose of digitonin (15 mg/kg). Digitonin decreased the free fatty 
acids level, and reduced triglyceride and VLDL cholesterol concentrations to 
the values of control rats. Digitonin also increased the value of 
HDL cholesterol/triglycerides ratio. 
A promising neuroprotective effect of digoxin and its semisynthetic 
derivates related to lipid contents was observed by de Souza Gonçalves et al. 
(2019) in their work focused on neural partial ischemia/reperfusion injury on 
a murine neuroblastoma cells neuro-2a model. When the cells were treated 
with sodium azide to induce ischemia, the content of phospholipids and 
cholesterol decreased. However, the cells pretreated with low concentrations 
of digoxin showed an increase in both phospholipids and cholesterol levels.  
Much earlier than this, digitonin was reported to also exert an 
interesting influence on phospholipids. Tsao and Cornatzer (1967) observed 
that digitonin and digitoxin in a mammalian cell culture influenced the 
metabolism of phospholipids. Digitonin stimulated the incorporation of 
inorganic orthophosphate into the phospholipids. Further, digitonin caused a 
linear increase in the specific activity of phosphatidylinositol and 
diphosphatidylglycerol. Digitoxin stimulated the incorporation of inorganic 
orthophosphate into phosphatidylinositol and sphingomyelin fraction of 
human heart culture cells. 
The effect of digitonin on Langmuir monolayers of phospholipids was 
investigated by Orczyk, Wojciechowski and Brezesinski (2017). Digitonin was 
able to adsorb at the air/water interface, both bare and covered with the 
uncompressed phospholipid monolayers. Digitonin reacted with the 




2.3.5. SAFETY PROFILE OF THE FOXGLOVE PREPARATIONS 
 
 According to Botanical Safety Handbook (Gardner and McGuffin, 
2013), the genus Digitalis is considered to be in the safety class 3, meaning 
that the herb should be used only under the supervision of an expert qualified 
in the appropriate use of this substance. 
The cardiac glycosides have many adverse effects that are largely 
dose related and require careful monitoring of drug levels. The most common 
side effects include dizziness, fatigue, headache, anxiety, gastrointestinal 
upset, change in taste, and blurred vision (photopsia was also reported). 
Severe side effects include seizures and coma, heart block, atrial and 
ventricular arrhythmias, and sudden cardiac death. Digoxin toxicity was 
reported to be significantly more frequent in patients over 80 years of age 
than in younger patients. On the other hand, cardiac glycosides have not been 
reported to cause any clinically significant liver injury (Taylor, 1985; 
Carosella et al., 1996; Oishi et al., 2006; Ramlakhan and Fletcher, 2007; 
LiverTox, 2018). 
A large study (17897 patients) on the effect of digoxin on mortality in 
patients with atrial fibrillation concluded that the risk of death and sudden 
death was significantly higher in new digoxin users. Patients with serum 
digoxin concentration ≥1.2 ng/mL also had a 56% increased hazard of 
mortality compared with those not on digoxin. For patients both with and 
without heart failure, for each 0.5 ng/mL increase in serum digoxin 
concentration, the risk of death was 19% higher compared to patients 
without digoxin therapy (Lopes et al., 2018). An increased risk of all-cause 
death in patients with non-valvular atrial fibrillation on digitalis therapy was 
also reported by Kodani et al. (2019). Significant risk factors in digitalis 
treated patients were older age, male sex, heart failure, coronary arterial 
disease, and lower body mass index. 
Needless to say, Gonzalez-Loyola et al. (2018) in their cohort study, 
which included 13334 heart failure patients, found no association of digoxin 
or diuretics with higher mortality in these patients, which is a contradictory 
observation to the abovementioned studies. 
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The high interaction potential of Digitalis and digoxin has been 
recognized in several works. For example, Botanical Safety Handbook 
classified the genus Digitalis as herb belonging to the interaction class C 
meaning herbs with clinically relevant interactions. Digoxin has a narrow 
therapeutic index, its serum concentrations should be within the range of 0.5 
– 0.8 ng/mL. Supratherapeutic concentrations of digoxin may cause severe 
adverse effects (Lincová and Farghali, 2007; Gardner and McGuffin, 2013). 
The requirement of an experienced prescribing physician where digoxin 
therapy is considered is also mentioned by Ewy (2015) who noticed that 
digitalis toxicity was and is almost always iatrogenic. 
On the pharmacokinetic level, the mechanism of digoxin interactions 
with other drugs is mainly due to the interference with the P-glycoprotein 
transporter. Inhibitors of P-glycoprotein can enhance oral bioavailability of 
digoxin by decreasing its efflux from the enterocytes into the lumen of the 
intestine and decrease its active tubular secretion into the urine in the kidney. 
Well-known P-glycoprotein inhibitors are, for example, verapamil and 
amidarone used in cardiology, or macrolide antibiotics. Concomitantly 
administered verapamil and digoxin were shown to lead to an increase of 
serum digoxin concentration by 70% (Marcus, 1985; Mladěnka et al., 2018). 
Pharmacodynamic interactions of digoxin with other drugs have an 
impact on the pharmacological performance of digoxin by increasing or 
decreasing its therapeutic effect. For example, the additive negative 
chronotropic effect of beta blockers combined with digoxin can result in 
bradycardia or even an atrioventricular block (partial or complete 
interruption of impulse transmission from the heart atria to the ventricles), 
digoxin administered concomitantly with amiodarone may cause 
dysrhythmias. Antikaliuretic drugs amiloride and triamterene were reported 
to increase the inotropic actions of cardenolides. Interestingly, licorice was 
also reported to be able to increase digoxin toxicity. On the other hand, 
concomitant administration of digoxin with herbal preparations of another 
cardiotonic herb, hawthorn, was shown to be safe for the patients (Seller 
et al., 1975; Tachijan, Maria and Jahangir, 2010; Holubarsch, Colucci and Eha, 
2018; Mladěnka et al., 2018). 
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2.4. MOTHERWORT – LEONURUS SPP. – FAM. LAMIACEAE 
 
2.4.1. CHARACTERIZATION OF THE LEONURUS GENUS – A PHARMACOGNOSTIC CONTEXT 
 
According to the Assessment report on Leonurus cardiaca L., herba 
(EMA/HPMC/127430/2010), the Leonurus genus comprises 24 species, 
which are divided in 3 sections and in 5 sub-sections. The taxonomy of 
Leonurus is complicated, several different methods for identifying the 
individual Leonurus species have been suggested (Yang et al., 2011 –
 molecular analysis based on ITS sequences; Marciniuk et al., 2013 – 
molecular analysis based on RAPD markers; Pitschmann et al., 2017 –
 anatomical characteristics, such as corolla shape and trichomes; Garran et al., 
2019 – discriminating metabolite isomerism strategy). 
In this work, all of the names of the motherwort species are used as 
presented by the authors of the respective studies, however, the official 
botanical names are as follows: 
 Leonurus cardiaca L. – motherwort cardiaca 
 Leonurus japonicus Houtt. (synonyms: Leonurus heterophyllus 
Sweet, Leounurus artemisia (Lour) S.Y. Hu) – Chinese motherwort 
 Leonurus cardiaca L. var. villosus Desf. (synonyms: Leonurus 
quinquelobatus Desf.) 
L. japonicus Houtt. and L. cardiaca L. (Fig. 2.7.) are the typical species 
in Eastern Asia and in Europe, respectively. L. cardiaca L. is a perennial herb 
widespread in Europe, commonly found in rural areas throughout the 
lowlands and foothills. The plants are sparsely pubescent, reaching the height 
of 50 – 200 cm, pink blooming in June and July. Motherwort is even 
recognized as one of the most valuable melliferous plants (Wojtyniak, 













For medicinal use (Leonuri cardiacae herba), the blooming tops of 
the herb up to 40 cm are used only. They are collected at the beginning of the 
flowering. The thickness of the stems must not exceed 4 mm in diameter. The 
plant material can be whole or cut; it should be dried at a temperature of 
35 °C. The drying temperature seems to be important especially for the 
storing of labdane diterpenes, as they were reported to decompose as low as 
40 °C (Fuchino et al., 2013).  
For the quality control of the herb, different chemical compounds are 
applied as standards for various Leonurus species. For the Chinese Herba 
leonuri, the alkaloids leonurine (> 0.05%) and stachydrine, and for the 
Fig. 2.7. Leonurus cardiaca L. upper left – whole plant, upper right – closeup of flowers. Leonurus 
japonicus Houtt. down left –  whole plant, down right – closeup of flowers. From botany.cz, 
minnesotawildflowers.info, botany.hawaii.edu, alchetron.com. 
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European Leonuri cardiacae herba, a minimum of 0.2% of flavonoids, 
expressed as hyperoside; these are calculated with reference to the dried 
drug and respectively used as quality control markers (according to the 
relevant authorities: National Pharmacopoeia Committee, 2015 and European 
Pharmacopeia 10.0). 
 
2.4.2. PHYTOCHEMISTRY OF MOTHERWORT 
 
 The characteristic compounds of the Leonurus genus are alkaloids, 
diterpenes, triterpenes, iridoide glycosides, flavonoids, phenolic compounds, 
and sterols (Fig. 2.8.). Essential oils are also present in traces (about 0.03%). 
In the essential oil from the leaves of L. cardiaca L., mainly caryophylene 
(39.8%) and α-humulene (34.8%) occur. The essential oil of the aerial parts of 
L. panzeroides Popov contains mainly eugenol (30.93%) and p-vinyl-guaiacol 
(15.77%), while that of L. turkestanicus V. I. Krecz & Kuprian is rich in thymol 
(40.10%) and octen-3-ol (13.07%; Mamadalieva et al., 2017; 
Sermukhamedova et al., 2017; Fierascu et al., 2019 and references therein). 
 The Leonurus alkaloids, especially leonurine and stachydrine 
(Fig. 2.8.), are of great interest because of their pharmacological properties, as 
will be described in detail in the latter chapters. The guanidine alkaloid 
leonurine is more typical for the Chinese motherwort than for motherwort 
cardiaca: the respective content of leonurine was determined for the aerial 
parts of L. japonicus Houtt. within the range of 0.001% – 0.102% compared to 
a value of 0.0068% or not even detected for aerial parts of L. cardiaca L. 
(EMA/HPMC/127430/2010; Kuchta, Ortwein and Rauwald, 2012; Zhang 
et al., 2018). The process of synthesizing of artificial leonurine with the same 
pharmacological properties as the naturally occurring alkaloid was also 
reported (Cheng et al., 1979), and this synthetic leonurine or its derivates 
were tested in several studies (see Ch. 2.4.4.2.). 
 Stachydrine represents alkaloids with a quaternary ammonium cation. 
It is another important pharmacologically active compound found not only in 
the Leonurus genus but also in several other species within the family 
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Lamiaceae, or even belonging into other plant families. The content of 
stachydrine in the plant is higher than that of leonurine; in the aerial parts of 
L. cardiaca L. it was reported within the range of 0.6 – 1.5%, and within the 
range 0.2 – 1.0% for the aerial parts of L. japonicus Houtt. (Kuchta, Volk and 
Rauwald, 2013; Zhang et al., 2018). 
 Bitterly tasting diterpenes of the Leonurus genus usually belong to the 
labdane type. So far, around 147 labdane diterpenes were isolated from 
various Leonurus species; more than 90 of them can be found in L. japonicus 
Houtt. (Zhang et al., 2018; Miao et al., 2019). Knöss and Zapp (1998) 
investigated the accumulation of furanic labdane diterpenes in L. cardiaca L. 
The labdane diterpenes were produced and accumulated only in the aerial 
parts, especially in the leaves and flowers. The highest content of labdane 
diterpenes was found in the young leaves and buds. Labdane diterpenes are 
at least partially stored in the peltate glandular trichomes.  
According to Zhang et al. (2018), anti-inflammatory properties are the 
main action of the labdane diterpenes. However, in the last years a fair 
number of new labdane diterpenes were isolated from various Leonurus 
species, and several of them exhibit beneficial pharmacological actions, such 
as cytoprotection, anti-aggregation, antioxidant properties, and inhibition of 
acetylcholinesterase (Satoh et al., 2003; Boalino et al., 2004; Giang et al., 
2005; Cai et al., 2006; Romero-Gonzáles et al., 2006; Agnihotri et al., 2008; 
Fuchino et al., 2013; Xiong et al., 2015b; Lai et al., 2018b; Jiang et al., 2019). 
Several flavonoids were isolated from the Leonurus genus, including 
rutin, genkwanin, quercetin, and kaempferol. Hyperoside is used as the 
quality control of Leonuri cardiacae herba (Zhang et al., 2018, European 
Pharmacopoeia 10.0). 
Out of the other phenolic compounds present in the Leonurus genus, 
verbascoside (Fig. 2.8.) and lavandulifolioside are of great importance. 
Lavandulifolioside in fact represents the arabinoside of verbascoside, and the 
content of it in the aerial parts of L. cardiaca L. was determined to be 0.1%. On 
the other hand, verbascoside, also known under the name acteoside, can be 
found both in the aerial parts and the roots of motherwort, and in 
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approximately 200 other plant species belonging to 23 plant families 

















The phytochemistry of motherwort is fairly interesting – new 
compounds with different pharmacological properties have been isolated in 
the last few years, several of them for the first time in the Leonurus genus. 
Apart from the abovementioned labdane diterpenes, for example, iridoid 
Fig. 2.8. Some of the active compounds of the Leonurus genus. Up – leonurine, middle left – 




glycosides with antimicrobial activity (Tasdemir et al., 1999), phenylethanoid 
glycosides with hepatoprotective activity (Li et al., 2012), sesquiterpenoids 
and their glycosides (Li et al., 2012; Xiong et al., 2013), and glucarid acids 
with hepatoprotective activity (Jiang et al., 2015) were discovered.  Similarly, 
as reported by Garran et al. (2019), a total of 257 hydrophilic compounds 
were identified in the chemical profile of L. japonicus Houtt. and L. cardiaca L., 
using their developed discriminating metabolite isomerism strategy. Out of 
them, 212 compounds were found for the first time in the Leonurus genus. 
 Moreover, geographical and seasonal differences in motherwort's 
active constituents have been reported. Knöss and Zapp (1998) found that no 
labdane diterpenes were detected in L. cardiaca L. plantlets during the first 
four to five weeks following the germination. Tan et al. (2020) studied 
samples of L. japonicus Houtt. from 11 different producing regions in China 
and reported that the different geographical position could affect the 
accumulation of the active compounds. 
 
2.4.3. MEDICINAL USE OF MOTHERWORT 
 
 According to the EMA monograph on Leonurus cardiaca L. herba, the 
traditional use is for relieving symptoms of nervous tension and/or for 
relieving symptoms of nervous cardiac complaints such as palpitations, after 
serious conditions have been excluded by a medical doctor 
(EMA/HMPC/127428/2010). However, several Leonurus species were 
proven to exhibit a beneficial effect in more areas, including gynecological 
disorders, neuroprotection, anti-inflammatory, and antimicrobial activity 
(Wojtyniak, Szymański and Matławska, 2013; Sayed et al., 2016; Zhang et al., 
2018). 
 Motherwort can be used as a comminuted or powdered herbal 
substance, tincture, or liquid extract. In traditional Chinese medicine, Zhixion 
capsules are also used. They contain an equal mixture of extracts from four 
plants (including L. japonicus Houtt.) and leech extract, and are used against 
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inflammation, hyperlipidemia (their effect is comparable with that of 
simvastatin), or blood stasis (EMA/HMPC/127428/2010; Zhai et al., 2019). 
 
2.4.4. EFFECTS OF MOTHERWORT ON SELECTED CARDIOVASCULAR CONDITIONS 
 
2.4.4.1. ANTIOXIDANT EFFECT OF MOTHERWORT 
 
 Matkowski and Piotrowska (2006) performed several assays with 
methanolic extracts obtained from six wild European species belonging to the 
family Lamiaceae (including L. cardiaca L.) in order to assess their antioxidant 
effects. In the free radical-scavenging activity (DPPH) test, the motherwort 
extract was evaluated as the strongest one. In the lipid peroxidation assay, the 
maximum inhibition reached was 78% (Salvia officinalis L., Marrubium 
vulgare L.), L. cardiaca L. slightly exceeded 70%. These results indicate a great 
antioxidant potential in L. cardiaca L. 
 The high antioxidant activity of a L. cardiaca L. fluid extract was also 
confirmed by Bernatoniene et al. (2009). In the free radical-scavenging 
activity test, motherwort extract was assessed as the strongest one of the 
extracts tested (inhibition by nearly 85%). An antioxidant activity about 15-
fold lower than the antioxidant activity of ascorbic acid was observed in 
polyphenol-rich extract from L. cardiaca L. (Sadowska et al., 2017), while 
Pereira et al. (2019) reported the antioxidant activity of a hydroethanolic 
extract from L. cardiaca L. to be approximately three times higher than that of 
ascorbic acid. This extract also showed an antioxidant activity in a cell culture 
previously exposed to potassium dichromate in order to cause a massive 
increase in reactive oxygen species. This effect could be countered by the 
extract from L. cardiaca L. 
In the free radical-scavenging test, ethanolic extract from L. sibiricus L. 
exhibited a weak antioxidant effect, as reported by Park et al. (2016). 
However, Oliveira et al. (2017) investigated the antioxidant, anti-nociceptive, 
and local anti-inflammatory effect of the ethanolic extract from L. sibiricus L. 
(total phenolic and flavonoid contents 60.1 mg of gallic acid and 15.4 mg of 
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catechin equivalent/g extract, respectively). In the in vitro antioxidant assays 
this extract displayed strong antioxidant properties (including the inhibition 
of a spontaneous or a ferrous sulphate-induced lipid peroxidation).  
 All of these partially contradicting results may be the consequence of 
the variation in active compounds in the plants (see Ch. 2.4.2), and the various 
solvents used resulting in different chemical compositions and subsequent 
antioxidant activity of the tested extracts. For example, Jafari et al. (2010) 
used the aerial parts of L. cardiaca L. for the determining the total phenolics 
and flavonoids, and their antioxidant activity in different solvents. The 
primary extract was obtained by using methanol 80% (v/v), then it was dried 
and the dry extract was fractioned using chloroform, ethyl acetate, n-butanol, 
and methanol 50% (v/v). The highest inhibition in the extensively used DPPH 
assay was obtained by the n-butanolic extract (86.2%), although this extract 
did not contain the highest amounts of either phenolics or flavonoids. 
Similarly, Chua and Aminah (2013) tested the antioxidant activity of 
L. sibiricus L. leaves extracted by two different solvents in three bioassay 
systems (auto-oxidation of linoleic acid lipid system, xanthine oxidase 
superoxide scavenging activity, and DPPH radical scavenging activity). In all 
the bioassays performed, the aqueous leaf extract antioxidant activity was 
marked as high (72.2 – 78.2%), while the antioxidant activity of the ethanolic 
leaf extract was high in only one assay (71.6%) and moderate in two of the 
assays (69.7% and 48.8%, respectively). The most significant difference 
(29.4%) in the determined antioxidant activity of the two extracts was in the 
most used DPPH assay. Therefore, a standardization of the tested extracts 
would be very helpful. 
 Triterpenoids of the ursane class isolated from ethanolic extract of 
L. cardiaca L. (ursolic acid, ilelatifol D, corosolic acid, and euscaphic acid) 
were tested for their superoxide scavenging activity both in a cellular and a 
cell-free system by Ali et al. (2007). Ursolic acid did not exhibit any 
scavenging activity in the cell-free system (xanthine/xanthine oxidase 
system), while in the respiratory bursts activity with activated neutrophils it 
was the most effective compound tested (nearly 75% inhibition). Other 
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triterpenoids were only mildly active in the respiratory burst assay (11 -
16% inhibition) and also showed a low superoxide scavenging activity. 
 Other terpenic compounds occurring in the Leonurus genus also 
exhibit antioxidant properties, as reported by Lai et al. (2018b) in their 
screening of new diterpenes from L. japonicus Houtt. 
The alkaloid stachydrine was reported to decrease the number of ROS 
positive myocardial cells in a myocardial cell hypertrophy model (Guo et al., 
2012). The beneficial effect of stachydrine in the cardiac hypertrophy model 
was also observed by Cao et al. (2017; a reduced generation of ROS) and Zhao 
et al. (2017b; an increased activity of superoxide dismutase and decreased 
malonyl dialdehyde levels in the serum of rats with an isoproterenol-induced 
cardiac hypertrophy). 
Stachydrine likely also has a protective role in an anoxia/reperfusion 
model of endothelial cell injury. Stachydrine treatment of human umbilical 
vein endothelial cell culture restored the declined concentrations of 
superoxide dismutase and glutathione peroxidase after anoxia/reoxygenation 
(Yin et al., 2010). 
 The antioxidative properties of another Leonurus alkaloid, leonurine, 
were also reported in cardiomyocytes (Liu et al., 2010a, 2010b, 2013; Wang 
et al., 2019), endothelial cells (Liu et al., 2012a, 2012b; Zhang et al., 2012), 
podocytes (Liu et al., 2018), or brain tissue (Liu et al., 2012). In all the 
abovementioned studies, treatment of the respective tissue with leonurine led 
to a decreased ROS production and to the induction of various antioxidant 
enzymes, such as superoxide dismutase or catalase. 
 
2.4.4.2. DIRECT EFFECT OF MOTHERWORT ON MYOCARDIUM 
 
 Miłkowska-Leyck, Filipek and Strzelecka (2002) reported that both 
the n-butanolic extract and lavandulifolioside, a phenylpropanoid glycoside 
isolated from L. cardiaca var. vulgaris [Moench] Briquet aerial parts, exhibited 
negative chronotropic properties. Lavandulifolioside administered to the 
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isolated rat heart at doses of 1 – 100 µg non-significantly decreased heart rate 
(by 4 – 19%), while higher doses (200 – 2000 µg) managed to decrease the 
heart rate significantly (by 23 – 29%). The butanolic motherwort extract 
demonstrated its negative chronotropic action at an even lower dose than 
pure lavandulifolioside (50 µg). At higher doses, both lavandulifolioside and 
the butanolic motherwort extract also caused several significant EKG-changes 
(namely the prolongation of the P-Q interval, Q-T interval, and QRS complex).  
 On the other hand, another phenolic compound from Leonurus genus, 
the phenylethanoid glycoside verbascoside, was reported to exhibit positive 
chronotropic and inotropic properties. Pennachio et al. (1996) observed a 
significant increase in the heart rate (by 42%) and an increase in the 
contractile force (by 13%) after administration of verbascoside at the 
concentration of 1 mmol/L into isolated rat hearts. The positive chronotropic 
effect lasted for several minutes, while the positive inotropic effect 
diminished within two minutes after the onset (Pennachio, 1997). These 
effects coincided with remarkable increases in intracellular levels of cAMP 
(an increase by 1733%; Pennachio et al., 1996). Seeing as the verbascoside 
content in the aerial parts of motherwort is lower than the content of 
lavandulifolioside (91.1 µg/mL and 169.1 µg/mL, verbascoside and 
lavandulofolioside, respectively in a butanolic extract from L. sibiricus L.; 
Pitschmann et al., 2016), the predominant chronotropic effect is likely to be 
that of lavandulifolioside. 
 Sun et al. (2005) observed a cardioprotective effect from an aqueous 
extract of L. heterophyllus Sweet aerial parts on rats exposed to a myocardial 
injury (after a surgical procedure the developed infarct sizes ranged between 
40% and 60% of the left ventricular mass). The extract containing mainly 
stachydrine, quercetin, kaempferol, leonurine, and apigenin exhibited strong 
antioxidant activity in vitro, and helped, especially in the acute phase, to 
attenuate the damage to rat hearts caused by the myocardial infarction via 
restoring the activity of the cardiac antioxidant enzymes superoxide 
dismutase and glutathione peroxidase. 
 The protective effect of L. japonicus Houtt on a myocardial remodeling 
induced by isoproterenol was reported by Zhang et al. (2011). The authors 
97 
 
concluded that treatment with motherwort had a beneficial effect on both 
systolic and diastolic function, and downregulated the expression of collagen.  
 Subsequently, several studies with two pure compounds isolated from 
the Leonurus genus – the alkaloids stachydrine and leonurine – were 
performed on the model of a myocardial ischemia and/or fibrosis 
(remodeling), both in vitro and in vivo. Unfortunately, all of the studies that 
will be mentioned in the following text used only one of the abovementioned 
alkaloids (i.e. either stachydrine or leonurine), thus not enabling to provide 
information about the presence or absence of a possible synergistic effect of 
these two cardioprotective compounds. 
The effect of stachydrine on the noradrenaline-induced hypertrophy 
of cardiomyocytes in vitro was studied by Zhang et al. (2014a). Ventricular 
myocytes were isolated and cultured with noradrenaline in the presence or 
absence of stachydrine for 72 hours. The hypertrophy was characterized by 
increased cell surface area, protein synthesis, and changes in the intracellular 
calcium transients (an increased Ca2+ amplitude, an accelerated decay of the 
Ca2+ transient). In correlation to increased norepinephrine, the activation of 
β1-adrenergic system (an increased intracellular cAMP level leading to the 
overactivation of protein kinase A – PKA) was also observed. All of these 
changes were significantly inhibited with the addition of 10 µmol/L 
stachydrine to the cultivation medium. 
Zhao et al. (2017b) generated an overload-induced cardiac 
hypertrophy and heart failure in rats by performing an aortic constriction 
surgery. Animals were treated either with telmisartan (selective AT1R 
antagonist as the positive control) or stachydrine (8 mg/kg) for 12 weeks. 
Stachydrine treatment significantly attenuated the hypertrophy of the heart, 
characterized by increased weight of the heart, heart weight/body weight 
ratio, and left ventricle wall thickening. The hemodynamic parameters were 
also improved by the stachydrine treatment – the ejection fraction was 
enhanced; the cardiac output, the stroke work, and the potential energy were 
normalized. Moreover, rats treated with stachydrine showed considerably 
less fibrous tissue, suggesting that stachydrine was able to attenuate the 
myocardial fibrosis. Based on the Western blotting analysis of the heart tissue 
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protein lysates, increased levels of the two main receptors of TGF-β 
(transformation growth factor β1), TGF-βR1 and TGF-βR2, were found in the 
hypertrophic hearts. The TGF-β is an important fibrotic mediator and effector 
in the fibrotic process and the regulation of the extracellular matrix in 
general. The decrease of TGF-βR2 after stachydrine administration thus may 
represent a part of the antifibrotic effect of stachydrine (Zhao et al., 2017b 
and references therein). 
Confirmation of the antifibrotic effect of stachydrine in another animal 
heart failure model was presented by Liu et al. (2019,) who also tried to 
further elucidate the molecular mechanism of such an effect. The authors 
used mice with transverse aorta constriction surgery in order to generate the 
cardiac hypertrophy and heart failure. Animals were treated with either 
telmisartan as a positive control or stachydrine (a higher dose was used than 
in the previous study, 12 mg/kg) for 4 weeks. The cardiac hypertrophy was 
characterized firstly by increased heart weight/body weight ratio, which was 
significantly decreased with telmisartan treatment and showed a trend of 
such reduction in the stachydrine treated group, and secondly by the 
thickness of left ventricular wall – this parameter was also partially alleviated 
with stachydrine. Again, stachydrine treatment suppressed the markers of the 
myocardial fibrosis (including collagen I and III, and elevated transcriptional 
levels of ACE, AT1R, and TGFβ1). The molecular mechanism of the antifibrotic 
effect of stachydrine includes the suppression of the fibrotic axis regulated by 
angiotensin II and TGFβ1 via certain signaling pathways that finally enhance 
the transcriptional control of fibrosis-related genes. 
The cardioprotective effect of leonurine was investigated by Liu et al. 
(2009) on isolated neonatal rat cardiomyocytes and on infarcted rat hearts. 
The cardiomyocytes were treated with leonurine at 1 mmol/L concentration 
8 hours prior to exposure to the hypoxia and serum deprivation (in order to 
induce ischemia). Leonurine treatment led to the induction of the antioxidant 
enzymes superoxide dismutase and catalase, and to a significantly increased 
cell viability. In the leonurine treated cells, the gene expression levels of pro-
apoptotic genes (Bax, Fas) were significantly downregulated, while the anti-
apoptotic Bcl-2 gene expression was upregulated. In the whole-heart model, 
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rats were administered leonurine intraperitoneally one week prior to left 
coronary artery ligation, which induced ischemia. Leonurine treatment led to 
a significantly decreased infarct size in the hearts. 
In their following studies, Liu and his colleagues again confirmed the 
anti-apoptotic action of both naturally occurring leonurine (Liu et al., 2010a) 
and synthetic leonurine (SCM-198; Liu et al., 2010b; 2010c) on rat hearts and 
cardiomyocytes. The downregulation of the pro-apoptotic gene Bax and the 
upregulation of anti-apoptotic gene Bcl-2 were observed in the isolated rat 
hearts and in an H9c2 cardiac myocyte model (rat embryonic heart-derived 
cells). Furthermore, leonurine treatment led to a decrease in the infarct size 
of the ischemic rat hearts (Liu et al., 2010a) and it also significantly improved 
the myocardial function (Liu et al., 2010b). The H9c2 cells exposed to 
hydrogen peroxide, with a leonurine pretreatment for mere 4 hours, led to a 
concentration-dependent increase in cell viability and to the attenuation of 
apparent apoptotic characteristics (including the fragmentation of DNA, the 
translocation of the Bax protein to mitochondria, the loss of mitochondrial 
membrane potential, and the activation of caspase 3; Liu et al., 2010c).  
Similarly, Xu et al. (2018) reported on the anti-apoptotic properties of 
leonurine treatment in rats with a surgically induced myocardial infarction 
(ligation of the left coronary artery). Leonurine (15 mg/kg) was administered 
for 4 weeks. This treatment resulted in a significant downregulation of the 
pro-apoptotic gene Bax expression and a significant increase in the anti-
apoptotic gene Bcl-2 expression. Moreover, a significant reduction of the 
infarct size and a remarkable decrease in the collagen content was observed 
in the leonurine treated group. 
Based on their studies, Liu, Gu and Zhu (2010) even proposed a 
synthetic leonurine conjugate as a new cardioprotective agent. The conjugate, 
namely 3,5-dimethoxy-4-(2-amino-3-prop-2-ynylsulfanyl-propionyl)-benzoic 
acid 4-guanidino-butyl ester, was designed with an improved pharmacology 
efficiency by combining leonurine with S-propargyl-L-cysteine via a phenolic 
hydroxyl ester bond, which could be readily hydrolyzed. This conjugate was 
effective at a lower molar concentration than pure leonurine. 
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2.4.4.3. EFFECT OF MOTHERWORT ON BLOOD, BLOOD CELLS, AND BLOOD VESSELS 
 
A significant improvement in rheological properties of human blood (a 
decrease of platelet aggregation, blood viscosity, fibrinogen volume, and an 
increase of the red blood cells deformability) was observed by Zou et al. 
(1989) in their clinical study with 105 patients who were administered with 
motherwort extract (L. heterophyllus Sweet) for 15 days.  
The inhibition of platelet aggregation by L. heterophyllus Sweet was 
again confirmed two years later by Lee et al. (1991). The authors had isolated 
prehispanolone, a labdane diterpene, from the herb and tested its activity on 
both rabbit platelet membranes and intact rabbit platelets. Prehispanolone 
inhibited the specific platelet activating factor (PAF) from binding to rabbit 
platelet membranes. The inhibitory potency of prehispanolone was increased 
in the presence of sodium chloride in a certain concentration range. In a 
concentration-dependent manner, prehispanolone also inhibited the PAF 
binding to intact rabbit platelets. The authors also tested prehispanolone 
binding to some other types of receptors, such as calcium channels, 
benzodiazepine receptors, nucleoside transporter, and A2 adenosine 
receptors, but it showed no binding activity whatsoever. With the structural 
changes in the molecule of prehispanolone the PAF-binding activity also 
differed: opening up of the tetrahydrofuran ring resulted in the loss of such 
activity, while the replacement of the keto moiety with a methoxy or hydroxyl 
moiety led to a significantly increased PAF-binding activity. Based on these 
findings, it was suggested that prehispanolone interacts with the PAF 
receptor as an antagonist (Lee et al., 1991). 
Xiong et al. (2013) reported a strong platelet aggregation inhibition of 
rat platelets induced by ADP with a sesquiterpenic compound (namely 
(2S,5S)-2-hydroxy-2,6,10,10-tetramethyl-1-oxaspiro[4.5]dec-6-en-8-one) that 
was isolated from the ethyl acetate fraction of an ethanolic extract of 
L. japonicus Houtt. Yang et al. (2014) also observed the in vitro inhibition of 
platelet aggregation of platelets induced by ADP in the presence of isogosferal 
and murrayone, two coumarins isolated from L. japonicus Houtt. 
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Similarly, a L. cardiaca L. polyphenols-rich extract with a 
concentration of 100 µg/L significantly reduced platelet aggregation, but only 
in the presence of arachidonic acid. No significant effect was found for either 
ADP- or collagen-induced platelets, regardless of the motherwort extract 
concentration. A significant reduction was found in the PAF secretion by the 
cells treated with 50 and 100 µg/L of motherwort extract for 4 hours as well 
as 24 hours (Sadowska et al., 2017).  
A possible explanation of the mechanism of platelet aggregation 
inhibition by L. cardiaca L. extract was proposed two years later by Sadowska 
et al. (2019). The authors again used a polyphenols-rich extract (with 
hydroxycinnamic acid derivates as the predominant phenolic compounds) on 
human platelets obtained from healthy volunteers. The motherwort extract 
significantly reduced both the adhesion of platelets to fibrinogen and the 
expression of the receptor GPIIB/IIa on the ADP-activated platelets. 
Moreover, the highest concentration of motherwort extract used (350 µg/L) 
also decreased the expression of the adhesion molecule P-selectin. These 
findings led the authors to the conclusion that the disruption of the platelet-
fibrinogen interactions may explain the antiplatelet effect of the motherwort 
extract. 
The motherwort alkaloid leonurine had been reported to induce 
vasorelaxation. Chen and Kwan (2001) observed a concentration-dependent 
and endothelium-independent vasorelaxation of rat aortic arterial rings 
pretreated with phenylephrine in the presence of leonurine. The authors 
tested the activity of leonurine in several mediums leading them to the 
suggestion that leonurine is an effective inhibitor of vascular smooth tone, 
most likely acting by inhibiting  the Ca2+ influx and the release of intracellular 
Ca2+.  
The more abundantly occurring alkaloid stachydrine also contributes 
to the vasorelaxation, as observed by Xie et al. (2018). Rat thoracic aortas, 
mesenteric arteries, and renal arteries were incubated with homocysteine or 
a control medium for one hour before measuring the acetylcholine-induced 
endothelium-dependent relaxation. Homocysteine significantly impaired the 
vasorelaxation in all three types of arteries but stachydrine effectively 
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restored the vascular relaxation in response to acetylcholine. As observed in 
tests with an inhibitor of the nitric oxide synthase (L-NAME), the stachydrine-
promoted vasorelaxation was dependent on nitric oxide signaling. 
Active compounds from a phenolic-rich L. sibiricus L. extract were 
reported to have a beneficial influence on the endothelial dysfunction, as 
demonstrated by Lee et al. (2010). Human umbilical vein endothelial cells 
were incubated with various concentrations of L. sibiricus L. extract for one 
hour before the addition of TNF-α, and then incubated for another 12 hours. 
The expression of adhesion molecules (namely the vascular cell adhesion 
molecule-1 (VCAM-1) and the intercellular adhesion molecule-1 (ICAM-1)) 
was significantly lower in the cells treated with motherwort extract than in 
the control. The reduction of VCAM-1 was up to 94% with the mothewort 
extract concentration of 400 µg/L. 
The protective effect of the alkaloid stachydrine on the endothelial 
function was observed by Xie et al. (2018) who used bovine aorta endothelial 
cells coincubated with homocysteine. In these cells, the nitric oxide 
production was significantly reduced, but 12 hours of pretreatment with 
stachydrine effectively attenuated the effect of homocysteine on 
NO production in the endothelial cell culture. The authors also reported that 
homocysteine decreased the production of BH4, an essential cofactor for 
endothelial nitric oxide synthase to completely couple the NADPH oxidation 
to the NO production. However, the stachydrine pretreatment effectively 
restored the BH4 level in the endothelial cell culture. More specifically, 
stachydrine can induce the phosphorylation of the endothelial nitric oxide 
synthase and the subsequent vasorelaxation by the activation of AMP-
activated protein kinase and protein kinase B/Akt (Xie et al., 2019). 
Liu et al. (2012a; 2012b) in their in vitro studies reported that the 
pretreatment of human umbilical vein endothelial cells, activated with 
lipopolysaccharide (2012a) or with TNF-α (2012b), with the alkaloid 
leonurine led to a significantly decreased expression of the adhesion 
molecules (ICAM-1, VCAM-1).  
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A decrease in the levels of the serum soluble adhesion molecules 
(sICAM-1, sVCAM-1) was also observed in an in vivo study with rabbits fed a 
high-cholesterol diet and treated with synthetic leonurine (SCM-198) for 
8 weeks. In the aortas of these rabbits, a decrease in the expression of 
platelet-endothelial cell adhesion molecule-1 and the mRNA levels of VCAM-1 
was also observed. Leonurine treatment significantly alleviated the 
development of atherosclerosis in a dose-dependent manner: the 
atherosclerotic lesions were smaller, the elasticity of the arteries and the 
hemodynamic status improved, and a decrease of the smooth muscle cell 
migration, and macrophage infiltration was observed (Zhang et al., 2012). 
 
2.4.4.4. ANTIHYPERTENSIVE EFFECT OF MOTHERWORT 
 
 Pure lavandulifolioside isolated from L. cardiaca L. administered 
intravenously at a dose of 77 mg/kg to normotensive rats produced a 
significant decrease in both systolic (by 13 – 15%) and diastolic (by 16 –
 19%) blood pressure. The duration of the action was for more than one hour 
(Miłkowska-Leyck, Filipek and Strzelecka, 2002). 
 Shikov et al. (2011) used L. cardiaca L. extracted with soybean oil 
(1:10, w/v) to ensure extraction of non-polar and middle-polarity 
compounds, such as iridoids. The extract was administered to 50 volunteers 
with stage 1 or 2 hypertension, accompanied with anxiety and sleep disorders 
(600 mg oil extract twice daily) for 4 weeks. In the patients with 
stage 1 hypertension, the statistically significant onset of the hypotensive 
effect was reported a week earlier than in patients with stage 2 hypertension 
(21 days and 28 days, respectively). In addition, a positive improvement in 
the psycho-emotional status of the patients (anxiety, emotional liability, 
headache, and sleep disorders) was observed. 
 Wojtyniak, Szymański and Matławska (2013) in their review on 
L. cardiaca L. mentioned old studies carried out by Rossyjskij (1949) who 
treated patients suffering from nervous cardiovascular conditions, 
hyperthyroidism, atherosclerosis, heart diseases, and hypertension with 
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various motherwort preparations. In the patients with essential hypertension, 
a decrease in blood pressure (8 – 20 mm Hg) was observed after 8 – 10 days 
of the treatment. 
 Interestingly, the alkaloid stachydrine was found to be the second 
most influential metabolite for discriminating between the DASH and control 
dietary patterns, as reported by Rebholz et al. (2018). The DASH dietary 
pattern (Dietary Approaches to Stop Hypertension) is rich in fruit, vegetables, 
and low-fat dairy products, while moderate in meat, fish, poultry, nuts, and 
beans. It leads to a reduction in systolic blood pressure (a reduction about 
5 mm Hg), and epidemiologic studies have shown that higher adherence to 
the DASH diet was associated with a multitude of favorable health outcomes, 
including a reduced risk of hypertension, cardiovascular disease, kidney 
disease, and mortality (Rebholz et al., 2018 and references therein). 
 
2.4.4.5. EFFECT OF MOTHERWORT ON PLASMATIC LIPID PROFILE 
 
The beneficial effect of L. sibiricus L. extract on the plasma lipid levels 
of mice fed an atherogenic diet was observed by Lee et al. (2010). The animals 
were administered with motherwort extract at a dose of 0.01 g of 
extract/20 g body weight for 14 weeks. Treatment with motherwort extract 
resulted in significantly decreased plasma total cholesterol levels, plasma 
triglyceride level (this level was even lower than in the control group fed with 
a normal diet), and atherogenic index, while the level of HDL cholesterol was 
significantly increased when compared to all other groups. The liver weight of 
the mice fed an atherogenic diet was higher than that of the mice on a 
standard diet (which may be due to the fatty liver), while the liver weight of 
mice with motherwort extract treatment recovered, and was comparable to 
that of the control group. 
Rabbits treated with high doses of synthetic leonurine (SCM-198) for 
8 weeks also exhibited some changes in the lipid parameters: a decrease in 




Pure leonurine treatment (administered intragastrically, 10 mg/kg) 
resulted in decreased levels of total cholesterol and triglyceride levels in the 
serum of mice treated for 8 weeks. A detailed assessment of the plasma 
lipoproteins showed a decrease in LDL-cholesterol and an increase in 
HDL cholesterol in the leonurine-treated animals. Moreover, the 
atherosclerotic lesion sizes in aortic roots of leonurine-treated mice were 
remarkably diminished when compared with the control group (Jiang et al., 
2017). 
Lee, Park and Ma (2017) investigated the effect of an ethanolic 
motherwort extract from L. japonicus Houtt. on the fat deposition and serum 
lipid levels of high-fat diet fed mice. The 14 weeks motherwort treatment led 
to a significantly reduced body weight gain, retroperitoneal and mesenteric 
visceral white adipose tissue, and to a significant decrease in serum 
triglycerides and LDL cholesterol. 
The effect of synthetic leonurine (SCM-198) on dyslipidemia in three 
mammal species (mice, rabbits, Rhesus monkeys) was studied by Suguro et al. 
(2018). Leonurine, especially at higher doses, decreased total cholesterol and 
triglyceride levels, and its effect was comparable to that of atorvastatin. In 
leonurine treated mice and monkeys, a reduction in LDL cholesterol was also 
observed, while in rabbits, leonurine failed to decrease the LDL cholesterol 
level. 
An ethanolic motherwort extract from L. sibiricus L. was used by Park 
et al. (2016) in their in vitro study with 3T3-L1 cells. These preadipocyte 
stadium cells were treated with motherwort extract (10 and 50 µg/mL) and a 
differentiation medium for 4 days. The higher concentration of motherwort 
extract inhibited the levels of intracellular lipid accumulation by 75%. 
Similarly, such a pronounced diminution of the lipid accumulation in 
human THP-1 macrophage-derived foam cells was observed by Jiang et al. 
(2017) who investigated the possible antiatherogenic effect of the pure 
alkaloid leonurine in the in vitro part of their work. THP-1 cells fully 
differentiated into foam cells were incubated with several concentrations of 
leonurine (5, 10, 20, 40, and 80 µmol/L) for 24 hours. All of the tested 
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leonurine concentrations significantly decreased the cellular cholesterol 
content (including total cholesterol, free cholesterol, and cholesteryl ester) 
and increased the apo-A-I-mediated or HDL-mediated cholesterol efflux. The 
decrease of the total cellular cholesterol at a leonurine concentration of 
80 µmol/L was 67%. Based on the performed assays, the proposed molecular 
mechanism of the leonurine effect on lipid metabolism in foam cells was the 
increase in certain cholesterol transporters of the cell membrane (namely 
ABCA1 and ABCG1). The expression of these cholesterol transporters is 
modulated by LXRα (liver X receptor alpha), and a common upstream factor 
of LXRα-induced signaling is the nuclear receptor PPARγ, which plays critical 
roles in lipid homeostasis. The authors demonstrated that leonurine does 
activate the PPARγ/LXRα pathway in a dose-dependent manner, and thus 
enables the increased cholesterol efflux. Furthermore, Jiang et al. (2017) 
tested this hypothesis on an animal model (mice) and found that the protein 
levels of PPARγ, LXRα, ABCA1, and ABG1 in the tissue homogenate of aortic 
roots of mice treated with leonurine were significantly increased when 
compared with the control group.  
The downregulation of markers of the lipogenesis by an ethanolic 
motherwort extract (from L. japonicus Houtt.) in hepatic HepG2 cells was 
observed by Lee, Park and Ma (2018) in the in vitro part of their study. 
HepG2 cells were exposed to free fatty acids to induce hepatic steatosis, and 
then incubated for 24 hours with different concentrations of motherwort 
extract (0, 250, 500, 750, and 1000 µg/mL). Free fatty acids-induced 
HepG2 cells showed significant increases in lipid droplets, the production of 
which was significantly inhibited by motherwort extract at the two highest 
concentrations used. The motherwort extract treatment in a concentration-
dependent manner also decreased the protein levels of lipogenic markers 
(namely SREBP-1c, FAS, SCD-1, and CD36), as showed by further analysis. 
Suguro et al. (2018) also reported the decreased protein levels of FAS 
and SCD-1 in mice treated with synthetic leonurine, which led to reduced 





2.4.5. SAFETY PROFILE OF THE MOTHERWORT PREPARATIONS 
 
EMA and the Botanical Safety Handbook both find L. cardiaca L. to be 
safe, except for pregnant women. L. japonicus Houtt. is also considered to be 
safe, with the same exception of its usage during pregnancy. No interactions 
with other medicinal products have been reported so far 
(EMA/HMPC/127428/2010; Gardner and McGuffin, 2013). 
On the cellular level in an in vitro study, a polyphenol-rich 
L. cardiaca L. extract (total polyphenol content ca 137 mg/g) exhibited no 
cytotoxicity up to a concentration of 4500 µg/L, when added to an 
endothelial cell culture (Sadowska et al., 2017). 
A large toxicity assessment of a motherwort aqueous extract (Herba 
leonuri) was performed by Han et al. (2013) on one animal model. The extract 
was administered orally once daily at doses 0 – 2000 mg/kg for 13 weeks to 
male and female rats. The only alteration was observed at the highest dose in 
the forestomach, where it caused squamous cell hyperplasia. Based on the 
results of the performed tests, the authors determined the acceptable daily 
value intake to be 10 mg/kg per day. 
Treatment of Rhesus monkey with synthetic leonurine (10 mg/kg) for 
178 days had no significant effects on the hepatic enzymes (ALT, ATS), 
hematologic parameters, or biochemical examinations (Suguro et al., 2018). 
Data on motherwort adverse effects in humans is sparse. Shikov et al. 
(2011) in their study with motherwort oil extract stated that all volunteers 
estimated the tolerability of motherwort oil extract as excellent. Meng et al. 
(2019) investigated the efficacy and safety of motherwort injection for the 
prevention of post-partum blood loss and observed that there were no 
statistical significant differences in the incidence of adverse events between 
the treatment and the control group. 
As for possible pharmacodynamic interactions with other active 
compounds, Tachijan, Maria and Jahangir (2010) mentioned that motherwort 
potentiates antithrombotic and antiplatelet effects, and increases the risk of 
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bleeding. Taken with benzodiazepines, motherwort can also have a 
synergistic sedative effect. 
 
2.5. BLACK CUMIN – NIGELLA SATIVA L. - FAM. RANUNCULACEAE 
 
2.5.1. CHARACTERIZATION OF THE GENUS NIGELLA – A PHARMACOGNOSTIC CONTEXT 
 
 The genus Nigella includes only about 18 species, all of which are 
therophytes – annual plants that complete their life cycle in a short favorable 
period and survive the inhospitable rest of the year as seeds. The most widely 
known and pharmaceutically most interesting is the species Nigella sativa L. 
(Fig. 2.9.), also known as black cumin, black seed, or (more contemporary and 
in the Unites States preferred) nigella. Black cumin is an annual herb with 
pale blue flowers, it can grow up to 45 cm. Black cumin is native to Southern 
Europe, North Africa, as well as South and Southwest Asia (Rajsekhar and 
Kuldeep, 2011; Engels and Brinckmann, 2017).  
 
 
 For the medicinal use, mostly seeds or seed oil are exploited. The 
seeds are black or dark grey on the outside and white inside, with angular, 
ovoid or obpyramidal shape, and small in size (Fig. 2.9., right). The length of 
 










the black cumin seed ranges from 2.5 to 3.5 mm, the width from 1.5 to 2 mm, 
and the weight of the seed is about 1 to 5 mg. The seeds have a slightly 
aromatic odor and are bitter to taste due to the presence of the protein 
nigellin (El-Tahir and Bakeet, 2006; Rajsekhar and Kuldeep, 2011; Abedi 
et al., 2017; Kalidasu et al., 2017). The stability study of black cumin seeds 
stored under different conditions was presented by Bustaman et al. (2017). 
The seed oil, also known as the essential oil, is cold-pressed from the 
seeds. The black cumin essential oil is a yellow to dark amber liquid and does 
not show fluorescence. The fixed oil is produced by the hydraulic expression 
of the black cumin seeds. And finally, the volatile oil is obtained by steam 
distillation of the black cumin seeds. It has a yellowish brown color and an 
unpleasant odor (Dajani, Shahwan and Dajani, 2016). 
 Abedi et al. (2017) suggested a microwave-assisted extraction of black 
cumin essential oil. This extraction method is thought to be energy-saving and 
effective: the extraction yields for 30 minutes were higher than the extraction 
yields of conventional hydrodistallation. Moreover, the content of the most 
active compound thymoquinone was pronouncedly higher in the microwave-
assisted extraction (20.41%) when compared to hydrodistallation (3.71%). 
 The influence of various extraction methods of black cumin seeds on 
the composition of essential oils was investigated by Kokoška et al. (2008). 
The black cumin seeds were extracted with four methods: hydrodistillation, 
dry steam distillation, steam distillation of crude oils obtained by solvent 
extraction, and supercritical fluid extraction. The thymoquinone content was 
the highest in the oil obtained by the supercritical fluid extraction (76.7% vs. 
0.5% by hydrodistillation), while the contents of p-cymene and α-thujene 
were dramatically decreased in the oil obtained by the supercritical fluid 
extraction (8.6% and 0.3% vs. 56.2% and 15.1% by hydrodistillation). 
The different extraction methods have significant influence on both 
quantitative and qualitative composition of the black cumin seed oil; this was 
also demonstrated by Mohammed et al. (2016). The analysis of black cumin 
oil extracted by supercritical fluid or cold press showed that while the content 
of thymoquinone was approximately the same (16.21% and 16.80%, 
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respectively), the cold press method was evidently more suitable for the 
extraction of α-pinene, γ-terpinene, and limonene (not detected in the 
supercritical fluid assay and 7.10%, 2.82%, and 0.41%, respectively using the 
cold press method). Carvacrol and longifolene also had higher yields using the 
cold press method than by the supercritical fluid method (3.90% vs. 1.82% 
and 4.49% vs. 3.50%, respectively). On the other hand, total phenolic content 
was higher in the oil obtained with the supercritical fluid extraction 
(Mohammed et al., 2016). 
 In order to increase the content of the most active black cumin 
compound thymoquinone in the essential oil, controlled heating of the black 
cumin seeds for 10 minutes at a temperature between 50 to 150 °C is 
recommended. Heating to temperatures of 200 °C or higher led to a 
significantly decreased thymoquinone content, while heating at 25 °C did not 
show any effect on the thymoquinone content (Agbaria et al., 2015). For the 
exact quantifying of the black cumin active constituents thymoquinone, 
dithymoquinone, thymodihydroqiunone, and thymol in the seed oil, Ghosheh, 
Houdi and Crooks (1999) developed an HPLC method. 
 
2.5.2. PHYTOCHEMISTRY OF BLACK CUMIN 
 
 N. sativa L. seeds contain 30 – 40% fat, 30 – 35% carbohydrates, and 
around 20% proteins. Aside from the oil, also saponins (α-hederin), terpenes 
(nigellamines), and alkaloids (nigelicine, nigellimine, and nigellidine) are also 
present in the seed (Morikawa et al., 2004a, b; El-Tahir and Bakeet, 2006; 
Mohammed et al., 2016 and references therein). 
 Black cumin seed fixed oil is primarily composed of unsaturated fatty 
acids (linoleic acid and oleic acid, 45 – 57% and 21 – 25%, respectively). The 
most abundant saturated acid in the fixed oil is palmitic acid (12 – 14%). 
Sterols constitute only about 0.5% of the total seed oil, and the major sterol 
forms are the steryl glucosides, although free sterols, steryl esters, and 
acylated steryl glucosides were also isolated from N. sativa L. Phospholipids 
are represented mainly by phosphatidylcholine (46 – 48%), followed by 
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phosphatidylethanolamine, phosphatidylinositol, and phosphatidylserine 
(Menounos, Staphylakis and Gegiou, 1986; Ramadan, Kroh and Mörsel, 2003; 
El-Tahir and Bakeet, 2016). 
 The chemical composition of black cumin volatile oil undergoes 
significant changes during the six stages of seed maturation (75 days), as 
reported by Botnick et al. (2012). Dramatical changes were observed 
especially in monoterpene levels and their composition. While in the flower 
stage, mainly 2E-hexenal and 2E-hexenol were detected. There were no 
accumulations of these compounds in the mature seed volatile oil. The first 
monoterpene detected in developing seeds was γ-terpinene (day 30). The 
accumulation of other important monoterpenes started even later 
(thymoquinone and carvacrol at day 50, p-cymene at day 55). It is possible 
that γ-terpinene serves as a precursor of p-cymene in the black cumin seed, as 
a strong decrease in γ-terpinene levels was observed at day 55 in parallel to a 
significant increase in p-cymene (Botnick et al., 2012). Some of the black 






   
 
The volatile terpenes of black cumin were only detected in the seed 
coat, while in the inner endosperm, embryo, leaves, shoot, or roots there were 
none. According to a fluorescence study, it appears that the volatiles 
accumulate in the subepidermal layer of the seed coat, in the form of droplets 
distributed evenly throughout this layer (Botnick et al., 2012).  
Fig. 2.10. Some of the Nigella genus monoterpenes. Upper left – thymoquinone, upper right – 




The quantitative and qualitative composition of the black cumin seed 
essential oil may also be different due to the geographical origin of the plant. 
For example, Tunisian black cumin essential oil was rich in the monoterpene 
p-cymene (60.5%), α-thujene (6.9%), γ-terpinene (3.5%), carvacrol (2.4%), 
and β-pinene (2.4%). The content of thymoquinone was only 3.0% (Bourgou 
et al., 2010). Indian essential oil contained predominantly thymoquinone 
(37.6%), p-cymene (31.4%), α-thujene (5.6%), and thymohydroquinone 
(3.4%), while the content of carvacrol, β-pinene, and γ-terpinene was low 
(1.4%, 1.7%, and 0.2%, respectively; Singh et al., 2014; and very similar 
amounts were provided by Kalidasu et al., 2017). Iranian essential oil differed 
significantly, with the major compound being trans-anethole (38.3%). Further 
it contained p-cymene (14.8%), limonene (4.3%), and carvone (4.0%), while 
the content of thymoquinone, carvacrol, α-thujene, β-pinene, and γ-terpinene 
were low (0.6%, 1.6%, 2.4%, 1.3%, and 0.5%, respectively; Nickavar et al., 
2003). And finally, Turkish volatile oil is rich in p-cymene (56.2%), α-thujene 
(15.1%), β-pinene (4.0%), and limonene (2.9%; Kokoška et al., 2008) For a 
compound India India 2 Iran Tunisia Turkey 
α-thujene 5.6 5.1 2.4 6.9 15.1 
β-pinene 1.7 1.3 1.3 2.4 4.0 
γ-terpinene 0.2 ND 0.5 3.5 1.2 
p-cymene 31.4 27.8 14.8 60.5 56.2 
trans-anethole ND ND 38.3 ND ND 
carvacrol 1.4 2.4 1.6 2.4 0.8 
carvone T ND 4.0 ND 1.1 
limonene 1.0 ND 4.3 ND 2.9 
longifolene 2.0 3.2 0.7 0.9 2.6 
thymohydroquinone 3.4 2.4 ND 0.4 T 
thymol 0.2 ND ND ND ND 
thymoquinone 37.6 28.7 0.6 3.0 0.5 
Tab. 2.1. The composition of black cumin essential oil with different geographical origin. Values 
are expressed as percentages. T – traces, ND – not detected. Sources: India – Singh et al. (2014), 
India 2 – Kalidasu et al. (2017), Iran – Nickavar et al. (2013), Tunisia – Bourgou et al. (2010), 
Turkey – Kokoška et al. (2008)  
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more detailed overview of the composition of the black cumin essential oil, 
see Tab. 2.1.   
 
2.5.3. MEDICINAL USE OF BLACK CUMIN 
 
 The European Medicines Agency does not recognize black cumin as 
medicinal plant. N. sativa L. is mentioned in two final assessment reports 
(Pimpinella anisum L., fructus and aetheroleum and Tilia cordata Miller, Tilia 
platyphyllos Scop., Tilia x vulgaris Heyne or their mixtures, flos) – as a 
component of a herbal mixture tested for its inhibitory effect on histamine 
released from rat peritoneal mast cells, and as a herbal product used by 
diabetic patients in Jordan, respectively (EMA/HPMC/321181/2012; 
EMA/HPMC/337067/2011). 
 On the other hand, black cumin is widely used in the African and Asian 
traditional medicine: Ayurvedic, Siddha, and Unani systems of medicine in 
India, traditional Arabic and Islamic medicine, Iranian traditional medicine, 
and Sudanese medicine among other systems of medicine (Engels and 
Brinckmann, 2017).  
 Black cumin is used in several diseases including cough, jaundice, skin 
diseases, conjunctivitis, abdominal disorders, dyspepsia, flatulence, diarrhea, 
and fever. N. sativa L. is also used traditionally as a part of a polyherbal 
formulation for the treatment of metabolic disorders like diabetes and 
hyperlipidemia in Pakistan. This formulation further contains Cichorium 
intybus L., Trigonella foenum-graecum L., and Gymnena sylvestre (Retz.) R. Br. 
ex Schult. All of the components are in equal proportion (Rajsekhar et al., 








2.5.4. EFFECTS OF BLACK CUMIN ON SELECTED CARDIOVASCULAR CONDITIONS 
 
2.5.4.1. ANTIOXIDANT EFFECT OF BLACK CUMIN 
 
 The antioxidant potential of black cumin was established quite early. 
For example, Houghton et al. (1995) tested fixed oils from different sources of 
N. sativa L. seeds and pure thymoquinone as possible inhibitors of eicosanoid 
generation and membrane lipid peroxidation. While both substances 
inhibited the non-enzymatic peroxidation in ox brain phospholipid liposomes, 
thymoquinone was about ten times more potent. The authors also observed 
that the inhibition of lipid peroxidation by the black cumin fixed oil was 
greater than is expected from its thymoquinone content, thus it is likely that 
other components of the fixed oil also possess antioxidant properties 
(Houghton et al., 1995).  
 Burits and Bucar (2000) proved that in the black cumin essential oil 
several other compounds beside thymoquinone also demonstrated 
respectable radical scavenging activity, namely carvacrol, trans-anethole, and 
4-terpineol. All compounds were effective hydroxyl radical scavenging agents 
in the assay for non-enzymatic lipid peroxidation but their antioxidant 
activity varied in the DPPH test. Probably no significant antioxidant activity 
can be expected from p-cymene or α-pinene, as these compounds, unlike 
thymoquinone, did not ameliorate the oxidative stress caused by carbon 
tetrachloride in mice (Mansour et al., 2001). This finding was confirmed 
several years later by Bourgou et al. (2010) who reported that monoterpene 
hydrocarbons p-cymene, γ-terpinene, and β-pinene from black cumin seed 
were inactive in the DCFH assay for antioxidant and pro-oxidant properties. 
Interestingly, the ex vivo antioxidant activity of phenolic carvacrol was also 
very low (Bourgou et al., 2010). 
Ramadan, Kroh and Mörsel (2003) investigated the radical scavenging 
activity of the black cumin crude seed oil and its fractions. The crude seed oil 
was extracted with n-hexane and then further fractionated into neutral lipids, 
glycolipids, and phospholipids that were tested for their radical scavenging 
activity toward the stable galvinoxyl radical and the DPPH radical. The 
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phospholipids, represented prevalently by phosphatidylethanolamine and 
phosphatidylcholine, exhibited the greatest radical scavenging activity, 
followed by glycolipids and neutral lipids. The inhibition of the DPPH radical 
was relatively low, 28.6% for phospholipids, 26.5% for glycolipids, and 16.2% 
for neutral lipids. On the other hand, phospholipids quenched 83.7% of the 
galvinoxyl radical.  
A high antioxidant activity of black cumin seed essential oil was also 
reported in DCFH assay by Bourgou et al. (2010) and by Singh et al. (2013) 
who determined the radical scavenging activity of the essential oil in the 
DPPH test (95.4%). Furthermore, Abdel-Wahhab and Aly (2005) investigated 
the ability of black cumin volatile oil to scavenge free radicals generated 
during aflatoxicosis in rats. Treatment with black cumin in rats fed an 
aflatoxin-contaminated diet resulted in a significant protection against 
aflatoxicosis, indicating good free radicals scavenging activity of N. sativa L.  
Kökdil et al. (2006) also observed a significant increase in the total 
antioxidant status in rats treated with black cumin fixed oil at a dose of 
1 mL/kg for 4 weeks. Similarly, El-Gindy et al. (2019) reported a significant 
increase in blood total antioxidant capacity and a significant decrease in 
malonyl aldehyde values in rabbits treated with black cumin seeds at doses of 
300 or 600 mg/kg for 8 weeks. An in vitro evaluation of antioxidant effects of 
black cumin extract and black cumin oil showed that the highest antioxidant 
activity (80%) was observed at the concentrations of 10 and 20 mg/mL that 
were equal to the concentration 200 mg/mL of vitamin E (Soleimani et al., 
2008). 
Fixed and essential oils from N. sativa L. seeds probably improve the 
antioxidant status through modulation of antioxidant enzymes. Sultan et al. 
(2014) found that both the fixed and essential black cumin oils fed to rats 
enhanced the expression of hepatic enzymes. Their results also indicated that 
the antioxidant potential is positively correlated with the increase of hepatic 
enzyme levels. In their following study, the investigators confirmed that the 
black cumin fixed and essential oils positively modulated the activities of 
several antioxidant enzymes, such as catalase, superoxide dismutase, 
glutathione transferase, glutathione reductase, and glutathione peroxidase. 
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Furthermore, markers of the antioxidant status like tocopherols and 
glutathione were in a linear correlation with the levels of glutathione 
peroxidase, glutathione reductase, and glutathione transferase (Sultan et al., 
2015). 
As black cumin seeds, extracts, fixed, or volatile oils exhibit strong 
antioxidant properties, they thus also exhibit the ability to protect cells from 
oxidative stress, as demonstrated in a fair amount of studies focused on 
different cells and organs, such as erythrocytes (Suboh, Bilto and Aburjai, 
2004; Kanter, Coskun and Gurel, 2005), fibroblasts (Ashraf et al., 2011), 
macrophages (Tripathi, Chaturvedi and Pandey, 2012), pre-adipocytes 
(Bordoni et al., 2019), brain (Hamdy and Taha, 2009; Abdel-Zaher, Abdel-
Rahman and Elwasei, 2010; Erşahin et al., 2011; Hassan et al., 2016), heart 
(Seif, 2013), intestines (Terzi et al., 2010), kidney (Bayrak et al., 2008, Yildiz 
et al., 2010; Attia et al., 2011; Hassan et al., 2016; Norouzi et al., 2017), liver 
(Al-Ghamdi, 2003; Kanter et al., 2003; Kanter, Coskun and Budancamanak, 
2005; Yildiz et al., 2008; Attia et al., 2011; Hassan et al., 2016), and lung (Zaki, 
2019). 
 Similarly, the antioxidant potential of pure thymoquinone was 
demonstrated in several studies. Badary et al. (2003) performed various 
assays with thymoquinone (namely microsomal lipid peroxidation, DPPH, 
hydroxyl radical, and superoxide anion scavenging test) and concluded that 
thymoquinone is acting mainly as a potent superoxide anion scavenger with 
IC50 3.35 µmol/L. 
 Treatment with thymoquinone was reported to attenuate the 
oxidative stress and injury in various tissues including: brain (Hamdy and 
Taha, 2009), brown adipose tissue (Mahmoudi et al., 2018), kidney (Badary 
et al., 2000; Khattab and Nagi, 2007; Nader, El-Agamy and Suddek, 2010), 
heart (Hamdy and Taha, 2009; Nagi et al., 2011; Xiao et al., 2018), liver 
(Mansour et al., 2001; Zafeer et al., 2012), lung (Pourgholamhossein et al., 
2016), skeletal muscle (Hosseinzadeh, Taiari and Nassiri-Asl, 2012), and 
smooth muscle (aorta and pulmonary artery – Nader, El-Agamy and Suddek, 
2010). The main protective effect of thymoquinone was the restoration of the 
antioxidant capacity in the respective tissue. 
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However, thymoquinone, especially at higher doses, might be 
metabolized to reactive species and increase the oxidative stress, as observed 
in hepatocytes by Khader, Bresgen and Eckl (2009; see also Ch. 2.5.5.). On the 
other hand, thymoquinone treatment in hypercholesterolemic rats led to 
significantly increased liver antioxidant enzyme levels (including superoxide 
dismutase 1 and glutathione peroxidase) and to the upregulation of the 
superoxide dismutase 1, catalase, and glutathione peroxidase genes (Ismail, 
Al-Naqeep and Chan, 2010). 
 
2.5.4.2. DIRECT EFFECT OF BLACK CUMIN ON MYOCARDIUM 
 
 Shafei, Boskabady and Parsaee (2005) investigated the effect of an 
aqueous extract from aerial parts of N. sativa L. (the plant ingredient 
concentration was 10 g/100 ml) and diltiazem on isolated guinea pig hearts. 
Four different concentrations of black cumin extract (0.5, 1, 2, and 5 mg) and 
diltiazem (0.1, 1, 10, and 100 µmol/L) were used on hearts perfused with 
either a standard or a calcium free Krebs solution. Both diltiazem and the 
black cumin extract significantly reduced heart rate and contractility of the 
isolated hearts. However, the negative chronotropic and negative 
inotropic effects were more pronounced in the hearts perfused with the 
calcium free Krebs solution. This greater effect of black cumin extract on the 
heart rate in the calcium free Krebs solution and differences in the slope of 
concentration-response curves between extract and diltiazem may indicate 
an additional effect for aqueous extracts other than the calcium  
channel-inhibitory effect. The authors suggested that the additional effect 
could be a potassium opening effect (Shafei, Boskabady and Parsaee, 2005). 
Interestingly, all other works presented in the available literature and 
that will be mentioned in the following text, reported positive inotropic and 
chronotropic effect of either black cumin seed oil or pure thymoquinone. 
This apparent discrepancy may be due to the fact that the aqueous N. sativa L. 
extract was prepared from whole aerial parts of the plant that may contain 
other compounds than black cumin seeds.   
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Oral supplementation of N. sativa L. seeds in rats at a dose of 
800 mg/kg for 8 weeks led to a significantly increased myocardial flow rate, 
baseline heart rate, baseline peak tension, and baseline maximum rate of 
tension development. Furthermore, the black cumin seeds administration 
induced a moderate homogenous cardiac hypertrophy, evident by 
significant increases in the left ventricular and whole heart weights, and the 
relative heart weight/body weight ratio, as observed by El-Bahai et al. (2009).  
This homogenous heart hypertrophy, very similar to the hypertrophy 
induced by exercise-training in rats treated with black cumin (800 mg/kg) for 
8 weeks, was reported by Al-Asoom et al. (2014a; b). The ventricular 
myocytes were normal, with no signs of excessive extracellular collagen 
fibrosis but with significantly increased diameter. The heart weight/body 
weight and left ventricle weight/body weight ratios were also significantly 
higher in rats treated with black cumin and/or rats with physical training 
(running on treadmill for 2 hours daily). Rats with both treatments exhibited 
even a significant reduction in the heart rate, which may indicate that black 
cumin supplementation has an additive effect that helps to potentiate the 
adaptive response of exercise training (Al-Asoom et al., 2014a). Moreover, an 
elevation of the total serum antioxidant activity was also observed in rats 
obtaining both treatments (Al-Asoom et al., 2014b). 
Al-Asoom and Al-Hariri (2019) in another study of theirs observed a 
positive inotropic effect of pure thymoquinone administered orally at a dose 
of 10 mg/kg to rats for 8 weeks. This effect was demonstrated by a 
significantly higher peak tension in the thymoquinone treated group when 
compared to the control. On the other hand, no hypertrophy was noted, with 
comparable heart and left ventricle weights, and the heart weight/body 
weight, left ventricle weight/ body weight, and left ventricle weight/heart 
weight ratios between the two studied groups. The authors concluded that 
either thymoquinone is not responsible for the cardiac hypertrophy or it 
needs another compound(s) for the induction of the cardiac hypertrophy (Al-
Asoom and Al-Hariri, 2019). 
The cardioprotective effect of a N. sativa L. hydroalcoholic extract 
administered daily at a dose of 100 mg/kg to rats with inflammation-induced 
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myocardial fibrosis was reported by Norouzi et al. (2017). Treatment with 
black cumin reduced cardiac fibrosis, collagen deposition, and inflammatory 
cell infiltrates that were induced by lipopolysaccharide administration. 
The dose-dependent reduction of cardiac fibrosis and heart 
permeability after a chronic exposure to lipopolysacharide (1 mg/kg 
intraperitoneally for 3 weeks) in rats treated with pure thymoquinone (2, 5, 
and 10 mg/kg) was also observed by Asghardeh et al. (2018). Treatment with 
thymoquinone improved pathological changes in the heart tissue, such as 
infiltration of inflammatory cells, disarrangement of myofibers, and collagen 
deposition in myocardium. The highest tested dose of thymoquinone 
reversed the cardiac permeability to the control level. 
Furthermore, thymoquinone pretreatment (oral administration of 
12.5, 25, and 50 mg/kg for 7 days) in rats before the onset of an 
isoproterenol-induced myocardial injury attenuated the effect of 
isoproterenol. In the heart tissue, the injury induced by isoproterenol was 
represented by patchy areas of mild necrosis with the infiltration of 
polymorphonuclear cells, while thymoquinone-pretreated hearts had the 
histological appearance of the passive control hearts. On the biochemical 
level, isoproterenol significantly (up to 5 times) increased the activity of 
glutathione reductase and lipid peroxidation, while it significantly decreased 
the activity of superoxide dismutase. These changes were reversed by 
thymoquinone pretreatment. At the highest dose of thymoquinone, almost all 
of the studied parameters were even reversed back to normal levels 
(Randhawa, Alghamdi and Maulik, 2013).  
A prolonged thymoquinone pretreatment (for 21 days) before 
isoproterenol administration was performed by Ojha et al. (2015). 
Thymoquinone at a dose of 20 mg/kg decreased the infarct area size, as 
observed by the presence of less necrotic tissues. Furthermore, 
thymoquinone had a significant effect on the myocardial histoarchitecture 
negatively influenced by isoproterenol: only very mild degree of myonecrosis, 
edema, and infiltration of inflammatory cells was observed. The lipid 
peroxidation and the decrease in superoxide dismutase activity induced by 
isoproterenol were also attenuated by thymoquinone. 
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Similarly, a cardioprotective effect of pure thymoquinone on the 
ischemia/reperfusion cardiac injury in rats was reported by Gonca and Kurt 
(2015). Thymoquinone at a dose of 10 mg/kg was administered 
intraperitoneally 20 minutes before the ischemic period induced by the left 
coronary artery ligation. Thymoquinone reduced the infarct area (by 54%) 
and decreased the incidence of arrhythmias (ventricular tachycardia and 
ventricular fibrillation) during the reperfusion period. Xiao et al. (2018) also 
observed that thymoquinone pretreatment led to a reduction of the infarct 
size in isolated rat hearts after an ischemia/reperfusion injury. The authors 
furthermore reported a decrease of the oxidative stress and a suppression of 
apoptosis in hearts with thymoquinone pretreatment. 
 The supposed cardioprotective mechanism of thymoquinone on the 
myocardial ischemia/reperfusion injury was suggested by Lu et al. (2018). 
Based on their experimental protocol with isolated rat cardiomyocytes, 
thymoquinone at low doses (i.e. up to 8 µmol/L) increased cell viability of 
injured cardiomyocytes. This effect was likely due to the activation of the 
silent mating type information regulator 2 homolog 1 (SIRT 1; an NAD+-
dependent histone deacetylase, which plays a critical role in many cellular 
pathways, including apoptosis). Upregulation of SIRT 1 can attenuate the 
mitochondrial oxidative stress and maintain mitochondrial function which is 
crucial in averting the apoptotic cell death. The upregulation of SIRT 1 further 
leads to the suppression of p53 acetylation. Thymoquinone treatment also led 
to an upregulation of the anti-apoptotic protein Bcl-2 expression, and to a 
downregulation of expression of the pro-apoptotic proteins Bax and cleaved-
caspase 3. All of the abovementioned changes in regulatory proteins most 
likely prevent the death of cardiomyocytes. 
 
2.5.4.3. EFFECT OF BLACK CUMIN ON BLOOD, BLOOD CELLS, AND BLOOD VESSELS 
 
The effect of methanolic extract of black cumin seeds on platelet 
aggregation and blood coagulation was investigated by Enomoto et al. 
(2001). The methanol soluble part was further fractioned by silica gel column 
chromatography to give ten fractions, some of them active in the assays. 
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Namely, fractions II and IV showed a high inhibitory activity on arachidonic 
acid-induced platelet aggregation (inhibition by 92% and 88%, respectively). 
Further, fractions II and IX exhibited a strong inhibitory effect on blood 
coagulation. All ten fractions displayed only a low level of inhibitory effects on 
ADP-induced platelet aggregation. Purification of the active fractions led to 
the identification of active compounds. A platelet aggregation-inhibitory 
effect had two known compounds (carvacrol and thymol), and a new 
compound, namely 2-(2-methoxypropyl)-5-methyl-1,4-benzendiol. 
The influence of black cumin on the platelet count is according to the 
available literature a little confusing. Firstly, Zaoui et al. (2002a) observed 
some significant changes in rat blood parameters after 12 weeks of treatment 
with black cumin seed fixed oil. The counts of leukocytes and platelets 
decreased (by 35% and 32%, respectively), while the hemoglobin level 
increased (by 17.4%). On the other hand, Al-Jishi and Abuo Hozaifa (2003) 
reported that black cumin treatment (for 1, 2, or 4 weeks) did not change the 
platelet count at any dose tested (90, 180, 360, and 540 mg/kg of powdered 
seeds). And finally, Asgary et al. (2012) observed that rabbits fed a normal 
diet in combination with black cumin for 8 weeks had significantly increased 
platelet count, with the risk of enhanced coagulation. The only other available 
investigation of black cumin effect on platelet count was conducted by Saadia 
et al. (2017). The authors used an aqueous extract of black cumin seeds in 
rats administered with chloroquine phosphate which induced 
thrombocytopenia along with a significant decrease of antioxidants and trace 
metals. Treatment with the black cumin aqueous extract at a dose of 
15.25 mg/kg for 12 days increased the platelet count 1.59 fold and elevated 
the serum levels of catalase. The aim of the study was to investigate the effect 
of black cumin extract in alleviating the severity of dengue fever that is 
accompanied with very a low platelet count (7.62 fold lower than control 
patients). 
Awat and Binder (2005) studied the impact of black cumin oil on the 
fibrinolytic system of the human umbilical vein endothelial cells (HUVECs) 
and human uterine arterial endothelial cells (HUA-ECs). Both cells cultures 
exhibited a concentration-dependent increase in the tissue-type plasmogen 
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activator. The maximum effect for both HUVECs and HUA-ECs was achieved at 
a black cumin oil concentration of 100 µg/mL. 
A positive effect of black cumin on erythrocytes was reported by 
Suboh, Bilto and Aburjai (2004). Preincubation of human erythrocytes with 
black cumin before the exposure to hydrogen peroxide protected the 
erythrocytes against the oxidative stress influence, including protein 
degradation, loss of deformability, and increased osmotic fragility. Similarly, 
Kanter, Coskun and Gurel (2005) in their investigation of the protective effect 
of black cumin in cadmium-induced oxidative stress in rats, found that 
treatment with black cumin reduced the membrane destruction remarkably, 
as well reducing hemolytic changes of erythrocytes. Further, black cumin 
significantly decreased the elevated malonyl aldehyde level in erythrocytes 
(Kanter, Coskun and Gurel, 2005).  
The decrease of malonyl aldehyde formation in both intact 
erythrocytes and an erythrocyte homolysate was also reported by Ahmad and 
Beg (2013) who used the thymoquinone-rich fraction of black cumin extract 
in rats fed an atherogenic diet for 4 weeks.  
Endothelial dysfunction is also positively influenced by black cumin. 
For example, Nader, El-Agamy and Suddek (2010) investigated the possible 
protective effect of thymoquinone on development of atherosclerosis in 
rabbits fed a high-cholesterol diet. Treatment with thymoquinone for 4 weeks 
attenuated the negative impact of high-cholesterol diet, such as endothelial 
damage and thickened foam cell formation. Similar results were obtained 
when black cumin either powdered (1000 mg/kg) or in oil (500 mg/kg) was 
administered to rabbits fed an atherogenic diet for 8 weeks. Both black cumin 
forms were efficient in the inhibition of the plaque formation and in the 
reduction of the intima/media ratio (Al-Naqeep et al., 2011). 
Moreover, pure thymoquinone was also shown to improve the aging-
related endothelial dysfunction characterized by blunted nitric oxide- and 
endothelium-derived hyperpolarizing factor (EDHF)-mediated relaxation in 
arteries. Middle-aged rats were treated with thymoquinone at a dose of 
10 mg/kg for 2 weeks. This treatment resulted in the restoration of both 
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nitric oxide- and EDHF-mediated relaxations of the mesenteric artery. 
Furthermore, thymoquinone normalized the oxidative stress and the 
expression level of endothelial nitric oxide synthase (eNOS) and components 
of the angiotensin system (Idris-Khodja and Schini-Kerth, 2012). 
The regulation of eNOS level is most likely a part of the endothelium-
protecting mechanism. Black cumin was reported to significantly increase 
eNOS both in mRNA level and function in rats treated with a seed 
hydroalcoholic extract at different doses (100, 200, and 400 mg/kg) for 
6 weeks. Meanwhile, the expression of vascular cell adhesion molecule-1 and 
receptor for oxidized low-density lipoprotein (markers of endothelial 
dysfunction) was decreased in the vascular cells of aortic tissue in rats treated 
with black cumin (Abbasnezhad et al., 2019). The authors furthermore 
observed markedly improved vasorelaxant responses of the aortic rings to 
acetylcholine in rats in the black cumin group. 
Similar results were obtained in streptozocin-induced diabetic rats 
treated with a hydroalcoholic black cumin extract (100, 200, or 400 mg/kg) 
for 6 weeks. Both the contractile and dilatation responses of isolated aortic 
rings of black cumin treated rats were improved when evaluated with the 
administration of different agents (phenylephrine, acetylcholine, potassium 
chloride, and sodium nitroprusside; Abbasnezhad et al., 2016). 
 The vasorelaxant mechanism of black cumin was in part elucidated 
by Suddek (2010) who investigated the effect of pure thymoquinone on 
isolated rat pulmonary arterial rings precontracted with phenylephrine. 
Thymoquinone decreased the tension of the precontracted arterial rings in a 
concentration-dependent manner. The vasorelaxant effect of thymoqiunone 
was partially abolished by pretreatment of the arterial rings with a non-
selective blocker of the ATP-sensitive K+ channels (glibenclamide), and 
significantly potentiated by an endothelin receptors ETA and ETB antagonist 
(bosentan). Hence, the vasorelaxant effect of thymoquinone is at least 
partially mediated by the activation of ATP-sensitive potassium channels and 




 The involvement of the ATP-dependent K+ channels in vasorelaxation 
caused by black cumin was also confirmed by Niazmand et al. (2014). The 
authors used a hydroethanolic extract (ethanol 50%) of black cumin seeds on 
isolated intact or endothelium-denuded rat aorta precontracted by potassium 
chloride and phenyleprhine. The black cumin extract exhibited a 
concentration-dependent relaxation of the aorta, independent on the 
endothelium presence. Furthermore, this vasorelaxation was significantly 
reduced by diltiazem (a Ca2+ channel blocker) and heparin (an IP3 receptor 
blocker. The IP3 receptors act as intracellular Ca2+ channels), which indicates 
that the vasorelaxation was mediated through the inhibition of the calcium 
flow. These observations suggest that thymoquinone is not the only 
vasorelaxant active compound present in black cumin. 
 
2.5.4.4. ANTIHYPERTENSIVE EFFECT OF BLACK CUMIN 
 
 A dose-dependent decrease of arterial blood pressure and heart rate 
in rats after intravenous administration of black cumin volatile oil  
(4 – 32 µmL/kg) and pure thymoquinone (0.2 – 1.6 mg/kg) was observed by 
El-Tahir, Ashour and Al-Harbi (1993). Similarly, Hebi et al. (2016) observed a 
dose-dependent reduction in the mean arterial blood pressure accompanied 
by a significant fall in heart rate after an intravenous application of black 
cumin aqueous extract (50, 100, or 200 mg/kg) in normotensive rats. 
 Zaoui et al. (2000) orally administered a dichloromethane extract of 
N. sativa L. seeds at a dose of 0.6 mL/kg/day to spontaneously hypertensive 
rats for 15 days. Black cumin extract treatment led to a significantly increased 
diuresis (by 16%) and decreased mean arterial pressure (by 22%). The 
diuretic effect of black cumin was also reported by Asif et al. (2015) who used 
a crude aqueous extract. Rats were administered with either furosemide 
(10 mg/kg) or black cumin extract (10, 30, or 50 mg/kg) intraperitoneally. 
The black cumin extract had a dose-dependent diuretic, kaliuretic, and 
natriuretic effect. At the highest concentration tested, the black cumin extract 
showed a 46% diuretic activity compared with furosemide. 
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 Similarly, Toma et al. (2015) observed the diuretic effect of N. sativa L. 
in rats treated with 100 mg/kg of ethanolic extract. Black cumin extract did 
exhibit a higher natriuretic than kaliuretic effect. Interestingly, when the 
investigators tested another Nigella species for the presence of the diuretic 
effect, N. damascena L. ethanolic extract did not exhibit a diuretic effect.  
 The hypotensive effect of a traditionally used polyherbal composition 
containing equal portions of N. sativa L., Cichorium intybus L., Trigonella 
foenum-graecum L., and Gymnena sylvestre (Retz.) R. Br. ex Schult and its 
individual components were evaluated by Malik et al. (2017a, b) in rats 
treated for 7 weeks. The intervention with this polyherbal mixture resulted in 
a significant decrease of mean arterial pressure (Malik et al., 2017b) and 
systolic blood pressure (Malik et al., 2017a). Administration of particular 
components demonstrated that black cumin exhibited the most effective 
hypotensive action of the polyherbal composition (Malik et al., 2017b). 
  The beneficial effect of N. sativa L. on blood pressure in humans has 
also been reported in literature. For example, Dehkordi and Kamkhah (2008) 
treated patients with mild hypertension, with black cumin seed extract orally 
(100 or 200 mg, twice daily) for 8 weeks. The values of diastolic blood 
pressure were found to be significantly reduced after 8 weeks in a dose-
dependent manner. Similarly, Fallah Huseini et al. (2013) observed a 
significant decrease in both systolic and diastolic blood pressure in healthy 
volunteers aged 34 to 63 years treated with 2.5 mL of black cumin oil for 
8 weeks.  
Badar et al. (2017) provided results of a one-year long trial with 
114 poorly controlled type 2-diabetes patients who were treated with 
2 g/day of powdered black cumin seeds. Both mean arterial blood pressure 
and diastolic blood pressure were significantly lower in the black cumin 
group at the end of the trial, and the systolic blood pressure value also 
exhibited a decrease, although it was statistically non-significant. Moreover, 
after three months of black cumin treatment, the heart rate showed a 
significant decrease that was even more pronounced at the end of the trial.  
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Qidwai et al. (2009) also observed a tendency of blood pressure 
lowering after 6 weeks of administration of N. sativa L. powdered seeds 
(1000 mg twice daily). The changes were not significant due to the small 
sample size – only 39 patients out of 64 in the treatment group completed the 
study. 
The mechanism of hypotensive action of active constituents from N. 
sativa L. was investigated by several scientists and it appears to be the 
combination of various actions that contribute to the complex, including the 
aforementioned diuretic effect.  
Based on their experiments with reserpine, atropine, and 
cyproheptadine, El-Tahir, Ashour and Al-Harbi (1993) concluded that the 
cardiovascular depressant effects of black cumin volatile oil and 
thymoquinone in rats were mediated mainly centrally, via indirect and direct 
mechanisms that involved both muscarinic and 5-hydroxytryptaminergic 
mechanisms. The direct mechanism may be due to the presence of 
thymoquinone in the volatile oil, because the cardiovascular depressant effect 
of thymoquinone was not antagonized by reserpine.  
A peroral daily treatment of rats with pure thymoquinone (0.5 mg/kg) 
after chronic inhibition of nitric oxide synthesis with L-NAME attenuated the 
increase of systolic blood pressure induced by L-NAME in a dose-dependent 
manner. Thymoquinone treatment also increased glutathione to normal 
levels (Khattab and Nagi, 2007). Similar results were obtained by Jaarin et al. 
(2015) in L-NAME-induced hypertensive rats treated with black cumin oil 
(2.5 mg/kg) for 8 weeks. The blood pressure reduction was associated with a 
reduction in cardiac lipid peroxidation product, NAPDH oxidase, angiotensin 
converting enzyme activity, and plasma nitric oxide. 
Furthermore, Mahmmoud and Christensen (2011) identified a 
modulator of the Na+/K+ ATPase in black cumin seed oil as a mixture of oleic 
and linoleic acid that are found in the seed oil in high amounts (see Ch. 2.5.2.). 
This mixture strongly modified the K+-dependent reactions in pig kidney 
ATPase. The authors moreover observed that oleic and palmitic acid 
stabilized a pump conformation that binds ouabain with high affinity. For the 
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modulation of the pump sensitivity to cardiac glycosides, the dynamic 
changes in plasma levels of oleic and linoleic acids are important. 
The involvement of calcium flow in the antihypertensive mechanism of 
black cumin was suggested by Malik et al. (2017b) who proposed the 
mediation through the inhibition of Ca2+ influx via membranaceous 
Ca2+ channels and α-adrenergic receptor operated pathways. This suggestion 
was based on the results of a dose-dependent decline of mean arterial blood 
pressure caused by black cumin aqueous extract that was similar to the effect 
of verapamil (a Ca2+ channel blocker). 
 
2.5.4.5. EFFECT OF BLACK CUMIN ON PLASMATIC LIPID PROFILE 
 
The favorable effect of black cumin on lipid profile is well documented 
in both animal models and humans. Mollazadeh, Mahdian and Hosseinzadeh 
(2019) in their review of medicinal plants used for treatment of 
hypertriglyceridemia even classified black cumin as one of the five herbs with 
the best triglyceride lowering effect.  
Among the first studies of hypolipidemic effect of black cumin 
conducted on animal models, El-Dakhakhny, Mady and Halim (2000) 
observed a significant decrease in serum total cholesterol, LDL cholesterol, 
triglycerides, and a significant elevation of serum HDL cholesterol in rats 
treated with black cumin oil at a dose of 800 mg/kg for 4 weeks.  
A similar result was obtained by Zaoui et al. (2002a, b) who used an 
oral dose of 1 mL/kg of black cumin fixed oil in rats for 12 weeks. This 
treatment caused a significant decrease in serum total cholesterol and 
triglyceride levels (by 15.5 and 22%, respectively). Le et al. (2004) also 
reported that rats treated with petroleum ether extract of N. sativa L. seeds by 
intragastric gavage for 4 weeks had lower plasma levels of triglycerides and 
higher HDL cholesterol. The effect of black cumin on serum lipid levels in rats 
after a more prolonged administration (20 weeks) was investigated by Dahri 
et al. (2005). And again, a significant decrease in serum LDL cholesterol (by 
33%) and a significant increase in HDL cholesterol (by 100%) were observed. 
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El-Gindy et al. (2019) used two doses of black cumin seeds (300 or 
600 mg) in rabbits for 8 weeks. The supplementation of black cumin resulted 
in a significant decrease of serum total lipids, triglycerides, and 
LDL cholesterol, while it significantly increased the HDL cholesterol level. 
The hypolipidemic effect of black cumin is most likely both dose- and 
duration-dependent, as observed by Kocyigit, Atamer and Uysal (2009). They 
used four doses of black cumin powdered seeds (100, 200, 400, and 600 
mg/kg) and the treatment of rats with black cumin seeds lasted for 1, 2, or 
4 weeks. After one week, a significant increase in the HDL cholesterol level 
was observed with the 400 mg dose. LDL cholesterol levels decreased 
significantly after one week for 400 and 600 mg doses and after 2 weeks for 
all doses. After 2 weeks for 400 mg dose and after 4 weeks for all doses, a 
significant decline in triglyceride levels were noticed. The last to decline was 
the total cholesterol level that needed 4 weeks of treatment to decrease 
significantly. 
As to investigations of black cumin hypolipidemic effect on human 
volunteers, for example, Dehkordi and Kamkhah (2008) accomplished a 
randomized, double-blind, placebo controlled trial to evaluate the efficacy of 
treatment with an oral N. sativa L. seed extract supplement in patients with 
mild hypertension. After 8 weeks of administration of either 100 or 200 mg of 
black cumin extract twice daily, a significant decline in total cholesterol and 
LDL cholesterol levels were observed.  
Najmi et al. (2008) used black cumin oil (2.5 mL twice daily) in 
combination with atorvastatin (10 mg) and metformin (500 mg twice daily) 
for 6 weeks in a total of 60 patients. A significant reduction of total 
cholesterol and LDL cholesterol was observed in the black cumin treated 
group compared with the control receiving only atorvastatin and metformin.  
A favorable effect of black cumin seeds (500 mg twice daily) on serum lipid 
levels was also reported by Quidway et al. (2009), however, because of the 
small sample size (only 39 patients in the treatment group completed the 
study), the results were not statistically significant. 
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Kaatabi et al. (2012) recruited 94 patients who were treated with 
three doses of black cumin seeds (1, 2, or 3 g/day) for 12 weeks. The only 
statistically significant change in lipid parameters at the lowest dose was the 
increase in HDL cholesterol after 4 weeks of treatment. The dose of 2 g of 
black cumin led to a significant decrease in total cholesterol, triglyceride, and 
LDL cholesterol levels and to a significant increase in HDL cholesterol levels. 
The highest dose did not exhibit more hypolipidemic effect than the dose of 
2 g/day.  
Furthermore, the coadministration of black cumin with simvastatin 
was evaluated as more effective than simvastatin alone in the correction of 
dyslipidemia in patients treated for 8 weeks (Ahmad Alobaidi, 2014). When 
compared, treatment with black cumin or simvastatin in rats fed a high-
cholesterol diet, both substances showed a significant improvement in the 
lipid profile. However, in the black cumin treated group, no significant 
elevation of the alanine amino trasferase level was observed as in the 
simvastatin treated group, thus indicating a hepatoprotective effect of black 
cumin (Muneera, Majeed and Naveed, 2015). 
Also, black cumin treatment combined with a low-calorie diet or 
aerobic training is more effective in the normalization of the lipid profile in 
overweight women than the diet or training alone. The combination of black 
cumin and aerobic exercise even has a synergistic effect in the improvement 
of the lipid parameters (Farzaneh et al., 2014; Mahdavi et al., 2015). The 
hypolipidemic effect of black cumin, however, lasted for only 2 months after 
cessation of the black cumin supplement in menopausal women, and then 
they tended to move towards the pre-treatment levels (Ibrahim et al., 2014). 
Interestingly, black cumin has a favorable effect on the serum lipid 
profile disturbed not only by a high-cholesterol diet, but also in cases where 
the hyperlipidemic state is induced by various chemicals. For instance, 
lindane, a highly persistent organochlorine insecticide, causes oxidative stress 
in cells and tissues, and has a very negative influence on different serum 
biochemical parameters. However, pretreatment with black cumin seed oil 
alleviated the harmful effects of lindane on rat lipid profiles, as noticed by 
Attia et al. (2011). Black cumin oil administered for 20 days prior to a 
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sublethal dose of lindane significantly reduced total lipids, total cholesterol, 
and triglyceride levels and at the same time significantly increased the HDL 
cholesterol level in rats. The most marked reduction was in the triglyceride 
level where black cumin pretreatment reversed the effect of lindane almost to 
a normal level. A decrease in LDL cholesterol was also observed but it was not 
statistically significant (Attia et al., 2011). 
Treatment with pure thymoquinone also seems to improve the serum 
lipid spectrum. Badary et al. (2000) administered thymoquinone at a dose of 
10 mg/kg to rats with a doxorubicin-induced hyperlipidemic nephropathy. 
Thymoquinone supplementation with drinking water 5 days prior to the 
doxorubicin application and then daily thereafter led to a significant decrease 
in serum total cholesterol and triglycerides.  
Ragheb et al. (2008) investigated the effect of two different doses of 
thymoquinone (10 and 20 mg/kg) in rabbits fed a hypercholesterolemic diet. 
After 8 weeks of treatment, thymoquinone at lower dose decreased serum 
total cholesterol (by 26%) and LDL cholesterol (by 29%). Thymoquinone at 
higher dose further decreased serum triglycerides. Nader, El-Agamy and 
Suddek (2010) also used the rabbit model for investigating the effect of 
thymoquinone on the development of atherosclerosis. The administration of 
thymoquinone with a high-cholesterol diet led to significantly decreased 
levels of total cholesterol, LDL cholesterol, and triglycerides, while it 
significantly elevated the level of HDL cholesterol. 
The proposed hypolipidemic mechanism of black cumin was 
presented by Al-Naqeep, Ismail and Allaudin (2009). They investigated the 
effect of pure thymoquinone (2 µg/mL) or thymoquinone-rich fraction 
obtained by the supercritical fluid extraction from black cumin seeds 
(80 µg/mL; thymoquinone content 2.77% w/w) on two genes involved in the 
cholesterol metabolism (LDL receptor and 3-hydroxy-3-methylglutaryl 
coenzyme A reductase; HMG-CoA reductase) in a cell culture of HepG2 cells. 
Both tested substances significantly upregulated the LDL receptor 
mRNA level (thymoquinone-rich fraction 7-fold and pure thymoquinone 2-
fold) and significantly downregulated the mRNA level of HMG-CoA reductase 
(thymoquinone-rich fraction by 71% and pure thymoquinone by 12%). These 
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results indicate that black cumin contains more compounds with 
hypolipidemic properties. Furthermore, black cumin and thymoquinone 
influence the cholesterol metabolism on two levels: the uptake of LDL 
cholesterol (which they increase) and the synthesis of cholesterol (which they 
decrease).  
Consistent with these findings are the results obtained by Ahmad and 
Beg (2013) who used a methanolic extract (100 mg) and the volatile oil 
(20 mg) extracted from black cumin seeds in rats fed an atherogenic diet. 
Both tested fractions significantly decreased the hepatic HMG-CoA reductase 
activity (by 44% and 42%, respectively). The methanolic extract containig 
high amount of linolenic acid (an ω-6 unsaturated fatty acid; 75%) along with 
palmitic acid (3%) was more effective than the volatile oil. The linolenic acid 
shows hypocholesterolemic activity in the presence of palmitic acid in the 
ratio of 27:1 (Ahmad and Beg, 2013). 
Furthermore, Haas et al. (2014) demonstrated a significant elevation 
of apolipoprotein A-I (apo A-I), as well as apo A-I mRNA and gene promoter 
activity in hepatocytes (a HepG2 cell culture) and intestinal cells (a Caco-2 cell 
culture) treated with black cumin seed extract. As apo A-I is the major 
structural and functional protein component of HDL cholesterol, the increase 
in its expression may explain the heightened levels of serum HDL cholesterol 
after black cumin treatment. 
Some of the dolabellane-type diterpene alkaloids also contribute to the 
hypolipidemic effect of black cumin. Morikawa et al. (2004a, b) isolated 
several nigellamines from N. sativa L. and examined their effect on stored 
triglycerides in primary cultured mouse hepatocytes. A potent reduction of 
the triglyceride levels exhibited mainly nigellamines A1, A5, B1, and B2 with 
their activities being equivalent to that of clofibrate (a hypolipidemic agent 
acting as a PPARα agonist). For example, the activity of nigellamine A5 
represented a 64% inhibition of triglyceride levels in the hepatocytes 





2.5.5. SAFETY PROFILE OF THE BLACK CUMIN PREPARATIONS 
 
Black cumin has been used for hundreds of years as a spice or in 
traditional medicine. It can therefore be considered safe for use in humans. 
For example, the American Food and Drug Administration agency categorized 
black cumin as one of the "substances generally recognized as safe" and it is 
listed in §182.10 Spices and other natural seasonings and flavorings.  
There are several works mentioning N. sativa L. seeds or seeds oil 
toxicity investigations. On the cellular level, for example, Le et al. (2004) used 
isolated rat hepatocytes. The addition of a petroleum ether extract of black 
cumin seeds at a concentration of 500 µg/mL and subsequential incubation 
for 2, 4, or 6 hours did not significantly affect the cell viability.  
The safety of N. sativa L. was also tested in various animal models. For 
instance, black cumin oil administered to rats orally at a daily dose of 
800 mg/kg for 4 weeks did not adversely affect the serum transaminases 
(ALT and AST), alkaline phosphatase, or serum bilirubin, indicating low 
subchronic toxicity to liver tissues (Al-Dakhakhny, Mady and Halim, 2000).  
Similarly, the safety profile of N. sativa L. seed fixed oil was 
investigated by Zaoui et al. (2002b) on two animal models. The acute toxicity 
was tested in mice. Black cumin seed fixed oil was administered both orally 
and peritoneally. The found LD50 values were 28.8 mL/kg for oral 
administration and 2.06 mL/kg for peritoneal administration. In their another 
study with N. sativa L. seed fixed oil, no mortality was observed in mice after 
an oral administration of 10 mL/kg of oil during the 15 day period after the 
administration (Zaoui et al., 2002a). The chronic toxicity of black cumin seed 
fixed oil was studied in rats treated daily with an oral dose of 2 mL/kg for 
12 weeks. After this period, there were no changes in key hepatic enzymes 
(transaminases AST, ALT, and GGT) and histopathological modifications 
(heart, liver, kidneys, and pancreas). 
Le et al. (2004) also found no physicial or behavioral signs of toxicity, 
such as lethargy, hyperactivity, restlessness, respiratory distress, or 
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convulsions, in rats treated with a black cumin seed petroleum ether extract 
at a dose equivalent to 2 g/kg of the original seed powder for 4 weeks.  
In 136 patients with chronic kidney disease, black cumin oil (2.5 mL 
perorally, once daily) was used as an add-on therapy for 12 weeks. Most of 
the observed adverse effects were mild (no hospitalization, no change of 
therapy, no additional treatment needed). All of the adverse effects were 
latent or subacute in onset, no case belonged to the category of acute onset 
(within 60 minutes). Mild nausea in the beginning of the trial was reported, 
but it did disappear during the second week of the duration of the study 
(Alam et al., 2020).  
Ibrahim et al. (2008) even observed a hepatoprotective effect of the 
crude N. sativa L. seed oil in rats with a tetrachloride carbon-induced 
downregulation of cytochrome P450 isozymes. Oral pretreatment with 
1 mL/kg of black cumin oil for 7 days before the intraperitoneal application of 
carbon tetrachloride alleviated the suppression of CYP2B, CYP3A2, CYP2C11, 
and CYP1A2 enzymes. The role of black cumin and its bioactive constituents 
(namely thymoquinone, thymol, and α-hederin) as hepatoprotectant agents 
was in detail reviewed by Tabassum, Ahmad and Ahmad (2018). The 
abovementioned compounds protect from liver injury mainly via their 
antioxidant and anti-inflammatory activities. 
As to the toxicity of pure compounds contained in black cumin, the 
situation is more complicated. Unlike the complex N. sativa L. seed oil, the 
most active compound, thymoquinone, is evidently less safe. Mansour et al. 
(2001) stated that higher doses of thymoquinone were found to induce 
oxidative stress leading to a hepatic injury. The LD50 for thymoquinone in 
mice was 90.3 mg/kg.  
The same unfavorable effect was observed on the cellular level by 
Khader, Bresgen and Eckl (2009). They used isolated rat hepatocytes 
incubated for 48 hours with different concentrations of thymoquinone 
ranging only from 1 to 20 µmol/L, because higher concentrations induced 
severe cell death within minutes to hours of treatment. At the concentration 
of 1 mmol/L, thymoquinone induced immediate cytotoxicity, as evidenced by 
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nuclear shrinkage and plasma membrane blebs within minutes of application. 
The concentrations of 20 and 10 µmol/L also showed cytotoxic effects by 
inducing high levels of cell necroses. The lower concentrations of 
thymoquinone were less toxic but induced adverse effects, such as increased 
levels of necroses, frequencies of chromosomal aberrations, and formation of 
micronuclei (Khader, Bresgen and Eckl, 2009).  
Notable decreased cell viability after treatment of rat cardiomyocytes 
with thymoquinone at concentrations of 16 and 32 µmol/L was also reported 
by Lu et al. (2018). However, lower concentrations of thymoquinone (1, 2, 4, 
and 8 µmol/L, respectively) did not negatively affect the cell viability of 
cardiomyocytes (Lu et al., 2018). A similar concentration of thymoquinone 
was found to be safe for hepatocytes HepG2 cell culture by Al-Naqeep, Ismail 
and Allaudin (2009). They reported that incubation of the cells with 2 µg/mL 
(equals to approximately 12 µmol/L) did not alter the proliferation rate of 
HepG2 and most cells (87%) were found to be in the stage of viable cells. 
Llana-Ruiz-Cabello et al. (2015) again showed that oxidative stress 
plays a role in the damage induced to intestinal cells (a Caco-2 cell culture) by 
carvacrol and its mixture with thymol at high concentrations (460 µmol/L for 
carvacrol and 300/30 µmol/L for the mixture). However, at lower 
concentrations both compounds and their mixture protected cells against the 
damage induced by hydrogen peroxide.  
 
2.6. OLIVE – OLEA EUROPAEA L. – FAM. OLEACEAE 
 
2.6.1. CHARACTERIZATION OF OLEA EUROPAEA L. – A PHARMACOGNOSTIC CONTEXT 
 
Olea europaea L. (Fig. 2.11.) is a subspecies of the subgenus Olea, one 
of the three subgenera of the genus Olea. The whole genus Olea includes 
approximately 40 taxa of shrubs and trees. Olive is a small evergreen tree, 
most likely native to parts of southern Europe and Asia Minor. It is found 
mostly in tropical and subtropical areas (e.g. the forests of Mediterranean, the 
Sahara, Australia, and China). The olive tree can, however, survive in a wide 
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range of environments. Olive oil and its fruit are edible (Ray et al., 2009 and 
references therein). 
For medicinal use, usually fresh olive leaves are collected (Oleae 
folium). The leaves are of elliptical shape, thick and leathery, whole-
marginated. The upper surface of the leaf is bright green with a particular 
shine to it, while the bottom surface of the leaves is silvery, slightly haired. 
The content of secoiridoids must not be less than 5.0%, expressed as 
oleuropein, calculated with reference to the dried drug. The European 
Pharmacopoeia furthermore includes a monograph on the olive leaf extract 
(Oleae folium extractum siccum) and two monographs on olive oil (Olivae 
oleum raffinatum and Olivae oleum virginale; Rahfeld, 2017; European 









Fresh leaves are further processed by extraction with different 
solvents. The extraction of olive leaves with 80% ethanol leads to a high 
phenolic and flavonoid content, as demonstrated by Lee et al. (2009), and it is 
commercially used in the production of olive leaf extract EFLA 943 (see 
Ch. 2.6.3.), although the extraction with butanol or ethylacetate also yields 
high amounts of these compounds. 
Fig. 2.11. Olea europaea L. A closeup of a tree branch with unripe fruits. From shutterstock.com. 
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Lately, alternative methods for obtaining phenolics from olive tree 
plant material with the emphasis on the eco-friendly and sustainable 
extraction procedure were also reported. For example, Japón-Lujan and 
Luque de Castro (2007) proposed a simple and rapid (under 10 minutes) 
extraction process of biophenols from the small branches of olive trees, 
accelerated by microwave, as an alternative form of olive leaf extraction. Olive 
pomace, which is produced in great amounts as a waste product in the olive 
oil industry, also seems to be a promising source of several bioactive 
compounds. A multi-frequency multimode modulated ultrasonic technique 
for the extraction of phenolic compounds from olive pomace with a high yield 
of these compounds was presented by Nunes et al. (2018).  Further, Paze et al. 
(2019) optimalized the pressurized liquid extraction of phenolics from olive 
pomace without organic solvents. The yields of secoiridoids and flavonoids in 
this optimalized pressurized liquid extraction were three to four times higher 
than in the conventional extracts.  
 
2.6.2. PHYTOCHEMISTRY OF OLIVE LEAF 
 
The primary olive leaf compounds are secoiridoids (oleuropein and its 
derivates), hydroxytyrosol, polyphenols (verbascoside, apigenin-7-glucoside, 
luteolin-7-glucoside), triterpenes (including oleanolic acid), and flavonoids 
(rutin and diosmin). Oleuropein content is significantly higher in the leaf than 
in other parts of the plant (Olive Leaf Monograph, 2009).  
Up to 36 distinct phenolic compounds can be found in olive fruit. A 
defining structural component of the secoiridoid group of olive phenolic 
compounds is elenolic acid. The molecule of elenolic acid is incorporated 
within the most important phenolics, such as oleuropein, ligstroside, and 
elenolic acid-linked hydroxytyrosol and tyrosol (Ray et al., 2009). Some of the 
olive leaf phenolics are depicted in Fig. 2.12. 
Oleuropein is generally the most prominent phenolic compound in 
olive cultivars. Its molecule consists of three structural subunits: a polyphenol 
(hydroxytyrosol), a secoiridoid (elenolic acid), and a glucose molecule. The 
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biosynthesis of oleuropein proceeds via a branching in the mevalonic acid 
pathway from the secondary metabolism, forming the oleosides from which 













The content of oleuropein and other active compounds in olive leaves 
may vary considerably depending on several factors, such as genotype or 
season of the year. The genotype variation in oleuropein content was 
reported in seven Italian cultivars (Ranalli et al., 2006) and in nine Turkish 
olive cultivars (Orak et al., 2019). A comprehensive chemical analysis of 
Iranian olive cultivars (Ghasemi et al., 2018) demonstrated that oleuropein 
was even not detected in four out of the seventeen cultivars tested.  
The seasonal variation of phenolic content in olive trees was studied 
by Xu et al. (2018), who reported that the oleuropein content was high in 
spring and winter months (the highest oleuropein content was detected in 




March and November), while low oleuropein content was observed in the 
summer and autumn months (May and September, respectively). 
On the other hand, the developmental stage of the leaf does not seem 
to play any role in the oleuropein content which stays fairly constant from 
immature leaf stadium throughout the full expansion of the leaf (Malik and 
Bradford, 2006). Contrary to this observation, oleuropein content in the olive 
fruit varies significantly. The highest oleuropein content was reported in the 
growth phase. Later, in the green maturation phase and in the black 
maturation phase of the fruit, oleuropein content consequently decreases 
(Omar, 2010a and references therein). 
 
2.6.3. MEDICINAL USE OF OLIVE LEAF 
 
 According to the EMA monograph on Olea europaea L., folium, olive 
leaf is a traditional herbal product used to promote the renal elimination of 
water in mild cases of water retention after serious conditions have been 
excluded by a medical doctor. It can be used as an herbal tea (prepared of 
fresh or dried leaves) or in the form of dried leaves (comminuted or 
powdered; EMA/HMPC/359238/2016). However, most of the recent studies 
have focused on the other beneficial influences of olive leaf on human health 
with an emphasis on the antioxidant, antiatherogenic, antihypertensive, lipid-
lowering, and even anti-cancer properties of the active compounds. 
In several of studies mentioned in the following text, a commercially 
available olive leaf extract EFLA 943 was used. This extract is obtained 
through the extraction of olive leaves with 80% ethanol (w/w), and the 
resultant product is purified by a patented procedure to remove the 
undesired contaminants and residues. Then the solvent is removed, resulting 






2.6.4. EFFECTS OF OLIVE LEAF ON SELECTED CARDIOVASCULAR CONDITIONS 
 
2.6.4.1. ANTIOXIDANT EFFECT OF OLIVE LEAF 
 
There are numerous studies documenting the antioxidant activity of 
olive fruit, olive leaf, or olive oil extracts or their individual active compounds. 
Nearly all of the studies presenting the influence of olive leaf extract or 
individual olive compounds on the hypertension or the lipidic profile also 
mentioned the antioxidant activity of olive phenolics. Some of the works 
were, however, focused solely on the assessment of the antioxidant capacity 
of olive leaf extract and/or pure phenolics. 
For example, Visioli, Bellomo and Galli (1998) focused on the 
scavenging activity of oleuropein and hydroxytyrosol, and in their work 
demonstrated that both studied phenolics are potent scavengers of 
superoxide radicals and inhibitors of neutrophils' respiratory bursts. Kruk 
et al. (2005) performed a complex study on the antioxidant activity of 
oleuropein (and genistein, respectively) and confirmed the strong antioxidant 
activity of oleuropein against superoxide radicals. Furthermore, oleuropein 
also reacted with peroxyl radicals (60% inhibition) and hydroxyl radicals (up 
to 90% inhibition). 
Roche et al. (2005) tested the antioxidant activity of several olive 
phenolics in various models. The highest number of radicals trapped per 
antioxidant molecule was attributed to dihydrocaffeic acid. Oleuropein, 
hydroxytyrosol, and caffeic acid on the other hand had the highest rates of 
transfer of the most labile H-atoms of the antioxidant. 
As to the mechanism of antioxidant action, Stupans et al. (2002) 
tested the potency of selected natural antioxidants including oleuropein and 
hydroxytyrosol. Their results suggest that complex phenols, such as 
hydroxytyrosol, both inhibit the radical generation and act as free radical 
scavengers. Roche et al. (2005) described in detail the proposed mechanism 
of peroxyl radical scavenging by olive phenolics. This process includes the 
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oligomerization and a specific fragmentation of the formed dimers and 
trimers. 
Oleuropein in its chemical structure contains an ortho-diphenolic 
moiety, which is able to scavenge ROS through hydrogen donation, and to 
stabilize oxygen radicals with an intramolecular hydrogen bond. Tyrosol, on 
the other hand, has only a single hydroxyl substitution providing none of the 
antioxidant properties (Nediani et al., 2019 and references therein). 
 
2.6.4.2. DIRECT EFFECT OF OLIVE LEAF ON MYOCARDIUM 
 
Petkov and Manolov (1972) tested pure oleuropein obtained from 
olive leaves on isolated rabbit hearts. Their results show the activity of 
oleuropein against a barium chloride-induced arrhythmia in rabbits, and 
against a calcium-induced arrhythmia in cats. Esmailidehaj et al. (2012b) 
measured the effect of oleuropein treatment in rats on arrhythmia induced by 
ischemia and reperfusion. The administration of oleuropein at a dose of 
100 mg/kg one hour or three hours before the ischemia resulted in a 
significantly decreased reperfusion arrhythmia in various forms, such as 
ventricular ectopic beats, ventricular tachycardia, and ventricular fibrillation.  
In their another study with oleuropein on rats (Esmailidehaj et al. 
2012a), the authors tested a lower dose of oleuropein (20 mg/kg) 
administered one to 48 hours before an intravenous infusion of aconitine. 
This single dose did not offer any preconditioning effect against the aconitine-
induced arrhythmia. However, a prolonged administration of oleuropein 
(4 weeks) prior to the aconitine infusion led to a significant increase of the 
mean initiation time of both arrhythmia and ventricular tachycardia, to a 
significant increase of reversible ventricular fibrillation, and to a significant 
increase in the mean death time. 
Olive leaf extract EFLA 943 was further proven to have negative 
inotropic activity in isolated guinea pig hearts both when applied alone and in 
a mixture with Hibiscus sabdariffa flower extract. Moreover, the mixture 
showed negative chronotropic efficacy (Micucci et al., 2015; 2016). 
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The cardioprotective effect of olive leaf in an ischemic myocardium 
was reported by several authors in the last fifteen years. The authors used 
either isolated hearts or whole animals of several species and different 
pretreatment regimes with oleuropein in various concentrations, but the 
cardioprotective effect was observed in every work mentioned in the 
following text. The cardioprotective effect is evidently dose-dependent and 
time-limited. Esmilidehaj et al. (2012) estimated that the duration of the 
cardioprotective effect of a single dose of oleuropein (100 mg/kg) to be 
6 hours. 
In isolated heart experiments, the dosage of olive leaf extract is usually 
in the range of 10 to 50 µg per g of heart weight. For example, Manna et al. 
(2004) used isolated rat hearts pretreated with oleuropein (20 µg/g heart) 
and then subjected them to 30 minutes of global ischemia and following 
reperfusion. The release of oxidized glutathione, a sensitive marker of the 
heart's exposure to an oxidative stress, was significantly reduced in the hearts 
pretreated with oleuropein.  
Very similar results were presented by Esmailidehaj et al. (2016), who 
demonstrated the cardioprotective effect of oleuropein (10 and 50 µg/g 
heart) in isolated rat hearts 5 minutes before the induction of 30 minutes of 
global ischemia or at the beginning of 90 minutes of reperfusion. 
Pretreatment with oleuropein resulted in a significant improvement of both 
the coronary outflow and the decrease in the size of the infarct area. 
A higher dose of oleuropein (tenths to hundreds mg/kg of body weight 
per day) is used in the animal model studies. Janahmadi et al. (2015) treated 
rats with pure oleuropein (10, 20 or 30 mg/kg/day, respectively) for 7 days 
before coronary ligation, a surgically-induced model of myocardial infarction. 
This pretreatment with oleuropein prevented the impairment of cardial 
functions, such as left ventricular developed and systolic pressures, stroke 
volume, and ejection fraction and resulted in a decrease of the infarct area 
size.  
Andreadou et al. (2015) also used the oleuropein pretreatment 
(20 mg/kg/day) in rabbits for 6 weeks before subjecting the animals to 
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30 minutes of myocardial ischemia followed by 10 minutes of reperfusion. 
Myocardial biopsies were then taken from the ischemic areas. In the 
oleuropein treated rabbits, oxidative biomarkers (namely malonyl dialdehyde 
and nitrotyrosine) were significantly reduced.  
Xu et al. (2018) found that olive leaf extract can even ameliorate the 
effects of an isoprenaline-induced, acrolein-aggravated myocardial infarction 
in rats, a situation simulating the air pollution in big cities. In this case, the 
olive leaf extract pretreatment (200 and 400 mg/kg/day, respectively) again 
resulted in the reduction of myocardial tissue damage and in a decrease in the 
infiltration of inflammatory cells. Furthermore, the olive leaf extract 
pretreatment reversed the values of the parameters of cardiac systolic 
function, such as ejection fraction and fractional shortening.  
The mechanism of the cardioprotective effect of olive leaf extract or 
individual compounds may be partially explained by the inhibition of the 
apoptosis in the cardiomyocytes. Bali et al. (2014) tested the effect of olive 
leaf extract and pure compounds (namely oleuropein, hydroxytyrosol, and 
quercetin) on chemically induced oxidative damage to rat cardiomyocytes. 
The apoptosis induced by 4-hydroxynonenal was inhibited by both methanol 
and ethanol olive leaf extracts as well as by all tested individual compounds. 
The ethanolic extract had more protecting ability with a higher content of 
oleuropein, hydroxytyrosol, and quercetin. Olive leaf extract or pure 
compounds attenuated all studied parameters, including the reactive oxygen 
species production, the activation of the pro-apoptotic enzyme caspase-3, the 
phosphorylation of stress-induced transcription factors, and furthermore 
enhanced cell viability and mitochondrial function. 
Zhang et al. (2017) simulated an ischemia/reperfusion-induced 
cardiomyocyte injury in vitro. The addition of oleuropein to neonatal rat 
cardiomyocytes led to a significantly reduced intracellular reactive oxygen 
species generation as well as the stabilization of mitochondrial membrane 
potential (MMP). MMP is an important early marker of the mitochondrial 
apoptotic pathway. Further analysis of some apoptosis-related proteins in 
oleuropein-treated cells revealed the attenuation of the expression of  
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pro-apoptotic enzymes caspase-3 and caspase-9, and changes in the  
Bcl-2/Bax ratio (high values of this ratio indicate a pro-apoptotic status). 
Similarly, Xu et al. (2018) examined critical molecules in the 
endoplasmic reticulum stress pathway (namely GRP78 and CHOP) and 
apoptosis-related molecules (Bcl-2/Bax ratio) in the infarct tissue of rats with 
an isoprenaline-induced, acrolein-aggravated myocardial infarction. All of the 
mentioned molecules were increased at the protein and mRNA levels more 
obviously with the acrolein treatment. However, the altered expression of 
these molecules was significantly reversed by olive leaf extract pretreatment. 
Based on their in vitro part of the study with cardiomyocyte H9c2 cells, the 
pretreatment with pure oleuropein or hydroxytyrosol can protect the cells 
from the acrolein-induced apoptosis, with hydroxytyrosol being the more 
efficient compound.  
The assay of apoptosis-related proteins from rat heart tissue exposed 
to a simulated ischemia/reperfusion injury showed that oleuropein treatment 
led to an attenuated caspase-3 activity and p-53 protein expression, which 
again indicates the anti-apoptotic effect of oleuropein (Jin et al., 2018). 
 
2.6.4.3. EFFECT OF OLIVE LEAF ON BLOOD, AND BLOOD VESSELS 
 
The effect of a decoction of olive leaves on smooth vascular muscle 
was studied by Zarzuelo et al. (1991). The lyophilized decoction caused 
relaxation of isolated rat aorta both in the presence and in the absence of 
endothelium, indicating that the vasorelaxant activity of olive extract is 
independent of the integrity of endothelium.  
The vasorelaxant effect of virgin olive oil phenolic extract on isolated 
rat aorta was also reported by Benkhalti et al. (2003). The effect persisted 
even when the activity of nitric oxide synthase was inhibited. On the other 
hand, pure oleuropein did not exhibit any vasorelaxant activity, indicating 
another role of this compound. Further, the vasorelaxant potency of olive leaf 
extract on isolated guinea pig smooth muscle was noticed by Micucci et al. 
(2015). The potassium-induced contraction of vascular smooth muscle was 
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reduced by olive leaf extract in a dose-dependent manner. And similarly, a 
chronic administration of olive leaf extract in rats led to a reversion of the 
impaired aortic endothelium-dependent relaxation to acetylcholine in 
spontaneously hypertensive rats. Olive leaf extract restored the aortic 
endothelial nitric oxide synthase (eNOS) phosphorylation and increased the 
eNOS activity (Romero et al., 2016). 
The role of oleuropein may be the inhibition of endothelial 
activation (as a part of the antiatherogenic effect), as reported by Carluccio 
et al. (2003). The authors incubated several phytochemicals from olive oil and 
red wine including oleuropein, tyrosol, and hydroxytyrosol with human 
umbilical vein endothelial cells for 30 minutes, and then they attempted to 
trigger the adhesion molecule expression by the co-incubation with a 
bacterial lipopolysaccharide or cytokines. At nutritionally relevant 
concentrations, both oleuropein and hydroxytyrosol did reduce the activation 
of endothelium, measured as the monocytoid cell adhesion to the stimulated 
endothelium and the amount of the vascular cell adhesion molecule-1 mRNA. 
Similarly, Turner et al. (2005) investigated the activity of olive oil 
phenolics oleuropein, tyrosol, hydroxytyrosol, and homovanillic alcohol in cell 
cultures. Their results show that these tested phenolics lead to a significant 
decrease of the secretion of the intercellular adhesion molecule-1 and the 
vascular cell adhesion molecule-1. 
A polyphenol extract from olive pomace was also reported to have a 
beneficial effect on the endothelial function impaired by anoxia. Palmieri et al. 
(2012) exposed human endothelial cells to the anoxic stress in the presence 
or the absence of the polyphenol extract or pure oleuropein and tyrosol. The 
polyphenol extract was more effective in preventing endothelial dysfunction 
(measured as the expression of genes involved in proteolysis, angiogenesis, 
and inflammation) than pure oleuropein or tyrosol. The polyphenol extract 
moreover prevented the proliferation and migration associated with anoxia 
in the endothelial cells. 
The inhibition of platelet aggregation in the presence of the phenolic 
compounds of olive oil was reported by Petroni et al. (1995). The inhibition of 
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aggregation of platelet-rich plasma was more effective when either phenol-
enriched extract obtained from aqueous waste from olive oil, or a specific 
component of olive oil (namely DHPE: 2-(3,4-dihydroxyphenyl)-ethanol) was 
used. Oleuropein and some selected flavonoids (luteolin, apigenin, and 
quercetin) were found to be much less effective in the inhibition of platelet 
aggregation. In cell cultures, oleuropein was even shown to not exert any 
platelet aggregation-inhibitory properties (Turner et al., 2005).  
Singh et al. (2008) incubated full human blood from healthy 
volunteers with five different concentrations of commercially available olive 
leaf extract (standardized to contain 5.40 mg/mL of oleuropein) for 
6 minutes. The platelet aggregation was strongly inhibited at the two highest 
olive leaf extract concentrations, thus indicating that the anti-aggregant 
activity of oleuropein is dose-dependent. 
Similarly, DellꞌAgli et al. (2008) observed the ability of oleuropein to 
inhibit the platelet aggregation. The authors used human washed platelets 
stimulated with thrombin and subsequently treated with olive oil phenols 
(extract or pure compounds including oleuropein aglycone, tyrosol, 
hydroxytyrosol, and homovanillic alcohol) for the aggregation assay. Of all 
individual compounds tested, oleuropein aglycone exhibited the strongest 
inhibitory effect on the platelet aggregation. 
Zbidi et al. (2009) again confirmed the platelet aggregation-inhibitory 
activity of oleuropein and cycloolivil, another polyphenolic compound 
isolated from an ethyl acetate extract of olive tree wood. Both compounds 
reduced the ability of thrombin to stimulate platelet aggregation, and 
furthermore reduced the thrombin-evoked calcium release and entry. 
Interestingly, this effect was greater in the platelets from diabetes mellitus 







2.6.4.4. ANTIHYPERTENSIVE EFFECT OF OLIVE LEAF  
 
The research on the antihypertensive effect of olive extract (leaf or 
fruit) clearly shows that treatments with these extracts have a beneficial 
influence on blood pressure in both animal models and humans. The animal 
model for the majority of the studies is a spontaneously hypertensive rat 
model, although Khayyal et al. (2002), for example, treated L-NAME-induced 
hypertensive rats with olive leaf extract EFLA 943 (100 mg/kg) for 6 weeks. 
The blood pressure of the animals, which had risen after the L-NAME 
treatment, started to drop progressively over the course of the experiment to 
reach a normalized blood pressure at the end of the trial. 
Romero et al. (2016) treated rats with oleuropein-enriched olive leaf 
extract (containing 15% of oleuropein; 30 mg/kg) for 5 weeks and observed a 
significant reduction of the systolic blood pressure and heart rate at the end 
of the experiment. Furthermore, this treatment led to a reduction of the 
cardiac and renal hypertrophy.  
The influence of olive leaf extract EFLA 943 and pure oleuropein on 
systemic hemodynamic parameters in spontaneously hypertensive rats was 
studied by Ivanov et al. (2018). A bolus dose of olive leaf extract EFLA 943 (5, 
25, or 50 mg/kg) was administered to the animals directly before the 
measurement. After the application of both higher doses of EFLA 943, systolic 
pressure, diastolic pressure, and mean arterial pressure were all significantly 
decreased when compared to the values before treatment. Furthermore, the 
highest administered dose of EFLA 943 led to a significantly decreased heart 
rate and cardiac output.  
The hypotensive effect of olive leaf extract was also tested in human 
volunteers with untreated suboptimal blood pressure. Treatment with 
1000 mg of olive leaf extract EFLA 943 for 8 weeks led to a significantly 
decreased systolic blood pressure (Perrinjacquet-Moccetti et al., 2008). 
A comparative study on the efficacy of olive leaf extract EFLA 943 
versus captopril (an ACE inhibitor) in mildly hypertensive patients was 
presented by Susalit et al. (2011). The volunteers were given either olive leaf 
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extract (500 mg twice daily) or captopril (12.5 mg twice daily) for 8 weeks. 
The olive leaf extract demonstrated a comparable blood pressure lowering 
effect to that shown by captopril. Furthermore, the olive leaf extract was 
found to significantly reduce both the total cholesterol and the triglyceride 
levels, while in the captopril group no such beneficial effect occurred. 
The mechanism of the hypotensive activity seems to be multifactorial, 
according to various studies conducted through the last twenty years. Hansen 
et al. (1996) observed that in vitro, an aqueous extract of olive leaves (namely 
from the species O. europaea L. and O. lancea Lam.) exhibited an inhibitory 
effect on the angiotensin converting enzyme. The main inhibitory compound 
was identified as the secoiridoid oleacin. The authors further tested selected 
secoiridoid glycosides (including oleuropein) for the ACE-inhibitory activity. 
While the glycosides showed no significant ACE inhibition, after the process 
of enzymatic hydrolysis, inhibitory activity of the corresponding compounds 
rapidly increased. Oleacin, a dialdehyde derivate of oleuropein, was identified 
as a strong ACE inhibitor.  
The ACE-inhibitory activity of oleuropein was also observed in vivo in 
rats pretreated with oleuropein (20 or 40 mg/kg) for 7 days and then 
intoxicated with isoproterenol to induce a myocardial injury. While the 
application of isoproterenol resulted in a 78% increase of ACE activity, 
treatment with oleuropein induced a remarkable decrease of ACE activity by 
33 and 40%, respectively (Mnafgui et al., 2015). Sun et al. (2017) used a 
higher dose of oleuropein (60 mg/kg) and a prolonged treatment (8 weeks), 
and again confirmed the significantly reduced expression of the components 
of the renin-angiotensin system in spontaneously hypertensive rats. 
Gilani et al. (2005) tested an olive fruit extract on animal models and 
observed a fall in systolic, diastolic, and mean arterial blood pressure in 
normotensive rats. Pretreatment with atropine, a competitive blocker of 
acetylcholine at muscarinic receptors, did not change the hypotensive effect 
of olive fruit extract, thus leading to the suggestion that the olive extract 
mediates its hypotensive action through mechanisms independent of the 
muscarinic receptor activation. The existence of the calcium antagonistic 
activity was confirmed when the olive extract caused a dose-dependent 
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rightward shift in the Ca2+ dose-response curves, similar to verapamil (a 
standard Ca2+ channel blocker). Three years later Scheffler et al. (2008) used 
voltage clamp experiments in cultured rat cardiomyocytes to demonstrate 
that olive leaf extract suppresses the L-type calcium channel directly and 
reversibly.  
Non-phenolic compounds also contribute to the hypotensive effect of 
olive leaf extract, as demonstrated by Somova et al. (2003) who used only 
triterpenoids, isolated from the olive leaves of three cultivars (from Greece, 
South Africa, and a wild African olive). All three extracts were administered at 
a dose of 60 mg/kg to salt-sensitive insulin-resistant rats for 6 weeks and 
prevented the development of severe hypertension and atherosclerosis. 
 
2.6.4.5. EFFECT OF OLIVE LEAF ON PLASMATIC LIPID PROFILE 
 
The antioxidant properties of olive phenolics on the oxidation of low-
density lipoprotein (LDL) have been extensively studied. In 1994 Visioli and 
Galli tested the protective role of oleuropein against the copper sulfate-
induced LDL oxidation. Oleuropein effectively inhibited the LDL oxidation 
even at low concentrations (10-5 mol/L). Caruso et al. (1999) evaluated the 
potency of virgin olive oil phenolics, individual compounds tyrosol and 
oleuropein, and a widely used synthetic antioxidant probucol during the 
photo-induced LDL oxidation. Their results clearly demonstrated that olive 
phenolics had a significantly stronger influence on preventing of the 
cholesterol oxide formation and apoproteic moiety modification than the 
individual compounds, and even more than probucol. 
Coni et al. (2000) in their in vivo study with rabbits fed either a 
standard diet, a diet with addition of 10% extra virgin olive oil, or a diet with 
an addition of oleuropein (7 mg/kg) observed that the addition of oleuropein 
not only increased the ability of LDL to resist oxidation (evaluated as the less 
conjugated diene formation) but also decreased the plasmatic levels of total, 
free, and ester cholesterol. 
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Leenen et al. (2002) incubated blood plasma with individual 
compounds or olive oil extracts, and then LDL was isolated and exposed to 
oxidation. The results show that ortho-dihydroxy phenols (oleuropein 
aglycone and hydroxytyrosol) are more efficient than mono-hydroxy phenols 
(tyrosol and ligstroside aglycone) in increasing the resistance of LDL to 
oxidation. 
A fairly complex insight on the effect of various olive oil constituents 
on inhibition of the copper sulfate-induced LDL oxidation was presented by 
Andrikopoulos et al. (2002). The authors examined polyphenolic and  
non-phenolic compounds at various doses. All of the tested compounds had a 
higher LDL mean protection activity than tocopherol, with the only exception 
for the phytosterol stigmasterol. The highest LDL mean protection activity 
was found in triterpenoid ursolic acid, flavonoid luteolin, and phenolic 
oleuropein at the highest used concentration. 
Benkhalti et al. (2003) and Turner et al. (2005) again confirmed the 
inhibitory effect of oleuropein on LDL oxidation. A new insight on this effect 
was presented by Briante, Febbrario and Nucci (2004) who used individual 
compounds (oleuropein, hydroxytyrosol) or complex mixtures obtained by 
biotransformation of olive leaf extracts in their study on the copper ion-
induced LDL oxidation. The authors reported that when the concentration of 
phenols is higher than that of copper ions, the LDL oxidation is inhibited by 
oleuropein and hydroxytyrosol in the initiation phase of the reaction. 
However, at a lower concentration both phenols anticipated the initiation 
process of the LDL oxidation, thus exerting pro-oxidant capacities. The pro-
oxidant behavior of oleuropein was also reported by Mazziotti et al. (2006) in 
a Fenton-like in vitro experiment with ferrous ions. Needless to say, the effect 
of both oleuropein and hydroxytyrosol on the copper ion-induced 
LDL peroxidation is indeed determined by a balance of their pro-oxidant and 
antioxidant capacities. Furthermore, a synergistic effect among the phenolic 
compounds enhanced their antioxidant capacities and in this manner they 
avoided the pro-oxidant effects (Briante, Febbrario and Nucci, 2005).  
Olive leaf extract moreover has a beneficial influence on serum 
triglyceride and cholesterol levels, as observed by several authors on both 
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animal models and with human volunteers. For example, Ivanov et al. (2018) 
reported significantly decreased values of total cholesterol and triglycerides 
in the plasma of rats treated with olive leaf extract EFLA 943. Treatment with 
pure oleuropein at a dose of 10 mg/kg had no effect on total cholesterol 
concentration, but it lowered the concentration of triglycerides in the plasma. 
Similar results were obtained by Malliou et al. (2018) who tested the 
effect of oleuropein supplementation at a dose of 100 mg/kg on mice. After 
6 weeks, a significant reduction of serum triglyceride levels and liver 
triglyceride content as well as total cholesterol concentration was observed, 
indicating that a higher dose of oleuropein is needed for the total cholesterol 
reduction. 
Jemai et al. (2008) tested the effect of oleuropein-rich olive leaf 
extracts and their enzymatic and acid hydrolysates, respectively rich in 
oleuropein aglycone and hydroxytyrosol, on rats fed a high-cholesterol diet 
for 16 weeks. Administration of the olive leaf extracts significantly lowered 
the serum levels of total cholesterol, LDL cholesterol, and triglycerides and 
increased the level of HDL cholesterol. 
Similarly, Fki et al. (2020) administered hydroxytyrosol-rich and 
oleuropein-rich olive leaf extracts to rats fed a high-fat diet for 8 weeks. Both 
oleuropein and hydroxytyrosol treatment resulted in a decrease of total 
cholesterol, LDL cholesterol and triglyceride levels, while the HDL levels 
increased. Based on the data provided by the authors, hydroxytyrosol seems 
to be more effective in the alteration of the lipid profile than oleuropein. 
The beneficial effect of olive leaf extract on the lipid profile in human 
volunteers was demonstrated by Perrinjacquet-Moccetti et al. (2008) who 
used olive leaf extract EFLA 943 in their study with 40 pairs of monozygotic 
twins. The volunteers were provided either with placebo or 500 mg EFLA 943 
for 8 weeks, and subsequently either with 500 mg or 1000 mg EFLA 943 for 
another 8 weeks. Absolute cholesterol levels showed a decrease during the 
course of experiment in all treatment groups. A statistically significant 
decrease was observed for the total cholesterol and LDL cholesterol 
concentrations in volunteers treated with 1000 mg EFLA 943. 
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Araki et al. (2019) focused on the effect of olive leaf tea and  
low-concentration olive leaf tea on non-obese and non-diabetic volunteers 
(330 mL of the respective beverage, 3 times daily). After 12 weeks, a 
significant decrease in serum levels of LDL cholesterol and triglycerides was 
observed, this decrease being more pronounced in the olive leaf tea group.  
The mechanism of the hypolipidemic effect of olive active compounds 
is multifactorial and most likely involves the cessation of both adipocyte 
differentiation and the process of adipogenesis. Either way, transcription 
factors of the PPAR family (peroxisome proliferator-activated receptor; they 
play essential roles in the control of lipid metabolism and energy 
homeostasis) represent a key component.  
Svobodová et al. (2014) investigated the effect of oleuropein on an 
in vitro 3T3-L1 adipocyte cell culture and reported that oleuropein inhibited 
the differentiation of most adipocytes at the concentrations of 200 and 
400 µM, respectively. Furthermore, starting at a 10µM concentration, 
oleuropein in a dose-dependent manner reduced the expression of the genes 
for the transcription factor PPARγ and several others that are involved in the 
process of adipogenesis. The activity of PPARγ was inhibited by 30 – 50% by 
oleuropein at a concentration of 200µM. 
Four years later, Malliou et al. (2018), in the in vitro part of their study 
with a HepG2 hepatocyte culture, studied the role of oleuropein on the serum 
triglyceride reduction. Based on the structural characteristics of oleuropein, 
the transcription factor PPARα, and on the theoretical models, the authors 
assumed and later by several assays confirmed, that oleuropein acts as 
a PPARα ligand in the function of an agonist. On the contrary, hydroxytyrosol, 
a metabolite of oleuropein, does not posses any structural similarities to bind 
to PPARα.  
An in vivo study with adult Medaka fish (Torró-Montell et al., 2019) 
focused on the influence of olive extracts in the expression of genes involved 
in lipid metabolism. Fish were fed a diet rich in carbohydrates and various 
olive extracts for five days. Then the hepatic DNA for three lipolytic and three 
lipogenic enzymes was quantified. The expression of genes for the lipolytic 
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molecules (including PPARα) was significantly decreased and the olive 
extracts did not reverse the situation. However, the extracts did prevalently 
contain hydroxytyrosol, while the content of oleuropein was fairly low, and 
based on the knowledge of Malliou et al. (2018; see text above), any 
significant activation of PPARα could not be expected. The two lowest relative 
expression of PPARα were observed in the fish fed with the lowest oleuropein 
content, which is again in accordance with Malliou et al. (2018). On the other 
hand, the increased expression of lipogenic genes could be reversed by 
treatment with olive extracts, thus indicating that other enzymes involved in 
the lipid metabolism are also influenced by olive phenolics. 
 
2.6.5. SAFETY PROFILE OF THE OLIVE LEAF PREPARATIONS 
 
Phenols from olive leaf are absorbed and to some extent metabolized 
in humans, as observed by Vissers et al. (2002) in their study with healthy 
volunteers, both with a colon and ileostomy subjects. Based on the analyses of 
collected ileostomy effluent and urine, the authors estimated that the 
apparent absorption of phenols was at least 55 – 66% of the ingested dose. 
The olive leaf phenols are extensively modified in the human body and 
excreted mainly in urine in the form of hydroxytyrosol. Simple olive phenols, 
such as tyrosol and hydroxytyrosol, are found to be excreted as glucuronide 
conjugates (Visioli et al., 2000) or undergo the action of catechol-O-methyl 
transferase, and are excreted as homovanillic alcohol and homovanillic acid 
(Caruso et al., 2001). Various interactions with other drugs and preparations 
thus may be possible. 
However, EMA finds olive leaf to be safe for human health. No 
undesirable effects are known, nor interactions with other medicinal 
products, or other forms of interaction, have been reported. The only 
contraindication listed is the hypersensitivity to the active substance 
EMA/HPMC/359238/2016). O. europaea L. is even not mentioned in the 
Botanical Safety Handbook (Gardner and McGuffin, 2013). 
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The safety profile of olive leaf extract in animal models was in the 
focus of some studies. For example, Farag, El-Baroty and Basuny (2003) 
evaluated the effect of phenolic compounds extracted from olive fruits and 
leaves on the liver and kidney function and the lipid profile of rats after 
7 weeks of treatment. Only the highest tested concentration of olive phenolics 
(1600 ppm) caused a significant increase of liver transaminases and serum 
total lipids, as well as severe damage to the tissues of the kidney and liver. 
A comprehensive safety assessment of a commercially available water-
soluble olive leaf extract was performed by Clewell et al. (2016). The olive leaf 
extract was tested on mutagenicity (mammalian chromosomal aberration 
test), genotoxicity (mouse micronucleus test), mortality, and toxic effect (oral 
toxicity study). No adverse effect level was observed after administration of 
1000 mg/kg in rats in a 12 weeks study.  
A safety assessment of ethanolic extract of olive leaves on a rat animal 
model was provided by Guex et al. (2018). Acute toxicity was assessed using a 
single dose of 2000 mg/kg and subacute toxicity was tested by administration 
of different doses (100, 200, and 400 mg/kg) during 4 weeks. No signs of 
toxicity were observed after exposure to single or repeated doses of ethanolic 
olive leaf extract. 
Concerning the safety of olive leaf extract in humans, the data is 
scarcer. Since the olive fruit is used as a food and the olive leaf as medicine for 
several hundreds of years, it can be assumed that the use of olive leaf extract 
would be safe for human use. Susalit et al. (2011) in their study with 262 
volunteers also reported only tolerable mild adverse effects from olive leaf 
extract EFLA 943, such as cough, vertigo, muscle discomfort, and headache, 
which had resolved by the end of the study. The olive leaf extract also did not 
affect liver and renal functions, electrolyte balance, and hematological 
parameters of the participants, and therefore it was declared to be safe and 
tolerable for patients with stage-1 hypertension.  
As to the pharmacokinetic interactions of olive leaf active 
compounds, oleuropein was found to be a relatively weak inhibitor of 
CYP1A2-mediated 7-methoxyresorufin-O-deethylation (24% inhibition at 
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100 µmol/L oleuropein; Stupans et al., 2001). Further, pinoresinol, one of the 
three main olive oil phenols, was reported to inhibit vitamin D uptake both in 
vitro (intestinal Caco-2 cells) and in vivo (rats). However, oleuropein and 
hydroxytyrosol did not exhibit such an activity (Goncalves et al., 2016). 
A potentially significant interaction of olive leaf extract with some 
antihypertensive drugs was reported by Mmopele et al. (2018). The authors 
used an extract from wild African olive in an in vitro model (an intestinal 
Caco-2 cell culture). The olive leaf extract was found to increase the 
permeability of propranolol in the absorptive direction, and enhanced the 
permeation of diltiazem in both the absorptive and secretory direction. This 
suggests a potential increase in the blood levels of these drugs when 
administered simultaneously with the olive leaf extract. 
There is also a remarkable lack of data on the pharmacodynamic 
interactions of olive leaf active compounds. In fact, I have found only one 
work dealing with this topic in the available literature. Lim et al. (2016) 
investigated the antimicrobial properties of olive leaf extract and five of its 
phenolic compounds (including oleuropein and hydroxytyrosol) against the 
bacterial species Escherichia coli and Staphylococcus aureus. Their activity as 
stand-alone antimicrobial agents was weak, but when co-administered with 
ampicillin, a synergistic interaction between ampicillin and hydroxytyrosol 
was observed. Oleuropein, verbascoside, caffeic acid, and the whole olive leaf 
extract showed additive effects. 
 
2.7. MISTLETOE – VISCUM ALBUM L. – FAM. LORANTHACEAE 
 
2.7.1. CHARACTERIZATION OF VISCUM ALBUM L. – A PHARMACOGNOSTIC CONTEXT 
 
 The genus Viscum comprises hemi-parasitic species capable of 
nourishing off a large number of host species – Barney, Hawksworth and Geils 
(1998) identified as many as 452 host species of Viscum album L. The plants 
are dioecious small woody shrubs with a tendency to form globular shapes on 
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the host plant, extending up to 1 m in diameter (Fig. 2.13.). The branches are 
usually 15 – 80 cm long with opposite pairs of narrowly obovate, dark green 
leathery leaves capable of photosynthesis. Waxy white to yellowish colored 
fruits, berries, contain only one seed (Vicaş, Rugină and Socaciu, 2011).  
The taxonomy of the genus Viscum is partially confusing. Firstly, even 
the taxonomical placement of the whole genus is challenging. Some authors 
place the genus in the family Viscaceae, some state that, according to the 
genetic research provided by The Angiosperm Phylogeny Group, the genus 
should be in the family Santalaceae. According to EMA, the genus Viscum is 
currently placed into the family Loranthaceae (EMA/HPMC/246778/2009; 
Vicaş, Rugină and Socaciu, 2011). 
 
 Furthermore, the nomenclature of the individual species and 
subspecies is also troublesome. Therefore, to prevent misunderstanding, in 
the presented work I will use the term "European mistletoe" as a synonym for 
Viscum album L. subsp. album and "Korean mistletoe" for Viscum album subsp. 
coloratum Kom., regardless of the nomenclature used by the original authors. 
Visci albi herba are dried aerial parts of the mistletoe species Viscum 
album L. The thickness of the collected stems should not exceed 5 mm in 
diameter. The sessile leaves are 2 – 6 cm long, green, stiff, and leathery. The 
Fig. 2.13. Viscum album L. Left – whole plant, right – a closeup of a branch with fruits. From 
union.ces.ncsu.edu and flickr.com. 
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aerial parts are collected with the berries containing one seed and a sticky 
juice (Tomko et al., 1989; Wichtl, 2003). 
 
2.7.2. PHYTOCHEMISTRY OF MISTLETOE 
 
 It is necessary to remind that mistletoe as a hemi-parasitic plant 
nourishes to a certain extent on the host plant. Therefore, the phytochemistry 
of mistletoe is strongly affected by the host. 
 The main active compounds of mistletoe are the proteins lectins 
(mistletoe lectins I – III, glycoproteins binding with N-acetyl-D-galactosamine, 
D-galactose, and cell surfaces), polypeptides (especially viscotoxins A1 – B 
composed of 46 amino acids), oligosaccharides (mostly galactose and 
glucose), polysaccharides (prevalently galacturonans and arabinogalactans), 
sugar alcohols (mainly inositol), and alkaloids (Ochocka and Piotrowski, 
2002; Arda et al., 2003; Vicaş and Socaciu, 2007; EMA/HPMC/246778/2009 
and references therein). The mistletoe alkaloids remained long unidentified 
because of their claimed extreme lability, until Amer et al. (2012) isolated and 
characterized two aminoalkaloids (trihydroxy and tetraydroxy derivates of 
iminodibenzoic acid) that even define a novel group of aminoalkaloids. 
However, for the cardiovascular action of mistletoe (see Ch. 2.7.4.), 
phenylpropanoid compounds, flavonoids, and lignans are of greater 
importance (Nazaruk and Orlikowski, 2016). Becker and Exner (1980) 
isolated eight flavonoids with flavonol structure from European mistletoe; all 
of them were derivates of quercetin with a different degree and position of 
methylation. Lignans with various structures, such as syringoresinol and 
ligalbumosides A – E, were also reported in European mistletoe leaves and 
stems (Nhiem et al., 2012). Some of the mistletoe's active compounds are 
depicted in Fig. 2.14. 
 The content of individual compounds in mistletoe is very strongly 
influenced by the host tree. For example, Schaller et al. (1998) reported 
different content of viscotoxins isolated from European mistletoe grown on 
eight different hosts, with the highest total viscotoxin levels in acacia- and 
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poplar-grown mistletoe, while pine-grown mistletoe offered the lowest level 
of total viscotoxins. Further, Deliorman et al. (1999) observed differences in 
the amounts of phenylpropanoids isolated from mistletoe grown on three 
different hosts. The highest amounts of syringin, coniferin, and kalopanaxin D 
were found in mistletoe grown on apricot tree, while they were detected only 












Likewise, phenolic acids composition isolated from European 
mistletoe grown on six hosts (rowan, apple, pear, poplar, plane, and oak tree) 
exhibited significant variations. Mistletoe hosted by oak contained 
15 phenolic compounds with o-coumaric acid as a typical compound; digallic 
acid was specific for plane tree-grown mistletoe, and vanillic acid for 
mistletoe gathered from apple and pear tree. The authors noticed that the 
phenolic acids composition showed similarities in mistletoe grown on apple 
and pear trees (Łuckiewicz et al., 2001). Arda et al. (2003) even reported 
differences in monosaccharides (glucose 9% vs. 29%, galactose 17% vs. 44%) 
Fig. 2.14. Some of the Viscum album L. active compounds. Up – quercetin, down – oleanolic acid.  
Courtesy of doc. Macáková. 
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and polyols (inositol 58% vs. 21%, xylitol 8% vs. 1.5%) in mistletoes grown 
either on lime trees or on fir trees.  
Deliorman Orhan and Orhan (2006) noticed differences in fatty acid 
composition of European mistletoe. Apricot tree-grown mistletoe had the 
highest fatty acids content (36.15% of the lipophilic extract; it was especially 
rich in palmitic acid – 11.47%), followed by pear-grown mistletoe (19.49%). 
The lowest fatty acids content was found in quince-grown mistletoe 
(10.10%). 
Similarly, Vicaş et al. (2009) demonstrated the different content of 
phenolic compounds and carotenoids obtained from European mistletoe 
grown on five hosts (ash, poplar, acacia, apple, and maple tree). Phenolic 
content ranged from 0.44 to 0.65 mg of gallic acid equivalent/g of fresh 
weight, the highest being from mistletoe grown on maple tree. Carotenoid 
content ranged from 2.47 to 7.00 mg of β-carotene/g of fresh weight, the 
highest again originating from mistletoe grown on maple tree.  
Wójciak-Kosior et al. (2017) also observed differences in the amount 
of oleanolic and betulinic acids in European mistletoe grown on seven 
different hosts (acacia, rowan, birch, lime, apple, poplar, and pine tree). In 
general, oleanolic acid was the prevalent triterpenic acid in mistletoe with its 
content about 10-fold higher than that of betulinic acid. The highest content 
of oleanolic acid was found in pine-grown mistletoe, followed by poplar- and 
apple-tree-grown mistletoe. 
 Furthermore, seasonal changes were reported to have an impact on 
the content of the individual compounds of mistletoe. Escher et al. (2003) 
mentioned the seasonal differences in reduced sulfur containing compounds 
in poplar- and fir-grown mistletoe. High levels of the sulfur-containing 
compounds were detected in spring and autumn, and low levels in summer. 
Seasonal variation of amino acids concentrations in the xylem sap of 
European mistletoe grown on poplar and pine trees was observed by Escher 
et al. (2004a). Poplar-grown mistletoe exhibited significant changes, 
especially in the glutamine and asparagine content, with the total amino acids 
content generally being the highest in the spring and the lowest in the 
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autumn. Fir-grown mistletoe rather than seasonal changes in amino acids 
content exhibited significant changes between years. A seasonal variation in 
the amino acid arginine in European mistletoe was also reported. The 
increase in arginine during late autumn and winter time in mistletoe grown 
on deciduous trees suggested that continued transpiration within mistletoe 
after the shedding of the host leaves caused a displacement of the solutes 
from the host xylem into the mistletoe leaves (Urech, 1997). 
And finally, Escher et al. (2004b) noticed changes in the sugar levels in 
the xylem sap of European mistletoe grown on poplar- and fir-trees. In this 
case, however, the authors again suggested the changes are due to the 
physiology of the deciduous (high sugar concentrations in spring, low in other 
seasons) and coniferous trees (intermediate sugar concentrations throughout 
the year), rather than a seasonal variation in the respective mistletoes. 
Wójciak-Kosior et al. (2017) evaluated the levels of triterpenic acids in 
European mistletoe collected during four seasons (spring, summer, autumn, 
and winter). Mistletoes grown on deciduous trees exhibited the highest levels 
of oleanolic and betulinic acid in the summer, with a declining tendency 
during the autumn and winter, and the lowest levels of both acids being 
detected in the spring. On the contrary, mistletoe grown on a coniferous tree 
(pine) had the highest amounts of triterpenic acids in the winter, with a 
significant decrease in the summer. 
 The developmental stadium may also play a role in the qualitative 
and quantitative content of the individual compounds found in mistletoe. The 
changes in the composition of European mistletoe epicuticular waxes were 
investigated by Wollenweber, Wieland and Haas (2000) who reported that 
the predominant component in the epicuticular waxes is the triterpenoid 
oleanolic acid, with a 70% content in the young leaves and it may rise up to 
80% in the second vegetation period. On the contrary, flavonol aglycones 
(quercetin and kaempferol 5-methoxy derivates) accompanying the aliphatic 
compounds in the mistletoe epicuticular waxes reach their maximum amount 
in the young developing leaves, while in the second vegetation period they are 
found only in small amounts.  
160 
 
 Similarly, Vicaş, Rugină and Socaciu (2008) observed a higher 
antioxidant activity in young European mistletoe plants (collected in May, 
regardless of host plant) than in older ones, indicating important changes in 
the phytochemical composition. 
 The active compounds of mistletoe are not distributed evenly in the 
different plant organs, as observed by several investigators. For example, the 
content of phenolic compounds in leaves was up to 30% higher and 
carotenoids even up to 100% higher than that of stems in European mistletoe 
regardless of the host tree (Vicaş et al., 2009). 
 
2.7.3. MEDICINAL USE OF MISTLETOE 
 
 According to the Assessment report on Viscum album L. herba, 
European mistletoe has been used in the treatment of a variety of 
cardiovascular disorders and in the oncology. Mistletoe extracts for the use 
for cancer therapy were introduced around 1920, while the first written 
notice of mistletoe for cardiovascular action dates back several hundreds of 
years earlier, in 1564 (EMA/HPMC/246778/2009). The history of the 
medicinal use of mistletoe for the treatment of cardiovascular diseases was 
intriguingly written by Inci Bowman (Bowman, 1990). 
 For the cardiovascular use of mistletoe in Europe, herbal preparations 
in solid or liquid dosage forms for oral use are intended. The mistletoe herbal 
preparations include tea, infusion in cold water, syrup, expressed juice, 









2.7.4. EFFECTS OF MISTLETOE ON SELECTED CARDIOVASCULAR CONDITIONS 
 
2.7.4.1. ANTIOXIDANT EFFECT OF MISTLETOE 
 
 The antioxidant properties of mistletoe are strongly dependent on 
plant material, extractant, and host plant. Good antioxidant properties are 
attributed to phenolic compounds (and that including phenolic acids, 
flavonoids, and lignans), terpenoids, and carotenoids. In general, mistletoe 
offers respectable antioxidant qualities, as reported by Alali et al. (2007) who 
investigated the antioxidant activity of 95 Jordanian plants. Both aqueous and 
methanolic extracts from the mistletoe species V. cruciatum Sieb. exerted the 
third highest activity of all the evaluated plants. 
 Leu et al. (2006) investigated the ability of several individual 
compounds isolated from Korean mistletoe to scavenge the superoxide anion 
in human neutrophils. The most potent activities were exhibited by viscolin (a 
1,3-diphenylpropanone), oleanolic acid (a triterpenic acid), and pinocembrin 
(a flavanone). And similarly, all three flavanone glycosides obtained from a 
Korean mistletoe ethanolic extract (namely eriodictyol glucopyranoside/ 
diglucopyranoside, homoeriodictyol glucopyranoside/diglucopyranoside, and 
naringenin glucopyranoside) exhibited significant scavenging effects on both 
hydroxyl and superoxide anion radical, although naringenin glucopyranoside 
was less active than the other two compounds (Yao et al., 2006).  
 The ethanolic extract of European mistletoe isolated by Papuc et al. 
(2010) also offered a good hydroxyl radical-scavenging activity (inhibition by 
34.44%), although the activity against the superoxide anion was less 
pronounced (inhibition by 16.66%). This extract further exhibited slight nitric 
oxide-scavenging activity (inhibition by 28.43%; Papuc et al., 2010).  
Mistletoe methanolic extracts also possess strong antioxidant 
properties. Önay-Uçar et al. (2006) determined the antioxidant capacity of 
methanolic extracts obtained from acacia-, lime-, and maple-grown European 
mistletoe. The lime-grown mistletoe extract exerted the highest scavenging 
activity (95.12%) in the DPPH test and in the ferric thiocyanate assay, while 
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all tested extracts offered approximately the same inhibition of lipid 
peroxidation. Janakat and Al-Thnaibat (2007) reported a strong inhibition of 
lipid peroxidation of three olive-grown European mistletoe extracts 
(methanolic, non-boiled aqueous, and boiled aqueous), with the methanolic 
extract exerting the highest activity (the inhibition of lipid peroxidation by 
98.7% for leaves, by 90.5% for stems, and by 89.9% for fruits). Not 
surprisingly, the methanolic extract from mistletoe leaves offered the highest 
antioxidant capacity of all plants evaluated, even higher than that of 
Rosmarinus officinalis L., which was used as a control (Janakat and Al-
Thnaibat, 2007). 
High antioxidant activity and total phenolic content of a Turkish 
European mistletoe methanolic extract were reported by Sengul et al. (2009). 
In the β-carotene-linoleic assay, mistletoe had the highest antioxidant 
capacity of all the plant extracts tested (82.23%), while the phenolic content 
was the second highest (19.43 mg of gallic acid equivalent/g of dry weight). 
Likewise, a high total phenolic content and antioxidant activity of methanolic 
extracts obtained from cocoa- and cashew-grown European mistletoe was 
demonstrated by Ademiluyi and Oboh (2008). The extracts contained 
182 mg/100 g (cocoa tree) and 160 mg/100 g (cashew tree) of total 
phenolics. 
And similarly, flavanone and diphenylpropanone glycosides isolated 
from another Asian Viscum species, namely V. articulatum Burm., exhibited a 
strong antioxidant activity in the DPPH assay (Kuo et al., 2010).  
 Vicaş et al. (2009) determined the hydrophilic and lipophilic 
antioxidant activities of the European mistletoe grown on five different host 
trees (maple, apple, ash, poplar, and acacia tree). The hydrophilic antioxidant 
activity of European mistletoe was about 100-fold higher than the lipophilic 
antioxidant activity, as determined by the FRAP method. The stems exhibited 
slightly higher antioxidant capacity than the leaves. The highest antioxidant 
activity was exhibited by the extract of mistletoe grown on apple trees.  
Petrus (2011) also investigated the antioxidant properties of both 
hydrophilic and lipophilic fractions of another mistletoe species, namely 
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V. capitellatum Smith, growing as an obligate hyperparasite on another 
parasitic mistletoe. Again, the majority of the total antioxidant capacity of this 
mistletoe extract was concentrated in the more polar methanolic fraction 
(67.4%), while the less polar acetone fraction contributed to the antioxidant 
activity only with 18.4%, and the lipophilic dichloromethane fraction only 
with about 11.0%. In the hydrophilic fraction, especially phenolic acids 
(chlorogenic acid, caffeic acid, and p-coumaric acid) were identified as the 
most antioxidant-active compounds. In the lipophilic fraction, there were 
mainly triterpenic acids (oleanolic acid and betulinic acid), terpenes (lupeol 
and betulin), and carotenoids that acted as antioxidants (Petrus, 2011). 
 Mistletoe's antioxidant properties were also assessed in several 
in vivo studies. For instance, Shi et al. (2006) investigated the antioxidant 
and free radical scavenger properties of Korean mistletoe alkali in rats 
treated with carbon tetrachloride. The 4 weeks administration of mistletoe 
led to a normalization or even to an increase of the antioxidant enzyme values 
(superoxide dismutase, glutathione reductase, and glutathione peroxidase), 
and to the protection of liver and kidney against the oxidative damage. Very 
similar antioxidative and protective properties were observed in carbon 
tetrachloride-intoxicated rats treated with different fractions of European 
mistletoe (Cebovic and Popovic, 2006). 
Shahaboddin et al. (2011) treated alloxan-administered rats with an 
aqueous extract from mistletoe grown on oak tree at a dose of 500 or 
1000 mg/kg for 24, 48, or 72 hours. The serum antioxidant capacity was 
significantly higher in both treatment groups than in the control group after 
72 hours, but the onset of the restoration of antioxidant capacity was earlier 
at the higher dose: 24 hours vs. 48 hours at the lower dose after the 
application of alloxan injection. 
 
2.7.4.2. DIRECT EFFECT OF MISTLETOE ON MYOCARDIUM 
 
 Older works regarding mistletoe's influence on the myocardium were 
focused on the effects of the polypeptidic viscotoxins. For instance, Rosell and 
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Samuelsson (1966) reported that viscotoxin A3 exerted negative inotropic 
effect on the heart. Similarly, Andersson and Jóhannsson (1973) investigated 
the effects of mistletoe viscotoxins on a rabbit heart. The application of 
viscotoxin B at low concentrations (1 – 10 µg/mL) led to a contraction and 
progressive depolarization of the heart muscle that could be reversed by 
increasing the extracellular calcium concentration. The negative inotropic 
effect of dodonein, a compound isolated from an African mistletoe species 
(Agelanthus dodoneifolius (DC.) Polhill & Wiens, fam. Loranthaceae), on rat 
heart was also observed by Carré et al. (2014). The authors suggested that 
this effect of dodonein was associated with the hypotensive property and the 
blockade of the L-type calcium channels. 
 Wu et al. (1994) investigated the effect of Korean mistletoe flavonoids 
on the fast response action potentials of hearts (precisely, in canine Purkinje 
fibers and guinea pig ventricular papillary muscles). Mistletoe extract at a 
concentration of 100 µg/mL accelerated the depolarization of the fast 
response action potentials and increased the effective refractory 
period/action potential duration, thus indicating an antiarrhythmic effect. 
Chu et al. (2006) used Korean mistletoe flavonoid glycosides (15 and 
75 mg/kg) in rats with an aconitine-induced arrhythmia. Mistletoe flavonoid 
glycosides significantly shortened the action potential duration that was 
prolonged by aconitine via influencing the Ca2+ channels in cardiomyocytes. 
Khusmatov, Makhmudov and Mavlyanov (2015) confirmed the involvement 
of calcium channels in the antiarrhythmic mechanism of flavonoids in the 
aconitine-induced arrhythmias and reported that out of all tested flavonoids, 
quercetin exerted the strongest antiarrhythmic effect. 
 During the course of the last ten years, mistletoe's cardioprotective 
properties have been demonstrated by several authors. The protective effect 
of a methanolic extract of pear-grown European mistletoe and pure quercetin 
against the cyclophosphamide-induced cardiotoxicity in mice was 
investigated by Şekeroğlu, Aydın and Şekeroğlu (2001). Cyclophosphamide 
significantly decreased the activity of the antioxidant enzymes catalase, 
superoxide dismutase, glutathione peroxidase, and glutathione reductase, 
while the pretreatment with the mistletoe extract (250 mg/kg) and quercetin 
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(50 mg/kg) returned them to almost normal values, with quercetin being 
more effective than mistletoe extract in this task. Both mistletoe and 
quercetin also ameliorated the cyclophosphamide-induced lipid peroxidation. 
Bachhav and his colleagues treated L-NAME-induced hypertensive rats 
with either a methanolic extract (200 and 400 mg/kg; Bachhav et al., 2012) or 
pure oleanolic acid (60 mg/kg; Bachhav et al., 2015), isolated from the 
mistletoe species V. articulatum Burm., for 4 weeks. The administration of 
both methanolic extract and oleanolic acid was able to partially prevent the 
morphological abnormalities in the heart tissue induced by L-NAME, such as 
moderate diffuse myocardial degeneration and necrosis with inflammatory 
infiltration.  
Histopathological changes of an isoproterenol-induced heart injury 
improved by mistletoe treatment were also observed by Karagöz et al. 
(2016). Rats were administered with an aqueous extract obtained from pear-
grown European mistletoe (250 mg/kg) for 24 days. This treatment 
remarkably attenuated the isoproterenol-induced increase in heart weight, 
left ventricular wall thickness, and the presence of the brain natriuretic 
peptide (an indicator of heart failure) in cardiomyocytes (80% vs. 99% in the 
isoproterenol-only group). The left ejection ventricular fraction was also 
improved and the heart rate partially decreased to almost normal values by 
mistletoe treatment. 
 Moreover, mistletoe seems to have a beneficial effect on the 
ischemia/reperfusion heart injuries. Chu et al. (2008) and Li et al. (2009) 
investigated the effect of flavonoid glycosides of Korean mistletoe in rats with 
an acute myocardial infarction. Treatment with 15 or 75 mg/kg of mistletoe 
flavonoid glycosides significantly decreased the infarct size and recovered the 
activity of superoxide dismutase. Suveren et al. (2017) used European 
mistletoe extracts (methanolic and aqueous) in an ischemia/reperfusion 
injury model on isolated rat hearts. The hearts were perfused with different 
concentrations of the methanolic (5, 10, or 20 mg/L) and aqueous (1, 10, or 
50 mg/L) mistletoe extracts from 10 minutes prior to the onset of the 
coronary occlusion until 10 minutes after reperfusion. Both extracts 
significantly reduced the infarct size, although the best results were obtained 
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by applying the methanolic extract at a dose of 5 mg/L. Interestingly, a high 
dose of the aqueous extract (50 mg/L) exerted negative inotropy, decreased 
the contractile force, and subsequently abolished the heart function. This may 
be due to the presence of viscotoxins, where negative inotropic properties 
were reported (Rosell and Samuelsson, 1966). 
 The mechanism of mistletoe-mediated cardioprotection most 
probably involves the restoration of the antioxidant capacity, the blockage of 
the ATP-sensitive potassium channels (Suveren et al., 2017), the activation of 
NO-mediated vasodilatation by overexpression of NOS-2 and NOS-3 (Tenorio-
López et al., 2006), and by blocking of the platelet activating factor-induced 
Ca2+ overload in cardiomyocytes (Chu et al., 2008; Li et al., 2009). Taking into 
account that quercetin and its derivates are abundant in mistletoe, the 
cardioprotective effect of mistletoe most likely also involves the enhancement 
of the contraction and calcium transients of cardiomyocytes mediated by both 
quercetin itself as well as by its metabolite tamarixetin (Hayamizu et al., 
2018). 
 
2.7.4.3. EFFECT OF MISTLETOE ON BLOOD, BLOOD CELLS, AND BLOOD VESSELS 
 
Mistletoe lectins have long been known for their ability to aggregate 
human blood cells. Franz, Ziska and Kindt (1981) reported that all three 
lectins isolated from European mistletoe reacted with human erythrocytes 
without any specificity for the A, B, and 0 blood groups. Timoshenko, 
Cherenkevich and Gabius (1995) even specified the order in which the 
galactose-specific mistletoe lectin aggregated blood cells: neutrophils, 
mononuclear cells, thrombocytes, and erythrocytes. The galactose-specific 
mistletoe lectin was further found to induce the aggregation of human 
platelets in a dose- and sugar-dependent manner. The platelet aggregation 
was completely reversed with the addition of lactose (Samal, Gabius and 
Timoshenko, 1995). 
 Aside from lectins, other mistletoe active compounds exhibit an 
inhibitory effect on platelet aggregation. Panossian et al. (1998) assessed 
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the effect of phenylpropanoids isolated from pear-grown European mistletoe. 
The n-butanol-soluble fraction of the ethanolic mistletoe extract contained 
four major compounds: syringenin glucoside, syringin, coniferyl alcohol 
glucoside, and coniferin. All of these compounds inhibited the ADP-induced 
platelet aggregation at the concentration range of 0.001 to 1.0 µmol/L. 
Similarly, the inhibition of both ADP- and adrenaline-induced human platelet 
aggregation by the V. cruciatum Sieber crude extract at concentrations 0.3 – 
1.2 mg/mL was reported by Gilani et al. (2009). The mistletoe extract was 
more effective against the ADP-mediated than the noradrenaline-mediated 
aggregation. The authors suggested a possible intrinsic calcium-antagonistic 
effect of the mistletoe extract (Gilani et al., 2009). 
The vasorelaxant effect of four extracts (aqueous, ethanolic, 
petroleum ether, and n-butanolic) of European mistletoe grown on 
12 different hosts was investigated by Ergun et al. (1995). The most effective 
vasorelaxants were the ethanolic extracts, especially those obtained from 
pear-, cherry-, quince-, wild pear-, and acacia-grown mistletoes. On the other 
hand, no vasorelaxant activity on the noradrenaline-precontracted rat aortic 
rings was exhibited by the aqueous extracts. The extract obtained from plum-
grown mistletoe was even slightly vasoconstrict active. Vasoconstriction was 
also reported in the vessels in the skin and skeletal muscle (Rosell and 
Samuelsson, 1966), and rabbit aortic strips (Anderson and Jóhannsson, 1973) 
treated with mistletoe viscotoxin A3, especially in high doses. 
Deliorman et al. (2000) further fractioned the n-butanolic extract of 
apricot-grown European mistletoe into 38 subfractions, and these were 
screened for their vasorelaxant effect on noradrenaline-precontracted rat 
aortic rings. In the more polar subfractions, contractile responses were 
observed in a dose-dependent manner. The most vasorelaxant effects 
observed were that of the subfractions 18-20 and the subfractions 13-15 
(23.4% and 20.2%, respectively). Isolated phenolic compounds exhibited 
mostly slight vasoconstrictive actions (syringin 3.8%, coniferin 2.0%), with 
the exception of kalopanaxin D (1.0% relaxation). 
Tenorio-López et al. (2005) investigated the effect of an aqueous 
mistletoe leaf extract on isolated guinea pig hearts from normotensive 
168 
 
animals. A continuous infusion of mistletoe extract at a dose of 450 mg 
significantly decreased the coronary vascular resistance. This effect was 
blocked by L-NAME (an inhibitor of the nitric oxide synthase), gadolinium 
chloride (an inhibitor of the inducible nitric oxide synthase), and by the 
compound 1H-[1,2,4]oxadiazolo[4,2-a]quinoxalin-1-one (a selective inhibitor 
of the NO-sensitive guanylate cyclase), which indicated that the vasorelaxant 
effect of mistletoe was mediated through the NO release.  
The vasorelaxant effect of mistletoe may be mediated partially by 
viscolin, a diphenylpropane derivate isolated from Korean mistletoe. Hwang 
et al. (2006) observed that viscolin induced a substantial increase in 
cAMP levels that occurred through the inhibition of the phosphodiesterase 
(PDE) activity. PDE inhibitors demonstrated various pharmacological 
properties including  vasodilator and antihrombic (Rahimi et al., 2010). 
Mojiminiyi et al. (2008) investigated the vasorelaxant effect of oil palm 
tree-grown European mistletoe aqueous extract at a concentration range  
2 – 16 mg/mL on potassium chloride- and noradrenaline-precontracted rat 
aortic rings, and found that the noradrenaline precontraction seemed to be 
more susceptible to mistletoe extract than the KCl precontraction. Based on 
other experiments of theirs, the authors suggested that the vasorelaxant 
effect of mistletoe aqueous extract is mediated via the antagonistic action on 
the Ca2+ influx and via the inhibition of the mobilization of intracellular Ca2+. 
The presence of Ca2+ entry-blocking constituents in European mistletoe fruit's 
crude and ethyl acetate extracts was also confirmed by Khan et al. (2016) 
who used an isolated rabbit thoracic aorta precontracted with phenylephrine. 
Shen et al. (2018) reported that the flavanone compound 
homoeridictyol, previously isolated from Korean mistletoe, has the ability to 
protect endothelial cells from damage caused by ROS, namely hydrogen 
peroxide. The authors in their in vitro study with HUVEC cells demonstrated 
that homoeridictyol acts as an inducer of the nuclear factor- 
erythroid 2 -related factor 2, an important intracellular defense system 
protecting cells against the oxidative injury caused by ROS, thus alleviating 
the hydrogen peroxide-induced loss of the mitochondrial membrane 
potential. Furthermore, homoeriodictyol inhibited deleterious changes in 
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several apoptosis-related proteins, such as Bcl-2, caspase-3, and caspase-9, 
induced by hydrogen peroxide.  
 
2.7.4.4. ANTIHYPERTENSIVE EFFECT OF MISTLETOE 
 
 Eno et al. (2004) examined the antihypertensive effect of a crude 
extract of citrus-grown European mistletoe in both normotensive and 
hypertensive rats. The intravenous administration of the crude extract at a 
concentration range 5 – 160 mg/kg led to a significant blood pressure 
reduction in a dose-dependent manner. In normotensive rats, the blood 
pressure reduction ranged from 8.99% to 54.1%, while in the DOCA-induced 
hypertensive rats, the blood pressure reduction was 4.8% – 43.9%. The 
duration of the hypotensive effect was also dose-dependent. Very similar 
results were obtained in their following work (Ofem et al., 2007), again 
conducted with crude mistletoe extract. 
On the other hand, Radenković et al. (2009) investigated the effects of 
different extracts (ethanolic, ether, and ethyl acetate) of European mistletoe 
stems on the arterial blood pressure in rats. The ethanolic extract exerted the 
strongest hypotensive action with a significantly lowered arterial blood 
pressure even at the lowest dose, while the ether extract significantly 
decreased the arterial blood pressure only at the highest administered dose. 
A methanolic extract administered at doses of 200 and 400 mg/kg 
obtained from mistletoe V. articulatum Burm. grown on Cordia macleodii 
(Grift) Hook and Thoms. (an endangered ethnomedical tree belonging to the 
family Boraginaceae) was used by Bachhav et al. (2012) to treat rats with the 
L-NAME-induced hypertension for 4 weeks. Mistletoe remarkably decreased 
the systolic blood pressure that had been increased by the L-NAME 
administration. 
In their consequent study, Bachhav et al. (2015) used pure oleanolic 
acid isolated from epicuticular wax of V. articulatum Burm. in order to 
investigate its antihypertensive activity in relation to the NO system. Rats 
were administered with L-NAME to induce hypertension and oleanolic acid 
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(60 mg/kg), L-arginine, or enapril (15 mg/kg, an ACE inhibitor as the positive 
control) for 4 weeks. Significant decreases of both systolic blood pressure and 
mean arterial pressure were observed in rats treated with oleanolic acid. 
Unfortunately, there is a lack of information on the antihypertensive 
effect of mistletoe in humans. In fact, the only work published in the last 
twenty years that I was able to find was that of Poruthukaren et al. (2014). 
The authors evaluated the efficacy of a V. album L. mother tincture as an 
antihypertensive agent in 41 volunteers in prehypertension stage, as well as 
stage 1 and stage 2 hypertension, all of whom were untreated with any form 
of antihypertensive therapy. The volunteers had to take 10 drops of the 
tincture 3 times daily for 12 consecutive weeks. Treatment with the mistletoe 
tincture resulted in a significant decrease of both systolic and diastolic blood 
pressure. 
 The antihypertensive mechanism of mistletoe is most likely 
multifactorial. Firstly, Wagner et al. (1986) isolated two phenylpropanes 
(syringin and its derivate) and two lignans (eleutheroside E and a mono-
glucoside syringaresinol derivate) from leaves and stems of European 
mistletoe. Butanolic mistletoe extract containing these compounds showed a 
significant cAMP-phosphodiesterase inhibitory activity, indicating cardiotonic 
and vasodilator properties of mistletoe. 
 Eno et al. (2004), in concordance with their examinations, proposed 
that the crude mistletoe extract does not utilize the adrenergic or cholinergic 
system, and the moderation of the calcium availability to cardiomyocytes 
plays an important role in the antihypertensive properties of mistletoe. 
 Then Radenković et al. (2009), based on their examination of 
European mistletoe extracts coadministered with atropine and hexocycline 
(both compounds are blockers of muscarine receptors), suggested that the 
mistletoe extracts achieve their hypotensive effect mainly via the muscarine 
receptors. 
Furthermore, Jadhav et al. (2010) reported a strong and dose-
dependent diuretic and natriuretic activity from the methanolic extract of 
mistletoe V. artriculatum Burm., administered at doses of 100 – 400 mg/kg to 
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rats. Although the mistletoe extract partially mimicked the furosemide 
pattern (i.e. a significant potassium loss attributed to oleanolic acid), 
polyphenolic compounds present in the extract exhibited a potassium-saving 
effect, thus the resultant diuretic effect of mistletoe was more favorable than 
that of furosemide. The natriuretic effect of oleanolic acid isolated from 
V. articulatum Burm. was also confirmed by Bachhav et al. (2015), coupled 
with a nephroprotective activity, although the oleanolic acid failed to prevent 
the decrease in serum NOx. 
 
2.7.4.5. EFFECT OF MISTLETOE ON PLASMATIC LIPID PROFILE 
 
Ben et al. (2006) treated rats with a crude extract of European 
mistletoe grown on citrus  at a dose of 200 mg/kg for 10 weeks. A significant 
increase in both HDL cholesterol and total cholesterol, and a non-significant 
(by 6%) decrease in LDL cholesterol were observed. Both crude aqueous and 
ethanolic extracts of European mistletoe (100 mg/kg) were used by Avcı et al. 
(2006) in mice fed a hypercholesterolemic diet for 4 weeks. While the 
ethanolic extract significantly decreased total cholesterol, LDL cholesterol, 
and triglyceride levels and increased the HDL cholesterol level, the aqueous 
extract only significantly influenced the triglyceride level. 
The beneficial effect of European mistletoe on hyperlipidemia in 
diabetic rats was reported by Adaramoye et al. (2012). Rats received a 
methanolic extract obtained from mistletoe grown on kola tree at a dose of 
100 mg/kg for 3 weeks. Mistletoe significantly decreased both total 
cholesterol and triglyceride levels, while it significantly increased the 
HDL cholesterol level. 
Mistletoe also has a positive influence on human serum lipid profiles, 
as demonstrated by Poruthukaren et al. (2014) who used an European 
mistletoe mother tincture in volunteers in prehypertension to stage 2 
hypertension for 12 weeks. The triglyceride level was significantly reduced 




The hypolidpidemic mechanism of mistletoe has yet to be fully 
elucidated. Wang et al. (2008) compared the ability of parasitic mistletoes 
belonging to two families – Loranthaceae and Viscaceae – in the terms of their 
ability to irreversibly inhibit the fatty acids synthase. The genus Viscum was 
represented by two species, namely by V. articulatum Burm. and 
V. liquilambaricola Hayata. The inhibitory potential of the genus Viscum was, 
however, very low when compared with the plants belonging to family 
Loranthaceae, especially with the genus Taxillus Tiegh. The FAS-inhibitory 
activity of these mistletoes was 400 times higher than that of Viscum spp.  
On the other hand, Jung et al. (2013) used a preadipocyte 3T3-L1 cell 
culture incubated with a crude aqueous extract of oak-grown Korean 
mistletoe at a dose of 6 µg/mL in order to examine the effects of Korean 
mistletoe extract on adipogenic factors. The addition of mistletoe led to a 
remarkable decrease in the expression levels of the transcription factors 
PPAR-γ, C/EBP-α, and SREBP-1c (by 64%, 60%, and 32%, respectively) in 
3T3-L1 cells. Furthermore, the expression levels of adipogenic enzymes, such 
as fatty acid synthase, acyl-coenzyme A synthase, and acyl-coenzyme A 
carboxylase, was reduced (by 69%, 55%, and 22%, respectively) in the cell 
culture treated with mistletoe. All of these transcription factors and enzymes 
are crucial for adipogenesis and adipocyte differentiation. 
Kim et al. (2015) also examined the effect of a Korean mistletoe 
aqueous extract on dyslipidemia in rats. The hepatic triglyceride content was 
lowered with this extract by increasing the expression of carnitine 
palmitoyltransferase-1 and by decreasing the expression of SREBP-1c, which 
supports the findings of Jung et al. (2013). Furthermore, Kim et al. (2020) 
suggested that the main bioactive compound of Korean mistletoe responsible 
for the hypolipidemic action is viscothionin, a heat-stable 6 kDa polypeptide. 
In their former study, Kim et al. (2014) discovered a connection between 
viscothionin and the adenosine monophosphate-activated protein kinase 
(AMPK) signaling pathway, which is involved in lipid metabolism. The 
phosphorylation of AMPK and acetyl-coenzyme A carboxylase was increased 
by viscothionin treatment in a hepatic HepG2 cell culture. Moreover, 
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viscothionin-treated 3T3-L1 preadipocyte cells decreased the level of the 
expression of SREBP-1c and fatty acid synthase (Kim et al., 2020). 
 
2.7.5. SAFETY PROFILE OF THE MISTLETOE PREPARATIONS 
 
According to EMAgency, European mistletoe can be considered as 
non-toxic following oral ingestion. In Jordan, the mistletoe species 
V. cruciatum Sieb. is even used as an edible plant. The LD50 values of 
mistletoe extracts, lectins, viscotoxins, and polysaccharides can be found in 
the Assessment report on Viscum album L., herba (Janakat and Al-Thnaibat 
2007; EMA/HPMC/264778/2009). 
 The toxicity of European mistletoe is mostly due to the lectins and 
viscumin, a protein with a cytotoxic activity. Lectins react with human blood 
cells (Franz, Ziska and Kindt, 1981), and both lectins and viscumin were 
found to inhibit protein synthesis (Olsnes et al., 1982). However, in the 
parenterally administered mistletoe preparations, used as a complementary 
cancer treatment, no severe adverse effects were noted even in 
immunocompromised patients (HIV positive volunteers). During the gradual 
dose escalation (0.01 – 10.0 mg), more adverse effects occurred at the lower 
dose range. Registered drug-related adverse events were flu-like symptoms 
and transient exacerbations of gingivitis, fever, and eosinophilia (Gorter et al., 
1999).  
A comprehensive review on the safety of higher dosages of European 
mistletoe in both animals and humans was provided by Kienle, Grugel and 
Kiene (2011). They included 69 clinical studies and 48 animal experiments 
with a dosage >1 mg in humans, corresponding to >0.02 mg/kg in animals. 
Adverse effects consisted mainly of dose-dependent flu-like symptoms, fever, 
and local reactions at the injection site. Occasionally, allergic reactions were 
reported. The authors concluded that mistletoe extract seemed to exhibit a 
low risk. 
Flavonoids isolated from an European mistletoe ethyl acetate fraction 
(flavanone and chalcone derivates) were even shown to possess a remarkable 
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anti-nociceptive activity without inducing any apparent acute toxicity or 
gastric damage when administered orally at doses of 30 mg/kg for pure 
compounds or 250 mg/kg for ethyl acetate fraction to mice (Orhan et al., 
2006). 
The impact of mistletoe on the cytochrome P450 was also 
investigated. Engdal and Nilsen (2009) reported that although mistletoe 
inhibited the CYP3A4 metabolism in vitro, any clinically relevant systemic or 
intestinal pharmacokinetic interactions with CYP3A4 were considered 
unlikely due to the high IC50 value (3594 µg/mL). Doehmer and Eisenbraun 
(2012) assessed three commercially available mistletoe extracts for their 
potential to interfere with the cytochrome P450 metabolism. For all three 
extracts none or minor induction or inhibition was observed, thus indicating 
that the risk of herb-drug interactions is low. Other commercially available 
European mistletoe preparations were assessed by Schink and Dehus (2017). 
Again, no major inhibition occurred in any of the CYP marker reactions. 
Furthermore, no induction capacity was found, thus a clinically relevant herb-
drug interaction is not expected. 
Most of the information regarding pharmacodynamic interactions of 
mistletoe with other drugs is coming from the oncological use of mistletoe, 
thus conferring prevalently to lectins and viscotoxins. For example, a 
synergism was observed when mistletoe lectin ML-I was administered with a 
clinically important anticancer drug, paclitaxel, in cultured human 
hepatocarcinoma SK-Hep1 cells (Pae et al., 2001). Galm et al. (2002) also 
reported the synergistic effects of mistletoe viscumin and anticancer drugs 
vincristine, mafosfamide, idarubicin, and cisplatin in the human leukemia cell 
lines K562 and KG1a. 
 
2.8. LEGAL REQUIREMENTS ON HERBAL PREPARATIONS 
 
According to the Collection of Laws of the Czech Republic, all of the 
herbal preparations evaluated in the consumption analysis in this rigorous 
thesis fall into two categories: medicinal products or food supplements. These 
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two categories differ significantly in the legal requirements imposed on the 
respective herbal preparation.  
 
2.8.1. MEDICINAL PRODUCTS 
 
Medicinal products have to meet the requirements of the Act 
No 378/2007 on medicines and amending certain related acts, issued by the 
Parliament of the Czech Republic. They are registered with the SUKL and have 
a registration number. In principle, only medicinal products may be 
prescribed by the physicians or specialists as products intended for use in 
human (or animal) patients in the treatment or prevention of a disease.   
Furthermore, medicinal products have a clearly defined qualitative as 
well as quantitative composition regarding both the active compound(s) as 
well as excipient(s). The production, distribution, and expedition of medicinal 
products have to mandatory follow the guidelines of Good Manufacturing 
Practice, Good Distribution Practice, and Good Pharmacy Practice. Medicinal 
products may be (with the exception of a few selected medicinal products) 
sold only via pharmacies. 
Medicinal products containing medicinal plants, which are 
traditionally used in Europe, belong mostly to one of the following two 
categories: traditional herbal medicinal products or human homeopathic 
medicinal products. Both of these categories of medicinal products have a 
simplified registration procedure, and no preclinical or clinical trials are 
required. 
The use of human homeopathic medicinal products, based on a 
remarkably wide range of medicinal plant species, is also reflected in the 
European Pharmacopoeia: it has, for example, listed the monographs on garlic 
and foxglove for the use in homeopathic medicinal products (Allium sativum 
ad praeparationes homeopathicas and Digitalis purpurea ad praeparationes 
homeopathicas; European Pharmacopoeia 10.0). 
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Traditional herbal medicinal products* have to fulfill several legal 
conditions. Particularly important is the requirement on bibliographic or 
scientific evidence in order to demonstrate the therapeutic use of the 
medicinal product or an equivalent product for at least 30 years, including at 
least 15 years of the use in the European Union.  
Furthermore, the existence of sufficient data on the traditional use of 
such a medicinal product is mandatory – it shall be demonstrated that the 
product is not harmful under the conditions of use and that the 
pharmacological effects or efficacy of this medicinal product are apparent 
from the long-term use and experience.   
The package and any advertisements on a traditional herbal medicinal 
product have to include the information that "The use of this traditional 
herbal medicinal product is based exclusively on the long-term experience." 
 
*Note: According to the Act No 378/2007, the traditional herbal medicinal products may consist of 
plant substances or herbal products or a combination thereof. Herbal products in this context 
means products obtained by processing a herbal substance or substances by means such as 
extraction, distillation, pressing, fractionation, purification, concentration, or fermentation. Herbal 
products include crushed or powdered herbal substances, tinctures, extracts, essential oils, pressed 
juices, and processed secretions (Act No 378/2007). In the present work I use the term "herbal 
product" more widely, including both medicinal products and food supplements. 
 
 
2.8.2. FOOD SUPPLEMENTS 
 
Food supplements have to meet the requirements of the Regulation 
No 58/2018 on food supplements and food composition, issued by the 
Ministry of Agriculture. The most important difference between food 
supplements and medicinal products is the fact that food supplements are 
legally considered as foods, therefore no therapeutic or preventive effect can 
be attributed to them. The producer does not have to follow any of the Good 




There are, however, several legal requirements on these herbal 
preparations regarding the labeling of the supplement, permitted and 
prohibited substances and, in particular cases, also the maximal allowed 
amount of these compounds in a daily dose. For example, according to this 
regulation, the content of dried hawthorn fruit, leaves, or flowers must not 
exceed the dose of 1000 mg per day (Regulation No 58/2018).  
Furthermore, appropriate nutrition and health claims may be used 
for food supplements. There are several types of health claims and their use is 
strictly regulated, in the European Union namely by the regulation (EC) 
No 1924/2006 of the European Parliament (on nutrition and health claims 
made on foods).  
As of June 2020, the EU register on nutrition and health claims 
comprises a total number of 2338 claims, out of them only 261 were 
authorized, and thus they may be used in the specific written form. The main 
reason for rejecting an assessed health claim (and subsequently categorizing 
it as a non-authorized) was the non-compliance with the regulation (EC) 
No 1924/2006, more particularly: "because on the basis of the scientific 
evidence assessed, this claimed effect for this food has not been 
substantiated."  
Health claims regarding the medicinal plants reviewed in the present 
thesis are scarce. My search in the EU register on nutrition and health claims 
disclosed neither authorized nor non-authorized health claims on garlic, 
hawthorn, motherwort, black cumin, or mistletoe or their active compounds, 
with the exception of flavonoids. The assessed flavonoids (either as a mixture 
of individual compounds or simply defined as "bioflavonoids") were mostly of 
the Citrus spp. or Vitis vinifera L. origin, and none of the 21 assessed health 
claims were authorized. An individually assessed flavonoid was quercetin, the 
claim "For cardiovascular health" was, however, non-authorized for the 
intended cardiovascular use. 
 For the olive tree, a total amount of 17claims is listed in this register, 
with only one of these claims authorized. The authorized claim on olive oil 
polyphenols is as follows: "Olive oil polyphenols contribute to the protection 
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of blood lipids from oxidative stress." This claim may be used only for olive oil 
which contains at least 5 mg of hydroxytyrosol and its derivates per 20 g of 
olive oil. Other claims on the beneficial effects of olive on HDL cholesterol, 



























3. MATERIALS AND METHODS 
 
3.1. REVIEW PART 
 
 For the review part of the present work, mostly PubMed and Elsevier 
databases were searched for relevant scientific papers. In order to provide 
the most actual data on the chosen topic, works submitted after the year 2000 
were preferred when possible. Primary sources of information, such as 
research articles and clinical trials were preferred when possible. Prevalently 
English language written papers were exploited, however, some German and 
Czech language written works were also used. 
 To include a plant species in the review, the following conditions had 
to be fulfilled: (1) the plant is traditionally used in the treatment of one or 
more cardiovascular disease(s), (2) the availability of OTC or Rx products 
containing either the drug itself or pure compounds or their mixture obtained 
from the plant material in an authorized dosage form on the Czech 
pharmaceutical market between the years 2015 – 2019, (3) sufficient 
quantity and quality of scientific papers focused on the plant genus or species. 
 
3.2. MEDICINAL PRODUCTS AND FOOD SUPPLEMENTS USED FOR THE 
CONSUMPTION ANALYSIS 
 
Herbal preparations included for the consumption analysis were 
chosen according to their availability in pharmaceutical distribution. Only 
preparations marketed through pharmaceutical wholesaler companies 
(PHOENIX and ViaPharma) in the evaluated time period were included. Some 
of the preparations are multi-component, therefore they were included in the 
analysis for each of the medicinal plants contained in the respective product. 
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3.2.1. LIST OF OVER THE COUNTER HERBAL PREPARATIONS INCLUDED IN THE 
CONSUMPTION ANALYSIS 
  
The analysis of herbal preparations consumption in years 2015 – 2019 
included the following preparations:  
Herbal preparations containing garlic included in the consumption 
analysis are as follows (listed under their respective trade name in 
alphabetical order): 
 
1. Allnature Česnek Premium 1500 mg 100 tbl 
Contains: Allium sativum L. extract standardized to contain 3.75 mg allicin in 
each tablet  
Dosage: 1 tablet once to thrice daily 
Special warning(s): Not intended for use in children, pregnant and breast-
feeding women. 
Producer: Allnature s.r.o., Březhradská 148/3, 503 32 Hradec Králové, Czech 
Republic 
 
2. Allivictus Tinktura 25 mL 
Contains: garlic extract containing  11.75 mg sulfur compounds/ 100 mL 
Dosage: 1 drop/ kg of body weight, to be taken on an empty stomach 
Special warning(s): Not intended for use in children under 3 years of age. 






3. Allivictus Tinktura 3x25 mL 
Contains: garlic extract containing  11.75 mg sulfur compounds/ 100 mL 
Dosage: 1 drop/ kg of body weight, to be taken on an empty stomach 
Special warning(s): Not intended for use in children under 3 years of age. 
Producer: Allivictus s.r.o., Podhradní 437, 552 03  Česká Skalice, Czech 
Republic 
 
4. Bioaktivní Česnek 60 tbl 
Contains: dried garlic powder 300 mg containing 4.7 mg of alliin 
Dosage: 1 tablet once daily, to be taken on an empty stomach 
Special warning(s): Not intended for use in children. 
Producer: Pharma Nord Praha s.r.o., Valčíkova 1149/14, 182 00 Praha 8, 
Czech Republic 
 
5. Česnek extra strong 1500 mg 100 tbl 
Contains: extract of Allium sativum L. containing min. 3% of allicin (125 mg) 
Dosage: 1 tablet once to thrice daily 
Special warning(s): Not intended for use in children, pregnant and breast-
feeding women. Suitable for vegans. 
Producer: Nutritius s.r.o., Dopravní 500/9, 104 00 Praha 10 , Czech Republic 
 
6. Dr. MAX Česnek UlLTRA 120 cps  
Contains: Garlicin extract 10 mg (equivalent to 1000 mg of fresh garlic) 
Dosage: 1 capsule twice to thrice daily 
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Special warning(s): Not intended for use in children under 3 years of age. 
Producer: Dr. Max Pharma s.r.o., Na Florenci 2116/15, 110 00 Praha 1, Czech 
Republic 
 
7. Dr. Popov Kapky bylinné Tlak – srdce 50 mL 
Contains: Herba visci albi, Crataegi fructus, Melissae herba, Flos tiliae, Leonuri 
cardiacae herba, Bulbi allii sativi. Each 100 g of the preparation contain 
extract of 3.32 g mistletoe, 3.32 g hawthorn, 2.9 g motherwort, and 0.41 g 
garlic.  
Dosage: 20 drops thrice daily 
Special warning(s): Not intended for use in children, pregnant and breast-
feeding women. 
Producer: Dr. Popov s.r.o., Plzeňská 857, 348 15 Planá, Czech Republic 
 
8. Jamieson Česnek bez zápachu 500 mg 100 cps 
Contains: garlic powder extract 100:1 5 mg 
Dosage: 2 capsules daily, to be taken with meal 
Special warning(s): Not intended for use in children. Consultation with your 
physician is recommended if your symptomps or problems persist or worsen. 
Especially pregnant women, diabetics, people on blood thinners or protease 
inhibitors therapy should consult a physician about taking this preparation. 
Producer: Jamieson Laboratories Ltd., 4025 Rhodes Drive Windsor, ON N8W 
5B5, Canada 
 
9. Jamieson Česnek bez zápachu 500 mg 300 cps 
Contains: garlic powder extract 100:1 5 mg 
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Dosage: 2 capsules daily, to be taken with meal 
Special warning(s): Not intended for use in children. Consultation with your 
physician is recommended if your symptoms or problems persist or worsen. 
Especially pregnant women, diabetics, people on blood thinners or protease 
inhibitor therapy should consult a physician about taking this preparation. 
Producer: Jamieson Laboratories Ltd., 4025 Rhodes Drive Windsor, ON N8W 
5B5, Canada 
 
10. Liftea Hloh Jmelí Česnek 30 cps 
Contains: Allium sativum extract 150 mg, Crataegus spp. extract 60 mg, Viscum 
album extract 60 mg 
Dosage: 1 – 2 capsules per day 
Special warning(s): Not intended for use in children under 3 years of age. 
Producer: SWISS CAPS AG, Husenstrasse 35, CH-9533 Kirchberg, Switzerland 
 
11. MedPharma Česnek 1500 mg 107 cps 
Contains: garlic oil: Allium sativum extract 500:1 3 mg (equivalent to 1500 mg 
of fresh garlic) 
Dosage: 1 capsule once daily 
Special warning(s): Not intended for use in children under 3 years of age. 
Producer: MedPharma s.r.o., Sivice 510, 664 07 Pozořice, Czech Republic 
 
12. Nature's Bounty Garlic Oil 1000 mg 100 cps 
Contains: garlic oil 2 mg (equivalent to 1000 mg of fresh garlic) 
Dosage:1 capsule once daily 
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Special warning(s): Not intended for use in children under 3 years of age. 
Producer: Nature's Bounty, 2100 Smithtown Avenue, 11714 NY, USA 
 
13. Naturvita Allicor česnek 60 tbl 
Contains: garlic powder 150 mg 
Dosage: 1 tablet once to twice daily 
Special warning(s):  Not intended for use in children under 3 years of age. 
Producer: Naturvita a.s., Veselá 227, 763 15 Slušovice, Czech Republic 
 
14. Naturvita Allicor Forte 60 tbl 
Contains: garlic powder 150 mg, beta carotene 1 mg, vitamin C 15 mg, 
vitamin E 10 mg, rutin 4 mg 
Dosage: 1 tablet once to twice daily 
Special warning(s): Not intended for use in children under 3 years of age. 
Producer: Naturvita a.s., Veselá 227, 763 15 Slušovice, Czech Republic 
 
15. Naturvita Allicor Super 60tbl 
Contains: garlic powder 150 mg, beta carotene 0.4 mg, thiamin 0.7 mg, 
riboflavin 0.8 mg, niacin 9 mg, pantothenic acid 3 mg, pyridoxin 1 mg, 
cyanocobalamine 0.5 µg, folic acid 0.1 mg, biotin 75 µg, vitamin D3 2.5 µg, 
vitamin C 15 mg, vitamin E 5 mg, rutin 2.5 mg 
Dosage: 1 tablet once to twice daily 
Special warning(s): Not intended for use in children under 3 years of age. 




16. Terezia Černý česnek 60 cps 
Contains: fermented garlic powder 500 mg 
Dosage: 1 capsule once daily, to be taken before meal 
Special warning(s): Not intended for use in children under 3 years of age. 
Suitable for celiacs. 
Producer: TEREZIA COMPANY s.r.o., Na Návrší 997/14, 141 00 Praha 4 – 
Michle, Czech Republic 
 
Herbal preparations containing hawthorn included in the 
consumption analysis are as follows (listed under their respective trade name 
in alphabetical order): 
 
1. Arkokapsle Hloh 60 cps 
Contains: powder of hawthorn (Crataegus monogyna JACQ., Crataegus 
laevigata (POIR (DC.) leaves and flowers 350 mg in 1 capsule with a 
guaranteed minimum content of 1.5% flavonoids expressed as hyperoside). 
Dosage: 2 capsules daily, to be taken before dinner or before sleep 
Special warning(s): Intended for use in adults only. Not suitable for people 
with  heart problems. 
Producer: Laboratoires Arkopharma, Zone Ind 1ere Avenue 9eme Rue Carros, 
06511 France 
 
2. Čaj bylináře Krevní tlak 40x1.6 g 
Contains (in 1 infusion bag): Crataegi flos 800 mg, Filipendulae ulmariae 
herba 480 mg, Melissae herba 040 mg, Leonuri cardiacae herba 80 mg 
Dosage: 1 cup daily 
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Special warning(s): Not intended for use in children. 
Producer: MEDIATE s.r.o., Dolní Libchavy 325, 561 16 Libchavy, Czech 
Republic  
 
3. Dr. Popov Kapky bylinné Hloh obecný 50 mL 
Contains: Crataegi fructus extract  
Dosage: 20 drops thrice daily (contains extract of 174 mg of hawthorn) 
Special warning(s): Not intended for use in children, pregnant and breast-
feeding women. 
Producer: Dr. Popov s.r.o., Plzeňská 857, 348 15 Planá, Czech Republic 
 
4. Dr. Popov Kapky bylinné Tlak – srdce 50 mL 
Contains: Herba visci albi, Crataegi fructus, Melissae herba, Flos tiliae, Leonuri 
cardiacae herba, Bulbi allii sativi. Each 100 g of the preparation contain 
extract of 3.32 g mistletoe, 3.32 g hawthorn, 2.9 g motherwort, and 0.41 g 
garlic.  
Dosage: 20 drops thrice daily 
Special warning(s): Not intended for use in children, pregnant and breast-
feeding women. 
Producer: Dr. Popov s.r.o., Plzeňská 857, 348 15 Planá, Czech Republic 
 
5. Fytos Kapky pro optimální tlak 50 mL 
Contains: hawthorn 0.5 g, mistletoe 5 g, lemon balm 5 g, motherwort 5 g, 
valerian root 1 g, horsetail 5 g  




Special warning(s): Not intended for use in children under 3 years of age, 
pregnant and breast-feeding women. 
Producer: FIPO SOBOTKA s.r.o., Na Benešově 737, 507 43 Sobotka, Czech 
Republic 
 
6. Leros Alvisan Neo 1x100 g 
Contains: Visci albi herba 40.0 g; Hyperici herba 20.0 g; Crataegi folium cum 
flore 16.5 g; Crataegi fructus 10.0 g; Equiseti herba 7.5 g; Menthae piperitae 
herba 2.0 g; Melissae herba 2.0 g, Matricariae flos 2.0 g  
Dosage: 1 tablespoon of tea mixture, to be poured over with 250 mL of boiling 
water, twice daily 
Special warning(s): Not intended for use in children and adolescents under 
18 years of age, pregnant and breast-feeding women. When using products 
containing St. John's wort, intense UV radiation must be avoided. 
Registration holder: Leros s.r.o., U Národní galerie 470, 156 00 Praha 5 – 
Zbraslav, Czech Republic 
 
7. Leros Alvisan Neo 20x1.5 g 
Contains (in 1 infusion bag): Visci albi herba 0.600 g, Hyperici herba 0.300 g, 
Crataegi folium cum flore 0.247 g, Crataegi fructus 0.150 g, Equiseti herba 
0.113 g, Menthae piperitae herba 0.030 g, Melissae herba 0.030 g, Matricariae 
flos 0.030 g 
Dosage: 1 cup twice daily 
Special warning(s): Not intended for use in children and adolescents under 
18 years of age, pregnant and breast-feeding women. When using products 
containing St. John's wort, intense UV radiation must be avoided. 
Registration holder: Leros s.r.o., U Národní galerie 470, 156 00 Praha 5 – 
Zbraslav, Czech Republic 
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8. Liftea Hloh Jmelí Česnek 30 cps 
Contains: Allium sativum extract 150 mg, Crataegus spp. extract 60 mg, Viscum 
album extract 60 mg 
Dosage: 1 – 2 capsules per day 
Special warning(s): Not intended for use in children under 3 years of age. 
Producer: SWISS CAPS AG, Husenstrasse 35, CH-9533 Kirchberg, Switzerland 
 
9. MaxiMag Cardio 375 mg + B6 + hloh + srdečník 30 tbl 
Contains: magnesium 375 mg, Crataegus monogyna extract 100 mg, Leonurus 
cardiaca extract 50 mg, vitamin B6 1.4 mg 
Dosage: 1 tablet daily 
Special warning(s): none 
Producer: Naturprodukt CZ s.r.o, Na Viničkách 638, 250 92 Šestajovice, Czech 
Republic 
 
10. Megafyt Čaj z hlohu 20x1.5 g 
Contains (in 1 infusion bag): Crataegi folium cum flore 1.5 g 
Dosage: 1 cup thrice daily 
Special warning(s): Intended for use in adults only. Consulting a physician 
during use is recommended. 
Producer: MEGAFYT PHARMA s.r.o., U Elektrárny 516, 252 46 Vrané nad 






11. Naturvita Jmelí – hloh plus Hořčík 60 cps 
Contains: mistletoe 1000 mg (equals to 250 mg of extract 4:1), hawthorn 
100 mg (equals to 25 mg of extract 4:1), magnesium 40 mg 
Dosage: 1 capsule twice daily 
Special warning(s): Not intended for use in children, pregnant and breast-
feeding women. 
Producer: Naturvita a.s., Veselá 227, 763 15 Slušovice, Czech Republic 
 
Herbal preparations containing motherwort included in the 
consumption analysis are as follows (listed under their respective trade name 
in alphabetical order): 
 
1. Anti-stress 20 tbl 
Contains: Valerianae radix 170 mg, Melissae herba 50 mg, Lupuli flos 50 mg, 
Leonuri cardiacae herba 50 mg 
Dosage: 1 tablet thrice daily 
Special warning(s): Not intended for use in children.  
Producer: Laboratorium Farmaceutyczne Labofarm sp. z o.o. Sp. k, 
Lubichowska 176B, 83 250 Starograd Gdański, Poland 
 
2. Anti-stress 60 tbl 
Contains: Valerianae radix 170 mg, Melissae folium 50 mg, Lupuli flos 50 mg, 
Leonuri cardiacae herba 50 mg 
Dosage: 1 tablet thrice daily 
Special warning(s): Not intended for use in children. 
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Producer: Laboratorium Farmaceutyczne Labofarm sp. z o.o. Sp. k, 
Lubichowska 176B, 83 250 Starograd Gdański, Poland 
 
3. Čaj bylináře Krevní tlak 40x1.6 g 
Contains (in 1 infusion bag): Crataegi flos 800 mg, Filipendulae ulmariae 
herba 480 mg, Melissae herba 040 mg, Leonuri cardiacae herba 80 mg 
Dosage: 1 cup daily 
Special warning(s): Not intended for use in children. 
Producer: MEDIATE s.r.o., Dolní Libchavy 325, 561 16 Libchavy, Czech 
Republic 
 
4. Dr. Popov Kapky bylinné Tlak – srdce 50 mL 
Contains: Herba visci albi, Crataegi fructus, Melissae herba, Flos tiliae, Leonuri 
cardiacae herba, Bulbi allii sativi. Each 100 g of the preparation contain 
extract of 3.32 g mistletoe, 3.32 g hawthorn, 2.9 g motherwort, and 0.41 g 
garlic.  
Dosage: 20 drops thrice daily 
Special warning(s): Not intended for use in children, pregnant and breast-
feeding women. 
Producer: Dr. Popov s.r.o., Plzeňská 857, 348 15 Planá, Czech Republic 
 
5. Fytopharma Bylinný čaj na vysoký tlak 20x1.5 g 
Contains: Herba visci albi, Leonuri cardiacae herba, Millefolii herba, Melissae 
herba 
Dosage: 1 cup twice to thrice daily 
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Special warning(s): Not intended for use in children, pregnant and breast-
feeding women. 
Producer: FYTOPHARMA a.s., Duklianskych hrdinov 47/651, 901 27 Malacky, 
Slovak Republic 
 
6. Fytos Kapky pro optimální tlak 50 mL 
Contains: hawthorn 0.5 g, mistletoe 5 g, lemon balm 5 g, motherwort 5 g, 
valerian root 1 g, horsetail 5 g  
Dosage: adults: 7 drops twice daily, children over 4 years of age: 5 drops once 
daily 
Special warning(s): Not intended for use in children under 3 years of age, 
pregnant and breast-feeding women. 
Producer: FIPO SOBOTKA s.r.o., Na Benešově 737, 507 43 Sobotka, Czech 
Republic 
 
7. MaxiMag Cardio 375 mg + B6 + hloh + srdečník 30 tbl 
Contains: magnesium 375 mg, Crataegus monogyna extract 100 mg, Leonurus 
cardiaca extract 50 mg, vitamin B6 1.4 mg 
Dosage: 1 tablet daily 
Special warning(s): none 
Producer: Naturprodukt CZ s.r.o, Na Viničkách 638, 250 92 Šestajovice, Czech 
Republic 
 
Herbal preparations containing black cumin included in the 
consumption analysis are as follows (listed under their respective trade name 




1. Černý kmín olej 100% 50 mL 
Contains: cold-pressed black cumin oil 
Dosage: 1 teaspoon thrice daily 
Special warning(s): Not intended for use in children under 3 years of age. 
Producer: VIRDE s.r.o., Štemplovec 10, 747 74 Holasovice, Czech Republic 
 
Herbal preparations containing olive leaf included in the consumption 
analysis are as follows (listed under their respective trade name in 
alphabetical order): 
 
1. OptiTensin 30 tbl 
Contains: olive leaf extract 5:1 350 mg containing min. oleuropein 16%  
Dosage: 1 tablet once to twice daily, to be taken after meal 
Special warning(s): Not intended for use in children, pregnant and breast-
feeding women. Not suitable for people with low blood pressure. 
Producer: WALMARK a.s., Oldřichovice 44, 739 61 Třinec, Czech Republic 
 
2. OptiTensin 60 tbl 
Contains: olive leaf extract 5:1 350 mg containing min. 16% of oleuropein 
Dosage: 1 tablet once to twice daily, to be taken after meal 
Special warning(s): Not intended for use in children, pregnant and breast-
feeding women. Not suitable for people with low blood pressure. 




Herbal preparations containing mistletoe included in the 
consumption analysis are as follows (listed under their respective trade name 
in alphabetical order): 
 
1. Aromatica TlakTEA 20x1.5 g 
Contains: Herba bursae pastoris, Solidaginis herba, Equiseti herba, Millefolii 
herba, Herba cardui benedicti, Herba visci albi, Taraxaci officinalis folium 
Dosage: 1 cup twice daily 
Special warning(s): Intended for use in children over 3 years of age and 
adults. 
Producer: AROMATICA CZ s.r.o., Masarykovo náměstí 101/3, 664 51 
Šlapanice, Czech Republic 
 
2. Dr. Popov Kapky bylinné Jmelí bílé 50 mL 
Contains: Herba visci albi extract  
Dosage: 20 drops twice daily (equal to extract of 116 mg of mistletoe) 
Special warning(s): Not intended for use in children, pregnant and breast-
feeding women. 
Producer: Dr. Popov s.r.o., Plzeňská 857, 348 15 Planá, Czech Republic 
 
3. Dr. Popov Kapky bylinné Tlak – srdce 50 mL 
Contains: Herba visci albi, Crataegi fructus, Melissae herba, Flos tiliae, Leonuri 
cardiacae herba, Bulbi allii sativi. Each 100 g of the preparation contain 
extract of 3.32 g mistletoe, 3.32 g hawthorn, 2.9 g motherwort, and 0.41 g 
garlic.  
Dosage: 20 drops thrice daily 
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Special warning(s): Not intended for use in children, pregnant and breast-
feeding women. 
Producer: Dr. Popov s.r.o., Plzeňská 857, 348 15 Planá, Czech Republic 
 
4. Fytopharma Bylinný čaj na vysoký tlak 20x1.5 g 
Contains: Herba visci albi, Leonuri cardiacae herba, Millefolii herba, Melissae 
herba 
Dosage: 1 cup twice to thrice daily 
Special warning(s): Not intended for use in children, pregnant and breast-
feeding women. 
Producer: FYTOPHARMA a.s., Duklianskych hrdinov 47/651, 901 27 Malacky, 
Slovak Republic 
 
5. Fytos Kapky pro optimální tlak 50 mL 
Contains: hawthorn 0.5 g, mistletoe 5 g, lemon balm 5 g, motherwort 5 g, 
valerian root 1 g, horsetail 5 g  
Dosage: adults: 7 drops twice daily, children over 4 years of age: 5 drops once 
daily 
Special warning(s): Not intended for use in children under 3 years of age, 
pregnant and breast-feeding women. 
Producer: FIPO SOBOTKA s.r.o., Na Benešově 737, 507 43 Sobotka, Czech 
Republic 
 
6. Leros Alvisan Neo 1x100 g 
Contains: Visci albi herba 40.0 g; Hyperici herba 20.0 g; Crataegi folium cum 
flore 16.5 g; Crataegi fructus 10.0 g; Equiseti herba 7.5 g; Menthae piperitae 
herba 2.0 g; Melissae herba 2.0 g, Matricariae flos 2.0 g  
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Dosage: 1 tablespoon of tea mixture, to be poured over with 250 mL of boiling 
water, twice daily 
Special warning(s): Not intended for use in children and adolescents under 
18 years of age, pregnant and breast-feeding women. When using products 
containing St. John's wort, exposure to intense UV radiation must be avoided. 
Registration holder: Leros s.r.o., U Národní galerie 470, 156 00 Praha 5 – 
Zbraslav, Czech Republic 
 
7. Leros Alvisan Neo 20x1.5 g 
Contains (in 1 infusion bag): Visci albi herba 0.600 g, Hyperici herba 0.300 g, 
Crataegi folium cum flore 0.247 g, Crataegi fructus 0.150 g, Equiseti herba 
0.113 g, Menthae piperitae herba 0.030 g, Melissae herba 0.030 g, Matricariae 
flos 0.030 g 
Dosage: 1 cup twice daily 
Special warning(s): Not intended for use in children and adolescents under 
18 years of age, pregnant and breast-feeding women. When using products 
containing St. John's wort, exposure to intense UV radiation must be avoided. 
Registration holder: Leros s.r.o., U Národní galerie 470, 156 00 Praha 5 – 
Zbraslav, Czech Republic 
 
8. Liftea Hloh Jmelí Česnek 30 cps 
Contains: Allium sativum extract 150 mg, Crataegus spp. extract 60 mg, Viscum 
album extract 60 mg 
Dosage: 1 – 2 capsules per day 
Special warning(s): Not intended for use in children under 3 years of age. 




9. Naturvita Jmelí – hloh plus Hořčík 60 cps 
Contains: mistletoe 1000 mg (equals to 250 mg of extract 4:1), hawthorn 
100 mg (equals to 25 mg of extract 4:1), magnesium 40 mg 
Dosage: 1 capsule twice daily 
Special warning(s): Not intended for use in children, pregnant and breast-
feeding women. 
Producer: Naturvita a.s., Veselá 227, 763 15 Slušovice, Czech Republic 
 
3.2.2. LIST OF PRESCRIPTION RESTRICTED MEDICINAL PRODUCTS INCLUDED IN THE 
CONSUMPTION ANALYSIS 
 
 Medicinal products containing foxglove cardenolides included in the 
consumption analysis are as follows (listed under their respective trade name 
in alphabetical order): 
 
1. Digoxin Léčiva 0.125 mg tablety 
Contains: digoxinum 0.125 mg 
Dosage: individual 
Special warning(s): see SPC for more details 
Registration holder: Zentiva, k. s., U Kabelovny 130, 102 37 Praha 10, Czech 
Republic 
 
2. Digoxin Léčiva 0.250 mg tablety 
Contains: digoxinum 0.250 mg 
Dosage: individual 
Special warning(s): see SPC for more details 
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Registration holder: Zentiva, k. s., U Kabelovny 130, 102 37 Praha 10, Czech 
Republic 
 
3.3. STATISTICAL ANALYSIS 
 
 Data from participating pharmacies was either collected personally or, 
due to the epidemiological situation regarding the COVID-19, some of the 
participating pharmacies sent data electronically. For operational reasons, the 
data from e-shop pharmacies was sent only by electronic means.  
 For the statistical analysis data was divided into three categories: big 
city, small town, and e-shop. The category "big city" included pharmacies in 
cities with at least 50 thousand of inhabitants, "small town" included 
pharmacies in towns under 50 thousand of inhabitants, and "e-shop" included 
pharmacies offering delivery service regardless of the number of inhabitants. 
 The evaluation period for the consumption analysis is represented by 
the years 2015 – 2019. Data on sales of the selected herbal food supplements 
and medicinal products (see Ch. 3.2.1. and Ch. 3.2.2.) was collected as the total 
amount of packages sold per year. For all products, the number of daily doses 
of each package size was calculated according to the respective package 
leaflet. Daily dose for a product with a dosage range was calculated as the 
mean value of this range. In case of a dosage calculated with the reference to 
body weight, the body weight of 70 kg was used. For medicinal products 
containing digoxin, the defined daily dose as established by World Health 
Organization was used as a reference for the calculation of the number of 
daily doses. 
 Data was then processed to obtain percentile values calculated for 
each of the evaluated medicinal plants with the exception of digoxin-
containing medicinal products. In specific cases the number of respective 
daily doses of the chosen medicinal plant preparations was directly compared 
with the total number of daily doses – for example in order to establish the 
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trends of different dosage form sales (see Ch. 4.1.2., Ch. 4.1.3., and Ch. 4.1.6. 
for more details).  
To avoid the bias caused by differences in the amount of sold daily 
doses, which was strongly affected by the pharmacy category, firstly the 
percentage of daily doses of the respective plant was calculated for each 
pharmacy, and then these percentile values were compared between the 
pharmacy categories. The consumption of the respective medicinal plant was 
then expressed as the mean value of these percentages. 
During the data processing, a large disparity was discovered between 
the sale of garlic preparationss and other medicinal plants preparations. 
Therefore an additional data modification was applied – garlic preparations 
correction. In this case, the data on garlic preparations was omitted and 
respective percentages were calculated as described above with the total 
number of daily doses without garlic preparations. 
 For digoxin, the total number of defined daily doses (DDD) of each 
included year was divided by the number of inhabitants of the respective 
city/town, and the result for statistical purposes was expressed as number of 
DDD per thousand of inhabitants. The use of DDD for drug consumption 
analysis is widely accepted as a value not affected by the price or package size 
(Kořístková and Grundmann, 2006). In this case the more frequently used 















4.1. OVER THE COUNTER HERBAL PREPARATIONS 
  
A total number of 33 over the counter herbal preparations was 
included in the consumption analysis. Most of these OTCs are solid dosage 
form-products (20), 6 products are herbal teas, and the rest is marketed in a 
liquid dosage form (drops, tincture, or oil). Two of these products meet the 
legal requirements on a medicinal product and are registered with SUKL, 
while the majority of the evaluated herbal products are categorized as food 
supplements. For further details see the respective chapter on medicinal plant 
products consumption. 
 
4.1.1. GARLIC HERBAL PREPARATIONS 
 
Generally, the garlic-containing preparations represent the majority of 
the evaluated products. With the exception of three products (namely 
Allivictus tinktura in two package sizes and Dr. Popov Kapky bylinné Tlak – 
srdce), they are produced in solid dosage forms, i.e. tablets or capsules. No 
herbal tea containing garlic is marketed in the Czech Republic. 
Most garlic preparations (10) contain various garlic extracts, only 
6 preparations contain powdered garlic cloves. Six preparations were 
standardized for a certain garlic active compounds, namely alliin, allicin, total 
sulfur compounds, garlic oil, or a special extract marketed under the trade 
name garlicin.  
Garlic represents the majority of the herbal preparations bought by 
clients in big city, small town, and e-shop pharmacies, with the percentages of 
these products ranging from 72% to 86%. No distinctive fluctuation in garlic 
consumption during the evaluation time period occurred for the respective 
pharmacy category. A single interesting feature of the consumption curve is a 
rapid increase in garlic consumption in 2019 for e-shop pharmacies, 
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accompanied by a less pronounced decrease in garlic consumption in the 




4.1.2. HAWTHORN HERBAL PREPARATIONS 
 
Hawthorn-containing preparations are (together with mistletoe) the 
second most bought by clients both in pharmacies and e-shops. Out of the 11 
evaluated hawthorn preparations only one contains a hawthorn extract, and 
three of them contain Crategi folium cum flore, meeting the requirements of 
European Pharmacopeia on the amount of active compounds. Four 
preparations are herbal teas, three preparations are in a liquid (drops), and 
four are produced in a solid dosage form. The comparison of consumption of 
the hawthorn tea and non-tea preparations in total amount of daily doses 
regardless of the pharmacy category during the reporting time period, 
expressed as percentages, is shown in Fig. 4.2.  
The consumption of hawthorn preparations in the evaluated time 
period for big city, small town, and e-shop pharmacies exhibits a more or less 
balanced trend, not exceeding 12% of total daily doses of herbal preparations. 
This stability of the hawthorn consumption trend is even more highlighted 











Fig. 4.1. Garlic preparations consumption in the years 2015 – 2019. Values are expressed 


























Fig. 4.3. Hawthorn preparations consumption in the years 2015 – 2019 without the garlic 
preparations correction of data. Values are expressed as percentages. Small – small town 
pharmacies, big – big city pharmacies, e-shop – e-shop pharmacies. 
 
Fig. 4.2. Hawthorn tea and non-tea preparations consumption in the years 2015 – 2019. 
Values are expressed as percentages of hawthorn daily doses. Non-tea – preparations in all 






4.1.3. MOTHERWORT HERBAL PREPARATIONS 
 
Motherwort preparations marketed in the Czech Republic are very 
scarce, and only five of the seven evaluated preparations are primarily 
intended in cardiovascular use (see Ch. 5.4. for more details). The two other 
preparations (namely Anti-stress 20 tbl and Anti-stress 60 tbl) are mainly 
used in relieving of mild stress and anxiety conditions, often related with 
heart palpitations. The comparison of the consumption of motherwort 
sedative and non-sedative products in the total amount of daily doses 
regardless of the pharmacy category during the reporting time period, 
expressed as percentage, is shown in Fig. 4.5. 
 Out of the 7 marketed motherwort preparations, none of them meets 
the requirement for a medicinal product and they are all categorized as food 
supplements. Three preparations are in a solid dosage form, two are offered 
as tinctures, and the remaining two preparations are represented by the 













Fig. 4.4. Hawthorn preparations consumption in the years 2015 – 2019 with the garlic 
preparations correction of data. Values are expressed as mean percentages for each 







The consumption of motherwort preparations is fairly exiguous, 
ranging in minor percent units, not exceeding 4% of total herbal preparations 
during the whole evaluation time period. Interestingly, while in 2015 the 
majority of motherwort daily doses was sold in big city and small town 
pharmacies, there is a rapid drop in sales of motherwort preparations in 2016 
for these categories, and sales through e-shop pharmacies gained in 






















Fig. 4.6. Motherwort preparations consumption in the years 2015 – 2019 without the garlic 
preparations correction of data. Values are expressed as percentages. Small – small town 
pharmacies, big – big city pharmacies, e-shop – e-shop pharmacies 
 
Fig. 4.5. Motherwort sedative and non-sedative preparations consumption in the years 2015 – 2019. 
Values are expressed as percentages of motherwort daily doses regardless of pharmacy category. 
Sedative – preparations primarily used in treatment of stress and anxiety, non-sedative – 
preparations with primary cardiovascular use. 
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The fluctuations of motherwort preparation sales throughout the 
evaluated time period are more emphasized when the garlic preparations 
correction was applied, with markedly increases for the e-shop pharmacies, 
and an accentuated decrease in 2016 for big city pharmacies (Fig. 4.7.). 
 
 
4.1.4. BLACK CUMIN HERBAL PREPARATIONS 
 
Black cumin is marketed in the Czech Republic only in a liquid dosage 
form (oil) and this category is represented by a single food supplement 
available in one package size only. It contains pure cold-pressed seed oil with 
no standardization of active compounds.  
In the evaluated time period this product was bought predominantly 
via e-shop pharmacies. The consumption of black cumin shows a more or less 
linear decreasing trend with a pronounced reduction in 2016, in general not 
exceeding 2% of the total daily doses of herbal preparations. Note the 
emphasized linearity of the decreasing consumption curve for black cumin 
products when the sales for small town and e-shop pharmacies in 2016 were 











Fig. 4.7. Motherwort preparations consumption in the years 2015 – 2019 with the garlic 
preparations correction of data. Values are expressed as mean percentages for each pharmacy 




























Fig. 4.9. Black cumin preparations consumption in the years 2015 – 2019 with the garlic 
preparations correction of data. Values are expressed as mean percentages for each 
pharmacy category. Small – small town pharmacies, big – big city pharmacies, e-shop – e-
shop pharmacies. 
 
Fig. 4.8. Black cumin preparations consumption in the years 2015 – 2019 without the 
garlic preparations correction of data. Values are expressed as percentages. Small – 








4.1.5. OLIVE LEAF HERBAL PREPARATIONS 
 
Olive leaf preparations marketed in the Czech Republic are 
represented by a single herbal preparation, categorized as food supplement, 
and available in different package sizes. This supplement is produced in a 
solid dosage form (tablets), and it is standardized to contain a minimum 16% 
of oleuropein.  
The consumption of this olive leaf food supplement shows a 
decreasing trend in the evaluated time period, this trend being especially 
notable for the e-shop pharmacies, and partially also for the small town 
pharmacies. On the other hand, big city pharmacies exert a more or less non-
fluctuating trend of the olive leaf preparations sales with the exception of the 
year 2018. In general, the consumption of olive leaf preparations did not 
exceed 10% of total daily doses of herbal preparations except for e-shop 






2015 2016 2017 2018 2019
Fig. 4.10. Black cumin preparations consumption in the years 2015 – 2019 regardless of 
pharmacy category. Values are expressed as percentages. Note the strongly linear 











4.1.6. MISTLETOE HERBAL PREPARATIONS 
 
Mistletoe preparations marketed in the Czech Republic are prevalently 



















Fig. 4.12. Olive leaf preparations consumption in the years 2015 – 2019 with the garlic 
preparations correction of data. Values are expressed as mean percentages for each 
pharmacy category. Small – small town pharmacies, big – big city pharmacies, e-shop – 
e-shop pharmacies. 
 
Fig. 4.11. Olive leaf preparations consumption in the years 2015 – 2019 without the 
garlic preparations correction of data. Values are expressed as percentages. Small – 




3 preparations). The two remaining preparations are available in a solid 
dosage form. One preparation contains a mistletoe extract, two products meet 
the requirements on Visci albi herba. Two of these herbal products are 
registered with SUKL, thus fulfilling the legal conditions of a medicinal 
product. 
The comparison of the consumption of the mistletoe tea and non-tea 
preparations in the total amount of daily doses sold through the e-shop 




The consumption of mistletoe herbal preparations during the 
evaluated time period shows a stable trend for small town and big city 
pharmacies with a minor decrease in 2019 for big city pharmacies; it is, 
however, increased remarkably for e-shop pharmacies. This increase has 
become more emphasized when the garlic preparations correction was 
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Fig. 4.13. Mistletoe tea and non-tea preparations consumption in the years 2015 – 2019 in the 
e-shop pharmacies. Values are expressed as percentages of mistletoe daily doses. Non-tea – 









4.2. PRESCRIPTION-RESTRICTED MEDICINAL PRODUCTS 
 
 Only two of the evaluated medicinal plant preparations fall within this 



















Fig. 4.15. Mistletoe preparations consumption in the years 2015 – 2019 with the garlic 
preparations correction of data. Values are expressed as mean percentages for each 
pharmacy category. Small – small town pharmacies, big – big city pharmacies, e-shop – e-
shop pharmacies. 
 
Fig. 4.14. Mistletoe preparations consumption in the years 2015 – 2019 without the garlic 
preparations correction of data. Values are expressed as percentages. Small – small town 




medicinal products are registered with SUKL and prescription-restricted due 
to their indications. 
 
4.2.1. FOXGLOVE – DIGOXIN  
 
Digoxin consumption in years 2015 – 2019 is shown in Fig. 4.16. and 
Fig. 4.17. for big city and small town pharmacies, respectively. For the big city 
pharmacies, a decreasing trend in digoxin consumption can be seen with a 
pronounced reduction in 2018 followed by a slight increase in 2019 
(Fig. 4.16.).  
 
 
For the small town pharmacies, the decreasing trend in consumption 
was also observed, however, it had a prolonged onset (2017) and an 
emphasized change. Furthermore, for small town pharmacies in 2018 a slight 
increase and in 2019 a slight reduction to the values of the year 2017 of 
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Fig. 4.16. Digoxin consumption in the years 2015 – 2019 for big city pharmacies. Values are 































2015 2016 2017 2018 2019
Fig. 4.17. Digoxin consumption in the years 2015 – 2019 for small town pharmacies. Values 





5.1. GENERAL REMARKS ON THE EVALUATED HERBAL PREPARATIONS 
 
For the consumption analysis, a total of 35 herbal preparations 
containing garlic, foxglove cardenolides, hawthorn, motherwort, black cumin, 
olive leaf, or mistletoe were chosen. With the exception of the products Leros 
Alvisan Neo 1x 100 g, Leros Alvisan Neo 20x1.5 g, Digoxin Léčiva 0.125 mg 
tablety, and Digoxin Léčiva 0.250 mg tablety, none of the evaluated herbal 
preparations have the status of a medicinal product, and they are categorized 
as food supplements. In fact, there is no medicinal product in a solid dosage 
form (i.e. tablet, capsule) on the pharmaceutical market of the Czech Republic 
containing garlic, hawthorn, motherwort, black cumin, olive leaf, or mistletoe.  
Medicinal products containing hawthorn and mistletoe are marketed 
in the Czech Republic only in the form of herbal teas with defined contents. 
Visci albi herba and Crategi folium cum flore have to contain strictly defined 
amounts of the active compounds, according to the requirements of EMA or 
European Pharmacopoeia 10.0. 
Food supplements evaluated in the consumption analysis have to 
follow the requirements of the national regulation No 58/2018 (on food 
supplements and food composition), as well as the requirements of the (EC) 
regulation No 1924/2006 (on nutrition and health claims made on foods). 
According to these regulations, herbal preparations containing hawthorn 
have to follow the maximum allowed amount of the leaves and flowers extract 
(1000 mg daily). No health claims (see Ch. 2.8.2.) were authorized for any of 
the evaluated herbal preparations, which, in fact, makes it harder to offer as 
an alternative for treatment of different cardiovascular conditions.  
In the following chapters, the potential positive effects on human 
cardiovascular system are discussed separately for each of the selected 
medicinal plants. It is, however, necessary to emphasize that several of the 
evaluated preparations are multi-component, and thus the possibility of 
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interactions between the individual components needs to be considered. The 
interaction potential of each plant was also reviewed in the theoretical part of 
this thesis, see the relevant chapters for more details. Additive effects of 
medcinal plant combinations on cardiovascular health conditions were 
reported by several authors (e.g. Brändle et al., 1997; Malik et al., 2017a, b). 
 
5.2. GARLIC CONSUMPTION IN THE YEARS 2015 – 2019 
 
 Garlic preparations represent the most sold herbal peparations of all 
the OTC preparations evaluated in all of the pharmacies – being it in the small 
town, big city, or e-shop category, which is in concordance with the fact that 
garlic is one of the oldest medicinal herbs, and has been grown for centuries 
in this geographical area. Notably, the e-shop sales were usually lower than 
those of brick-and-mortar pharmacies. This discrepancy is probably due to 
the fact that garlic preparations are popular with the clients, and smaller 
pharmacies also regularly offer these preparations, so there is no need to 
place a special order (unlike, for example, black cumin preparations). 
 The lower consumption of garlic preparations in small town 
pharmacies compared to big city pharmacies may also be due to the fact that 
people in smaller towns and villages are more likely to grow their own garlic, 
as they are often living in houses with gardens. Also, the purchasing power of 
people living in big cities is usually higher than those of small town people, 
allowing them to pay for such "luxury goods" as garlic processed to capsules 
and tablets. 
 The fundamental issue with garlic herbal preparations is the lack of 
any medicinal products among them (see Ch. 5.1.). Although most of the 
marketed garlic preparations are standardized (10 out of 16), the majority 
use standardizations that, in fact, offer no valuable information on the active 
compounds content: sulfur compounds, garlicin, and garlic oil are just general 
and non-descriptive labels. Only three preparations are standardized to 




 High doses (2400 mg) of garlic preparations standardized to contain 
1.3% allicin were shown to significantly decrease blood pressure even in 
patients with a rather severe hypertension (diastolic blood pressure 
≥115 mm Hg), with the hypotensive effect persisting up to 14 hours 
(McMahon and Varga, 1993). When compared to the preparation 
standardized to contain allicin, the abovementioned work used a minimum of 
31.2 mg allicin – that is about four times as much as the allicin content in the 
recommended daily dose of the evaluated garlic supplement. Thus, the 
hypotensive performance of the evaluated preparation most likely will not be 
that significant, but this supplement could be considered for people in a 
prehypertensive stage, or in patients with a mild hypertension. Garlic as an 
add-on therapeutic to several standard antihypertensive drugs was observed 
to increase the hypotensive effect (Asdaq and Inamar, 2010; Ashraf et al., 
2013), in some cases even exhibiting synergistic effect with the 
antihypertensive drug (Asdaq and Inamar, 2011). 
 As to hypolipidemic effect of garlic, it has been shown that patients 
with mild dyslipidemia treated for a minimum of 8 weeks may benefit from 
garlic treatment (Ried, 2016). Reduction of triglyceride and/or cholesterol 
levels was reported in volunteers using 600 – 800 mg of garlic powder. Aged 
garlic extract needs remarkably higher doses (over 7 g daily) to exert its 
hypolipidemic properties (Steiner et al., 1996). None of the evaluated garlic 
preparations offer a daily dose that high, the recommended dosage for most 
preparations is about three to four times lower.  
 
5.3. HAWTHORN CONSUMPTION IN THE YEARS 2015 – 2019 
 
 Hawthorn herbal preparations are fairly popular with people and their 
consumption in the evaluation time period is more or less stable, with no 
remarkable changes, especially when the correction on garlic preparations 
was applied (see Ch. 3.3. and Ch. 4.1.2.). 
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 Interestingly, while in small town and big city pharmacies mostly 
hawthorn-containing herbal teas are preferred, a gradual but steady increase 
of the non-tea at the expense of tea hawthorn preparations can be observed in 
e-shop pharmacies (Fig. 4.2.). Partially due to limited selection of hawthorn 
herbal preparations offered by most pharmacies – mainly teas – and partially 
due to the fact that predominantly younger people are placing e-shop orders. 
Based on my ten years of experience, mostly the elderly prefer herbal teas to 
solid dosage forms. 
 Similarly to garlic preparations, the main issue with hawthorn herbal 
preparations is the content of active compounds. Crataegi folium cum flore 
should meet the requirement of a minimum 1.5% of flavonoids expressed as 
hyperoside, calculated with the reference to the dried drug (European 
Pharmacopoeia 10.0). This content is guaranteed for the two medicinal 
products in this category.  
According to the available literature, high doses of hawthorn extracts 
are needed for the onset of the blood pressure lowering effect (900 mg/day 
or higher; e.g. Walker et al., 2006 and Al-Gareeb et al., 2012). Lower doses of 
hawthorn extract effective in reduction of the blood pressure were reported 
by Schmidt et al. (1994) for the commercially available hawthorn extract 
LI 132. The extract LI 132 at the dose of 600 mg/kg exerts a statistically 
significant reduction of the systolic blood pressure in humans. This extract is 
standardized to contain at least 2.2% of flavonoids, therefore the daily dose of 
Crataegi folium cum flore should be 880 mg. Each teabag of the medicinal tea 
contains exactly 494 mg of the drug, thus with two teas recommended per 
day, the amount of active compounds should be sufficient enough. However, 
the LI 132 is extracted with 70% methanol, while teabags are extracted with 
boiling water. Therefore, the active compounds of these two extracts may 
differ significantly. 
 As to the lipid-lowering effect of hawthorn, a positive effect of 
hawthorn on the human lipid profile was observed at high doses of WS 1442 
extract (900 mg twice daily; Al-Gareeb, 2012). While none of the evaluated 
products offer such a high dosage, the WS 1442 extract is standardized for a 
certain content of proanthocyanidins not flavonoids (see Ch. 2.2.3.), therefore 
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the dosage used in this clinical trial and the hawthorn supplement marketed 
in the Czech Republic are not entirely comparable.  
 On the other hand, the flavonoid hyperoside was reported to exert a 
strong inhibitory activity against the key enzyme in cholesterol synthesis 
(HMG Co-A; Ye et al., 2010), thus a prolonged use of hawthorn products may 
be taken into consideration in mildly hypercholesterolemic patients. 
 
5.4. MOTHERWORT CONSUMPTION IN THE YEARS 2015 – 2019 
 
 The consumption of motherwort herbal preparations in the evaluated 
time period is fairly interesting: with a simple declining trend in small town 
pharmacies and an increasing trend in e-shop pharmacies, with a rapid 
reduction in 2016 and rapid increase in 2019 for big city pharmacies, it is 
quite difficult to estimate the background of such changes.  
 Two main issues arise with motherwort products. Firstly, two of the 
solid dosage form preparations are primarily intented for the use as a mild 
sedative, offering further a mild anxiolytic action in people with pronounced 
psychic tension, mostly caused by various stress situations. In these 
preparations, 50 mg of motherwort herb is accompanied by valerian root, 
lime balm herb, and hop cone. Thus, in this case it is not likely that people 
would buy such a product with the intention of a cardiovascular use.  Note, 
however, the rapid shift in the sold daily doses of these sedative versus non-
sedative motherwort preparations, and the switch toward the non-sedative 
motherwort preparationss in the evaluated time period (Fig. 4.5.).  
 On the other hand, all the five remaining preparations are marketed as 
food supplements for the cardiovascular use. Here is the second main issue of 
these products particularly noticeable: the uncertain content of active 
compounds. Motherwort content in these food supplements varies from 
50 mg to 370 mg in a daily dose. 
 According to European Pharmacopoeia, Leonuri cardiacae herba 
should contain at least 0.2% of flavonoids expressed as hyperoside, calculated 
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with the reference to the dried drug (European Pharmacopoeia 10.0), thus 
the motherwort products contain flavonoids at least within the range of 
0.1 mg to 0.75 mg. It is, however, quite complicated to estimate the 
hypotensive effect of such doses, especially with the significant lack of 
information on this topic in the available literature.  
 Namely, the hypotensive action of motherwort extract in human 
patients with stage 1 and stage 2 hypertension was reported by Shikov et al. 
(2011) who used higher doses of motherwort extract (600 mg) twice daily. 
Furthermore, the extract used in this study was obtained from extraction of 
motherwort with soybean oil in order to obtain the non-polar active 
compounds, which clearly is not the case of hyperoside. Therefore it is safe to 
presume that the chemical composition of this particular extract and that of 
evaluated motherwort preparations differ too much to draw any conclusions 
on their hypotensive actions.  
 It is also difficult to evaluate a possible positive effect of motherwort 
preparations marketed in the Czech Republic on human lipid profile, as 
relevant information is scarce. I was not able to find any trials regarding the 
lipid-lowering motherwort activity with human volunteers. The closest 
animal species was Rhesus monkey. In this case, however, the synthetic 
motherwort alkaloid leonurine (SCM-198) was used (Suguro et al., 2018). 
Leonurine is a compound more characteristic for Chinese motherwort than 
for motherwort cardiaca where its content is very low (under 1 per mille, see 
Ch. 2.4.2.), and thus no significant effect can be expected in this field of action. 
 
5.5. BLACK CUMIN CONSUMPTION IN YEARS 2015 – 2019 
 
 Similarly to olive leaf herbal preparations, the consumption of black 
cumin products exerts a decreasing trend in the evaluated time period 
(Fig. 4.9.). Only one black cumin preparation is marketed on the 
pharmaceutical market of the Czech Republic, although several black cumin 
oils are available mostly via specialized food stores. Also, the majority of this 
black cumin preparation was sold in e-shop pharmacies which is mostly due 
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to the unavailability of this products in brick-and-mortar pharmacies, be it in 
small town or big city. 
 The marketed black cumin oil is a pure, cold-pressed seed oil. 
According to the producer, the oil origin country is Egypt or Ukraine 
(personal communication). Since it has been reported that the black cumin 
active compounds differ significantly due to the origin of  the plant material 
(Nickavar et al., 2003; Kokoška et al., 2008; Bourgou et al., 2010;  Singh et al., 
2014; Kalidasu et al., 2017), it is necessary to know the geographical region 
where plants were grown. Tunisian and Turkish black cumin cultivars, that 
are most likely to be grown in the abovementioned countries, are 
characterized by a high content of p-cymene (about 60%) and a fairly high 
content of thymoquinone (about 3% for the Tunisian oil). 
 Fallah Huseini et al. (2013) reported a significant decrease of both 
systolic and diastolic pressure in volunteers treated with 2.5 mL of black 
cumin oil twice daily for 8 weeks. The dosage of the marketed product is 5 mL 
thrice daily, which should be sufficient enough. Furthermore, the 
abovementioned trial was conducted in Iran, using Iranian black cumin oil 
that was reported to be rich in trans-anethole and low in thymoquinone 
(under 1%; Nickavar et al., 2003; see also Tab. 2.1.). Thus, compared to the 
marketed black cumin oil, the dose of thymoquinone is likely higher in the 
evaluated preparation and in the recommended dosage it is expected to have 
a positive influence on the blood pressure reduction. 
 As to the impact of black cumin on the lipid profile, Najmi et al. (2008) 
and Ahmad Alobaidi (2014) both observed a pronounced hypolidpidemic 
action of statins (atorvastatin and simvastatin, respectively) coadministered 
with black cumin oil in dyslipidemic patients treated with black cumin. Najmi 
et al. (2008) used the dose of 2.5 mL of black cumin oil twice daily for eight 
weeks. Therefore, adding black cumin oil as an adjuvant therapy in 
hyperlipidemic patients should be taken into consideration.   
 Moreover, Amini et al. (2011) even reported a positive effect of black 
cumin oil administered at a dose of 2.5 mL twice daily in healthy volunteers. 
All of the trials were performed with Iranian black cumin oil (low 
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thymoquinone content), thus the evaluated black cumin preparation is most 
likely to exert a pronounced hypolipidemic activity because of its higher 
thymoquinone content. 
 
5.6. OLIVE LEAF CONSUMPTION IN THE YEARS 2015 – 2019 
 
 The consumption analysis of olive herbal preparations clearly shows a 
decreasing trend in both the amount of daily doses as well as percentage of 
sales of these products in the evaluated time period (Fig. 4.11. and Fig. 4.12.). 
As this trend is notable in all categories of pharmacies, there is clearly a 
reduction of interest from the clients.  
 Olive leaf herbal preparations marketed in the Czech Republic are only 
in solid dosage form, containing olive leaf extract standardized for a minimum 
of 16% of oleuropein. This amount is fairly high, as the European 
Pharmacopoeia requires a minimum of 5% of secoiridoids, expressed as 
oleuropein (European Pharmacopoeia 10.0). The commercially available olive 
leaf extract EFLA 943 is standardized for oleuropein content within the range 
18 – 26 %.  
 Perrinjacquet-Moccetti et al. (2008) and Susalit et al. (2011) both 
reported a significantly decreased blood pressure in volunteers taking 
1000 mg of EFLA 943 daily, divided in two doses. This two-dose pattern is 
recognized also by the producer of the olive leaf extract food supplement, 
however, the dose is lower, only 350 mg in each tablet, thus the daily dose 
contains about 112 mg of pure oleuropein. Contrary to that, the reported 
hypotensive effect of olive leaf was achieved with at least 180 mg of pure 
oleuropein. At this dose, the antihypertensive effect of oleuropein was 
comparable to that of 25 mg of captopril (Susalit et al., 2011). The difference 
in daily dose of oleuropein is about 30%, which is quite significant, on the 
other hand, this marketed olive leaf supplement is one of a few preparations 
at least nearing the requirements for an effective treatment of hypertension. 
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 As to the effect of olive leaf on lipid profile, Perrinjacquet-Moccetti 
et al. (2008) observed a statistically significant reduction in volunteers taking 
1000 mg of olive leaf extract EFLA 943. Again, this dose contains at least 
180 mg of oleuropein which is higher than 112 mg of oleuropein in the 
evaluated product. The authors, however, also observed a positive trend in 
the cholesterol reduction with the dose of 500 mg of EFLA 943 (i.e. 90 mg of 
oleuropein). Thus, in this case the dose of olive leaf preparation could be 
considered for clients with only slightly elevated cholesterol levels. Araki 
et al. (2019) also reported a positive effect of olive leaf tea on triglycerides 
and LDL cholesterol in volunteers drinking olive leaf tea, which surely 
contains less oleuropein than the evaluated supplement. 
  
5.7. MISTLETOE CONSUMPTION IN YEARS 2015 – 2019 
 
 The consumption of mistletoe herbal preparations during the 
evaluated time period shows a stable trend for small town and big city 
pharmacies, however, it increased remarkably for e-shop pharmacies. This 
increase is noticeable especially when the garlic preparations correction was 
applied (Fig. 4.14. and Fig. 4.15.).  
The mentioned non-fluctuation trend in big city and small town 
pharmacies is mostly due to the fact that mistletoe is predominantly sold as 
herbal tea, often bought by elder people. The increase in e-shop sales of 
mistletoe preparations is on the other hand strongly influenced by the 
increase of the non-tea mistletoe preparations (Fig. 4.13.). Again, as with 
hawthorn non-tea preparations, mostly people of younger age prefer these 
dosage forms, and often place their orders via e-shop pharmacies. 
 Out of the nine evaluated mistletoe preparations, only two are 
medicinal products registered with SUKL, both of them being herbal teas. All 
the remaining preparations, including those in a solid-dosage form, are 
categorized as food supplements. 
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 As the information on the dosage for an effective hypotensive action of 
mistletoe is scarce, I am not able to compare the effectivity of the evaluated 
mistletoe preparations. The only study giving a dosage for mistletoe in 
prehypertensive to stage 2 hypertension patients (Poruthukaren et al., 2014) 
administered 10 drops of a mistletoe tincture thrice daily. Two preparations 
marketed in this dosage form in the Czech Republic have a higher 
recommended daily dose, therefore it is likely to expect a similar beneficial 
effect in mildy hypertensive patients as that reported by Poruthukaren et al. 
(2014). 
 The lack of information on an effective mistletoe dosage for 
hyperlipidemia treatment makes it again almost impossible to evaluate the 
marketed preparations. The abovementioned study of Poruthukaren et al. 
(2014) also noted a significant reduction in triglycerides, and an increasing 
trend for the HDL cholesterol in patients treated with the mistletoe tincture. 
Thus, the two aforementioned mistletoe preparations should exert a similar 
hypolipidemic effect as the tincture used in the trial of Poruthukaren et al. 
(2014). 
 Furthermore, Ben et al. (2006) noted that aqueous mistletoe extract 
was less effective in the hypolipidemic action in rats than the ethanolic 
extract. It is therefore possible that the marketed herbal teas (be it food 
supplements or medicinal products) will not exhibit any positive effect on the 
lipid profile. 
 
5.8. DIGOXIN CONSUMPTION IN THE YEARS 2015 – 2019 
 
 The different trends of digoxin consumption between small towns and 
big cities in the years 2015 – 2019 (Fig. 4.16. and Fig. 4.17.) are likely due to 
several factors. Firstly, the consumption of prescription-restricted drugs is 
closely tied to the prescription of such a drug by the physicians. According to 
the guidelines for treatment of heart failure in the Czech Republic, digoxin 
should be considered in specific cases only (Hradec, 2018), therefore the 
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prescription and consequently the consumption of digoxin should decrease in 
time.  
This decreasing trend of digoxin can be observed in big cities 
(Fig. 4.16.), with a constant decrease throughout the evaluated time period. 
For digoxin consumption in small towns (Fig. 4.17.), the decrease in time is 
also evident, though the decreasing trend is less pronounced when compared 
to big city. Physicians in small towns probably tend to hold on on their usual 
prescription pattern but the changes were seen in the following years, most 
notably in 2017. 
Secondly, the digoxin consumption in the year 2018 and partially also 
in the beginning of the 2019 was strongly influenced by the unavailability of 
digoxin on the Czech pharmaceutical market. The producer stated production 
reasons for digoxin supply disruption. This digoxin outage lasted for about 
three months according to SUKL, and was longer for Digoxin 0.250 (October 
15th – January 15th) than for Digoxin 0.125 (December 10th – January 16th). 
The pronounced reduction of digoxin consumption in big cities is logically 
countered by the increase of digoxin consumption in small towns – when the 
resources in big cities were depleted, they still remained in small town 
pharmacies, thus increasing the consumption. The year 2019 represents a 
return to the original trend of digoxin consumption for both big city and small 















• The overview includes seven medicinal plants. For each plant its 
phytochemistry, medicinal use, effects on the cardiovascular system 
(including antioxidant, cardioprotective, vasorelaxing, antithrombotic, 
antiatherogenic, antihypertensive, and lipid-lowering actions) and 
safety profile of herbal preparations were reviewed with the emphasis 
on works published within the last twenty years. 
• Over the counter herbal preparations containing selected medicinal 
plants are predominantly categorized as dietary supplements (31). 
Only two medicinal preparations are marketed in the Czech Republic, 
both of these preparations are herbal teas. 
• The majority of herbal preparations are represented by garlic 
supplements. Their consumption exhibited no significant fluctuations 
during the reporting time period. Garlic supplements are the most 
sold herbal preparations in all pharmacy categories. Hawthorn 
preparations consumption exhibited a similarly non-fluctuating trend. 
The consumption of mistletoe and motherwort preparations increased 
in the evaluated time period, while the consumption of black cumin 
and olive supplements decreased in the evaluated time period. 
• Recommended dosages of the evaluated herbal preparations are in 
general lower than the dosages reported in the available literature. 
• Digoxin consumption in general exerts a decreasing trend during the 
reporting time period. 
• Digoxin consumption is different between big city and small town 
pharmacies, these differences are remarkable both in the time frame 
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